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I General Introduction 
Chemical space comprehends all theoretically possible small molecules, including those in 
biological systems. This space is huge, therefore, as of now only a tiny part of it has been 
explored. Yet, these explorations have greatly enhanced our understanding of biology, and have 
led to the development of many of today’s drugs. The discovery of new bioactive molecules, 
facilitated by a deeper understanding of the nature of the regions of chemical space with relevance 
to biology, will advance our knowledge of biological processes and is thus likely to lead towards 
new strategies for the treatment of diseases.1  
Natural products however, constitute only a small fraction of the available chemical space; they are 
defined chemical entities that often display biological activity. During evolution, only a small fraction 
of available chemical space was explored by nature. The same applies to the targets of those 
natural products, mainly being polymers of simple chemical moieties such as amino acids and 
nucleic acids. Structural matching between protein binding site and ligand is a prerequisite for high-
affinity interactions, thus the structural space of both proteins and their ligands has to be highly 
complementary. The fraction of chemical space used by natural products is possibly not the only 
region compatible with protein structural space, but the number and size of such regions within 
chemical space is likely to be limited. Therefore, space used by natural products is preferably 
enriched with bioactive structures and thus contains promising structural starting points in the 
search for bioactive entities aimed at the development of novel drugs.2  
In chemical biology research, cell-permeable and selective small molecules – commonly referred 
to as chemical probes – are used to perturb protein function rapidly, reversibly and conditionally 
with temporal and quantitative control in the biological system of interest. By analysing these 
perturbations, conclusions about the studied biological system can be drawn.3 However, this 
powerful approach relies on the accessibility of appropriate small molecules that can be employed 
as chemical probes. On the venture for such probes, chemists often resort to systematic 
screenings of small molecule compound libraries that are built up from pure, individual, well-
characterized molecules. Consequently, this screening process can only succeed if a high quality 
compound library with enriched biological activity is used and high-throughput screening 
technologies are available that allow a rapid, time- and cost-efficient screening and analysis 
process.4 
As modern organic chemistry allows the synthesis of vast numbers of synthetic small molecules 
enormous combinatorial libraries have become accessible. In theory all parts of chemical space or 
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more precisely the ‘multi-dimensional descriptor space’ – defined as the total descriptor space that 
encompasses all possible small molecules – are reachable by modern synthetic techniques.1 
However, the success rate of such libraries derived from ‘random’ synthesis in biological screens 
turned out to be rather low as only a subfraction of chemical space is biologically relevant.5 
Concepts focusing chemical synthesis on the biologically relevant areas in drug-like chemical 
space are of utmost interest for both academic and industrial research. Biology-oriented synthesis 
(BIOS) deals with this critical point and constitutes a theoretical concept for the design of small 
molecules on the basis of biologically relevant and prevalidated starting points in drug-like 
chemical space.4  
In order to advance chemical biology research, not only the generation of biologically active 
molecules, but also the development of state of the art screening techniques is essential. Small 
molecule microarray technology constitutes a rapid ultra-high throughput screening technique in 
order to investigate small molecule protein interactions. Small molecules are immobilized on the 
surface of glass slides employing a concept of functional group independent immobilization by UV-
triggered carbene insertion. Such glass arrays comprehend thousands of small molecules that 
simultaneously can be incubated with the protein of interest. After successive washing steps, 
compound-bound protein is visualized and thus reveals high affinity protein-small molecule 
interplay. Many successful examples of functional protein inhibitors highlight the potential of this 
inexpensive, time-efficient screening method.6,7  
This thesis is build around these two core paradigms of chemical biology research, namely, 
generation of biologically relevant small molecules - alkaloids of the class of 
tetrahydroisoquinolines - and application of small molecule microarray screening technology in 
order to identify modulators of pharmaceutically significant target proteins. 
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II Theoretical Background 
1 Biology-Oriented Synthesis (BIOS) 
1.1 Natural Products 
Natural products have been a source of medicinal agents since ancient times in the treatment of 
diseases and pathological states and continue to be an abundant source of novel chemotypes and 
pharmacophores.8,9 From 2600 B.C. on, in Mesopotamia for example, oils of the cedar Cedrus 
species and the cypress Cupressus sempervirens were used, and are still used today, against a 
wide range of malaises as colds, parasitic infections and inflammation. Also the Egyptian, Chinese 
and Indian cultures helped to develop the medicinal treatments with the use of natural products in 
the B.C. era.10 In the ancient Western world, the Greeks contributed substantially to the rational 
development of the use of herbal drugs (~300 B.C.). During the Middle Ages, monasteries in 
countries like England, Ireland, France, and Germany preserved the remnants of this Western 
knowledge. At that time, the Arabs took over responsibility for the preservation of much of the 
Greco-Roman expertise, as well as for expanding it to include the use of their own resources, 
together with Chinese and Indian herbs.9 An important date for the development of modern 
medicine was the isolation of morphine (1) by Friedrich Sertürner.11 Being the most abundant 
alkaloid in opium – the dried latex from the opium poppy Papaver somniferum - 1 was the first 
active incredient purified from a plant source. Morphine (1) acts directly on the central nervous 
system (CNS) to relieve pain and is used in clinical medicine as benchmark for analgesics used to 
relieve pain. In 1827, 1 was first commercially sold by Merck. From that time on, the development 
of pharmaceutical drugs obtained from natural sources gained increasing importance.  
Still today, many therapeutically useful compounds are based on natural products. Considering 
new chemical entities (NCE) approval, roughly about 50% of all small molecules over the last 30 
years are related to natural products. This fact highlights the continuing role that natural products 
and structures derived from or related to natural products from all sources have played and 
continue to play in the development of the current therapeutic armamentarium of the physician.8 
Over the years, natural product isolation ventures were not only limited to the plant kingdom but to 
all kingdoms of life. The alkaloids morphine (1) and quinine (2) were derived from plant sources, 
while daunomycin (3), mevastatin (4) and the macrolide zearalenone (5) were obtained from fungal 
and discodermolide (6) from marine sources (Figure 1). 
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Figure 1: Examples of natural product structures, their origin and biological activities. 
The quinoline alkaloide quinine (2) was isolated from the bark of Cinchona species in 1820 by the 
French pharmacists Caventou and Pelletier. They knew that the bark of these trees had been used 
for a long time in the Amazon region, especially for the treatment of fever. This usage found by 
indigenous groups was brought to Europe and it remained the antimalarial drug of choice until the 
1940s.12 According to tradition, the bitter taste of anti-malarial quinine led British colonials in India 
to mix it with gin, thereby creating the up to now very popular “gin & tonic” cocktail. The DNA 
intercalating agent daunomycin (3), extracted from Streptomyces peucetius, consists of a 
pigmented aglycone (daunomycinone) in glycoside linkage with an amino sugar (daunosamine) 
and is most commonly used to treat specific types of leukaemia.13 From the fungal source 
Penicillium species mevastatin (4), also known as compactin, was isolated and later on showed 
cholesterol-lowering properties.12 Lastly, the classical benzolactone, the fungal metabolite 
zearalenone (5) was first isolated from the fungus Gibberela zeae in 1962 and reported having 
anabolic, estrogenic and antibacterial effects.14 It has been used to treat postmenopausal 
symptoms in women and was patented as oral contraceptive.15 
Marine natural products provide a rich source of bioactivity that became gradually more available 
with the development of reliable diving technology within the last 40 years.16 Among these 
compounds discodermolide (6), isolated from the Caribbean sponge Discodermia dissolute, 
exerted potent inhibition of tumour growth and has been the target of various total syntheses.17,18  
     1                                                      2                                                           3 
Quinine
(Cinchona species)
antimalarial agent
N
H
HO
H
N
O
Morphine
(Papaver somniferum)
analgesic
Zearalenone
(Gibberella zeae)
estrogen agonist
Mevastatin (Compactin)
(Penicillium species)
cholesterol-lowering agent
Daunomycin
(Streptomyces peucetius)
antitumor agent
OH
OOHO
OO OH O
O
OH
NH2
O
OHO
H
O
OH
HO
O
O
O
O
HO
HO
H
H
N
(+)-Discodermolide
(Discodermia dissoluta)
potential anticancer agent
O
OH
OH O NH2O
OH
HO
O
      4                                                         5                                                         6 
Theoretical Background 5 
 
1.2 Starting Points for BIOS in Chemical Space 
Natural product structures rise from the evolutionary generation of secondary metabolites that 
provides advantages for survival of the producing organisms. Surprisingly, only a very small 
fraction of the total possible number of small carbon-based compounds in chemical space has 
been generated by biosynthesis. Interestingly, this observation is also true for the protein targets of 
natural products. During evolution, out of all possible amino acid sequences in ‘protein-space’, 
nature has chosen only a minute fraction.19 Hence, the natural product space and the protein 
structure space utilized by nature are limited in size. In order to identify small molecules that bind 
to their protein target, the space defined by the proteins’ ligand sensing cores and their ligands 
should be complementary. In the concept of biology-oriented synthesis (BIOS), natural product 
scaffolds encoding various biological activities are selected as biologically prevalidated starting 
points in chemical space for the development of small focused libraries with limited diversity. As a 
conceptually alternative approach to other library design concepts such as diversity-oriented 
synthesis (DOS),20 BIOS allows to elucidate prior unknown links between the protein world and 
natural products such as predicted target proteins of a natural product-based library by bio- and 
cheminformatic methods.2,4,21-23 
By introducing a hierarchical classification, Waldmann and co-workers developed a suitable tool to 
visualize the chemical space populated by natural products, their scaffolds, cyclic frameworks and 
linkers. As most small molecule inhibitors and drugs are based on ring-systems, the focus of the 
structural classification of natural products (SCONP) was set on molecules containing cyclic 
structures. The resulting rigidification of the molecule backbone results in enhanced target affinity 
due to less entropy loss upon binding. Hence, scaffolds based on rings, linker chains and ring-
based double bonds were isolated, following a set of defined rules from organic and medicinal 
chemistry to step-wise deconstruct the underlying natural product framework into smaller 
structures. This reductionistic approach resulted in a scaffold tree, in which each scaffold in the 
hierarchy represents a well defined chemical entity and substructure of the original natural product. 
Consequently, the scaffold tree allows relating more complex scaffolds to simpler frameworks and 
offers a tool to reduce molecular complexity from multiple annulated rings at the outer rims of the 
scaffold tree to monocyclic systems of the inner circle of the scaffold. The tree gives the possibility 
to categorize structural diversity in an intuitive and chemically meaningful way (Figure 2).4,24,25  
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Figure 2: A scaffold tree generated in the structural classification of natural products (SCONP), where only scaffolds that 
represent at least 0.2% of the natural products described in the Dictionary of Natural Products (DNP) database have been 
sketched. Figure reproduced from the literature.4 
The scaffold tree (Figure 2) can be classified in three classes – nitrogen heterocycles, carbocycles 
and oxygen heterocycles of which two to four ring systems are most common. The significance of 
the natural product tree lies on the one hand in its descriptive representation of biologically relevant 
scaffolds for the design of focused compound collections and on the other hand in the possibility of 
correlating different scaffold classes as performed during BIOS. Recently extensions for the 
identification of biologically relevant starting points in chemical space have been reported by 
scaffold tree generation using bioactivity data together with a process called ‘brachiation’ as 
intuitive guiding criteria for hierarchical scaffold selection. In analogy to the locomotion of primates 
along branches in trees, ‘brachiation’ describes moving from complex to simpler, but still similar, 
structures along lines of biological relevance.26,27 A program called Scaffold Hunter facilitates the 
complex cheminformatic analysis. It reads compound structures, bioactivity data and generates 
compound scaffolds, correlates them in a hierarchical tree-like arrangement, and annotates them 
with bioactivity.26 
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According to the BIOS-concept, a given biologically active compound does not have to be 
resembled in detail to exert the same biological effect. Moreover only the underlying core scaffold 
has to be retained while the necessary substitution pattern and stereochemistry can be evolved 
using structure-activity studies. Various studies have shown the potential of this concept.4,21,28 
In analogy to the SCONP concept, that facilitates chemical space navigation, also protein space 
can be analysed in a similar fashion. During evolution only a limited set of amino acid sequences 
and protein folds have emerged, thus these structures containing binding sites or ‘ligand-sensing 
cores’ can be regarded as prevalidated by nature. A concept called Protein Structure Similarity 
Clustering (PSSC)21,25,29,30 allows to group proteins according to their ligand-sensing core topology. 
Enzymes are grouped into the same PSSC if they share structural similarity in the ligand-sensing 
core part of the overall domain. Proteins sharing structural similarity despite low sequence identity 
are therefore of special interest. If a ligand for one member of the cluster is known, the scaffold of 
this ligand can then be expected to be a prevalidated starting point for the synthesis of ligands for 
the other members of the protein cluster. Consequently, members of a library of synthesised 
derivatives based on the scaffold should target several members of the protein cluster. This 
concept has proven successful in many cases.31-33 
1.3 BIOS of Compound Libraries 
The BIOS approach facilitates hit generation in two ways. On the one hand, it provides scaffolds 
prone to bind to the target protein and structurally simpler relatives as a starting point for small 
molecule compound collections. On the other hand, side chain diversity is the key to increase the 
probability of finding hits by matching the distinct interaction pattern of the target selectively. As 
protein binding pockets are shaped by the individual side chains of the amino acids, library 
synthesis of an identified scaffold is necessary for optimization of the distinct binding site. In the 
case of two nearly identical binding-sites with similar fold, one with negative charge and the other 
one with positive charge, a suitable small molecule inhibitor has to be adapted complementarily. 
Consequently the scaffold with the positively charged side chain would target the protein with a 
negatively charged pocket. This example highlights the importance of sufficient chemical diversity 
to match biological diversity on the search for potent protein ligands. In addition, BIOS can be used 
to generate target clusters that can be used to identify cross-inhibition and selectivity profiles from 
a very early stage on. Taking the BIOS approach as guideline and the SCONP tree as map of 
chemical space, the synthesis of focused libraries has yielded several successful inhibitors.4 
As an example, polyketide-based natural products exert various biological activities. In order to 
extend chemical diversity available for polyketide synthesis, Maier and co-workers chose a 
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framework inspired by the classical benzolactone zearalenone (5) for a systematic replacement of 
the acetate building blocks during synthesis by propionate moieties (Figure 3). The so-called 
‘propionate scanning’34 is a synthetic concept using biology-oriented synthesis for library design. 
The general idea of this concept is the use of a propionate building block instead of an acetate in 
polyacetate-based natural products. Propionate is thus incorporated in all possible (reasonable) 
positions. Due to the fact that acetate/propionate-polyketides are biologically validated, propionate 
scanning should lead to highly active natural product analogues. The additional hydrophobic 
methyl group reduces the conformational flexibility of the macrolactone and could for example 
detect hydrophobic holes within the binding domain. Both effects could increase binding affinity 
and selectivity. Indeed the concept of propionate scanning led to several new inhibitors with 
increased potency in comparison with the underlying zearalenone (5) core scaffold. The 
monopropionate analogue 7 turned out to be a quite potent (IC50 = 210 nM) and selective inhibitor 
of human carbonyl reductase 1 (CBR1).34 CBR enzymes play a critical role in cancer therapy as 
CBR1 is involved in the metabolism of xenobiotics. Doxorubicin, a hydroxyl derivative of 
daunomycin (3), is a common chemotherapeutic DNA-interacting drug used to treat solid and 
hematopoietic tumors. Serious side effects include cardiac injury and chronic congestive heart 
failure. As CBR1 has been identified to catalyse the reduction of doxorubicin to the cardiotoxic 
metabolite doxorubicinol, CBR1 inhibition might constitute a promising means of ameliorating the 
side effects of doxorubicin in patients undergoing chemotherapy. Further studies indicate CBR1 
inhibitors may enhance the effectiveness of anticancer anthracyclines by inhibiting metabolism.35,36 
The potential of the propionate scanning approach is further highlighted by the two 
monopropionate analogues 8 and 9 that targeted Hsp90 with higher affinity than the classical 
inhibitor geldanamycin.37,38 Though it has to be pointed out that this concept is not suitable for the 
generation of large compound libraries as basically every product of the propionate scan has to be 
synthesised separately by means of total synthesis (Figure 3). 
Over the years, Waldmann and co-workers have developed various BIOS examples - a few 
selected cases are shown in Figure 3. On the venture for phosphatase inhibitors, the screening of 
more than 300 chemically diverse natural products yielded yohimbine and ajmalicine – two 
structurally complex pentacyclic alkaloids – as moderate Cdc25A phosphatase inhibitors. SCONP 
analysis and brachiation along the line of pre-validation by nature led to the tetracyclic 
indolo[2,3-a]-quinolizidine, a scaffold frequently occurring in nature, e.g. in the antiviral natural 
product hirsutine (10). Library syntheses with focused diversity around the indoloquinolizidine 
scaffold yielded two compounds with IC50 values comparable with the corresponding natural 
product. By extending the screen to other phosphatases, structurally new inhibitors of the 
Mycobacterium tuberculosis phosphatase MptpB (11) could be identified.39  
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Further MptpB inhibitors were found using the ajmaline (12) macroline framework as lead scaffold. 
Ajmaline (12), isolated from Rauwolfia serpentine, is an antiarrhythmic agent with the trade name 
Gilurytmal®. In a focused library consisting of 100 compounds several new inhibitors of the 
Mycobacterium tuberculosis phosphatase MptpB were obtained (13).40  
Among the carbocycles a decalin-type core structure and quinoid or related aromatic side chain 
often are characterized by manifold biological properties. Based on the natural product and kinase 
inhibitor nakijiquinone A (14) a relatively small library of various decalines was synthesised leading 
to the identification of potent IGF1R, Tie-2, and VEGFR-3 inhibitors (15).41,42  
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Figure 3: From natural products via SCONP and BIOS to focused libraries with high activity hit rates. The inner circle depicts 
the starting structure of the natural products, the middle circle their underlying scaffold, and the outer circle structures of 
biologically active small molecules identified from BIOS compound libraries generated on the basis of these scaffolds. 
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1 Introduction 
1.1 Tetrahydroisoquinolines (THIQs) in Nature  
As early as 1804, the first known alkaloid and narcotic pain reliever morphine (1) was isolated by 
Friedrich Sertürner and named after the Greek god Morpheus, the creator of sleep and dreams in 
Ovid.11,43 The group of alkaloids constitutes an important class of low molecular weight nitrogen-
containing natural products found mainly in plants, but also in microorganisms and animals. More 
than 27,000 different structures have been found, with 21,000 from plants. Alkaloids incorporate 
one or more nitrogen atoms and this usually confers basicity. Therefore the name alkaloid is in fact 
derived from alkali. Classification of alkaloids is conducted according to the nature of the nitrogen-
containing structure (e.g. quinoline, isoquinoline 16, tetrahydroisoquinoline 17), though the 
structural complexity of some examples rapidly expands the number of subdivisions. The nitrogen 
atoms in alkaloids originate from an amino acid as well as the carbon skeleton that is also mainly 
retained intact in the alkaloid structure.44 As secondary metabolites, alkaloids are thought to play a 
defensive role in the plant against herbivores and pathogens. Due to their potent biological activity, 
various alkaloids have been utilised as pharmaceuticals, stimulants, narcotics and poisons. Plant-
derived alkaloids in clinical use involve the analgesics morphine (1) and codeine, the anti-
neoplastic agent vinblastine (29), the gout suppressant colchicine (30), the muscle relaxant 
papaverine, and the sedative scopolamine. Other well known alkaloids of plant origin include 
caffeine, nicotine, and cocaine, and the synthetic O-diacetylated morphine derivative heroin.43 
    
 
 
Figure 4: Core structures isoquinoline (16) and tetrahydroisoquinoline (17). 
1,2,3,4-Tetrahydroisoquinolines (THIQs) are part of the isoquinoline alkaloids that constitute the 
largest group among the alkaloids. Their structural backbone is derived from isoquinoline (16) and 
tetrahydroisoquinoline (17). The tetrahydroisoquinoline (THIQ) class of alkaloids is of great interest 
to the synthetic, medicinal and natural products chemistry community. Due to the interesting 
biological activities displayed by THIQ-containing molecules many are used in pharmaceutical 
applications. Natural products with the underlying THIQ core scaffold range from rather simple 
1-MeTHIQ (18) and carnegine (19) to complex structures with THIQs embedded like ecteinascidin 
743 (20), a THIQ extracted from a marine tunicate.45,46 Examples of medicinally important THIQs 
        16                                                 17 
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include 20, which is in several anti-cancer clinical trials and 1-MeTHIQ (18), a simple compound 
with activity against endogenous Parkinson’s disease.47-49 
 
Figure 5: Prominent THIQ examples. 
1.2 Noscapine Alkaloids 
A prominent member of the THIQ-family is noscapine (21), constituting 1-10% of the alkaloid 
content of opium, and has been used as an oral anti-tussive agent with few side effects in 
humans.50 In the last decade 21 has drawn a lot of interest due to its anti-cancer potential. 
Noscapine has been shown to bind stoichiometrically to tubulin, thus modulating microtubule 
polymerisation. It causes growth arrest of tumor cells in mitosis and induces apoptosis of tumor 
cells in vivo. The significant in vivo antitumor activity, coupled with its minimal toxicity, is probably 
derived from the weak interaction between noscapine and tubuline. Noscapine does not bind to 
tubulin as strongly as colchicine, but its interaction is adequate to arrest mitosis.51,50 The 
brominated analogue EM011 (22) is more potent than the natural product noscapine and achieved 
significant inhibition of hormone-refractory human prostate cancer. Mechanistically, in vitro data 
suggested that the antiproliferative and proapoptotic effects of EM011 (22) in human prostate 
cancer cell lines were through blocking of cell-cycle progression by impairing the formation of a 
bipolar spindle apparatus. The G2/M arrest was accompanied by activation of the mitotic 
checkpoint.52,53 Therefore, noscapine and its analogues are interesting lead compounds and 
noscapine is in clinical phase trials.54 
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Natural noscapine (α- or erythro-form) contains two stereogenic carbon centers: C-5’ at the THIQ-
ring and C-3 at the phthalide framework. Clinically used (–)-α-noscapine is obtained either by plant 
extraction or resolution of synthetic (±)-α-noscapine.55 The first total synthesis of (±)-α-noscapine 
by constructing the C5’-C3 bond was already accomplished by Robinson and Perkins in 1911 
(Figure 7). They could build up on the synthesis of cotarnine (23) from myristicine (24) by Salway56 
and obtained 21 via direct potassium carbonate-mediated condensation of cotarnine (23) with 
meconine (25), followed by resolution of the two resulting enantiomers.57 
   
Figure 7: First total synthesis of noscapine by Robinson and Perkins in 1911.57 
 
In a recent approach – about 100 years after the first total synthesis – Ni et al. reported a blocking 
group-directed diastereoselective total synthesis of (±)-α-noscapine (Figure 8). In this synthesis 
bromine as removable blocking group on C-9’ hinders the formation of the undesired regioisomer 
(C5’-C9’ connection) upon Bischler-Napiralski cyclization of precursor 26, that was synthesised 
Figure 6: Structures of the natural product noscapine (21) and its closely related derivative EM011 (22). 
         21                                           22 
24 
23 
25 
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from amine 27 and meconine-3-carboxylic acid (28). In the last step, bromine is removed by 
reduction (H2, Raney Ni-W2).55 
 
Figure 8: Synthesis of racemic noscapine via Bischler-Napieralski cyclization.55 
  
26 
27 28 
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1.3 Microtubule Inhibition 
Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an 
important therapeutic target in tumour cells. Microtubule-binding agents have been part of 
anticancer therapy for decades and until the advent of targeted therapy, microtubules were the 
only alternative to DNA as a therapeutic target in cancer. In eukaryotic cells microtubules play key 
roles in cell proliferation, trafficking, signalling and migration. Along with actin microfilaments and 
intermediate filaments, microtubules form the cytoskeleton. In mammalian cells microtubules are 
present both in interphase cells and in dividing cells. In dividing cells, microtubules are highly 
dynamic and especially sensitive to therapeutic inhibitors. Hence compounds that alter microtubule 
function have proven to be highly active in patients with cancer.58,59 
The biological functions of microtubules in cells are determined and regulated in large part by their 
polymerisation dynamics. They are formed by the association of α- and β-tubulin heterodimers that 
are folded and unfolded by chaperones as a heterodimer complex. These heterodimers assemble 
head-to-tail into linear protofilaments that further polymerise to result in hollow microtubule 
cylinders.59,60 
 
Figure 9: Microtubules are composed of αβ-tubulin heterodimers that arrange head to tail into protofilaments. 
13 protofilaments form a cylinder 24 nm in diameter. The end exposing the β-subunit is termed plus end and the end with the 
α-subunit exposed is named minus end. Figure reproduced from the literature.60 
During mitosis the cell’s duplicated chromosomes are separated by mitotic spindle microtubules 
into two identical sets before cleavage of the cell into two daughter cells. The correct movements 
of the chromosomes and their proper segregation to daughter cells require extremely rapid 
microtubule-dynamics, rendering mitosis exquisitely sensitive to microtubule-targeting drugs.60  
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Various chemically diverse compounds, generally originating from natural sources, bind to tubulin 
and/or microtubules, altering microtubule polymerisation and dynamics in diverse ways. Most likely 
plants and animals evolved these substances that mimic endogenous regulators of microtubule 
behaviour in order to avoid predation. Altering microtubule dynamics results in the activation of the 
spindle assembly checkpoint and thus induces a mitotic arrest.58 The simplest classification divides 
these agents into two types: microtubule-destabilizing and -stabilizing agents, according to their 
effects on microtubule polymer mass at high concentrations. Destabilizing agents inhibit 
microtubule polymerisation when present at high concentrations and most of these agents bind in 
one of the two domains of tubulin; either the vinca domain (e.g. vinblastine 29) or the colchicine 
(30) domain. Microtubule-stabilizing agents (e.g. paclitaxel 31, discodermolide 6) enhance 
microtubule polymerisation at high concentrations and bind to the same or to an overlapping 
taxoid-binding site on β-tubulin, which is located on the inside surface of the microtubule.61,58 
Taxol® (paclitaxel 31) is used to treat several types of cancer (e.g. breast cancer) and was isolated 
from the bark of Taxus brevifolia in 1971. It was known that the bark of Taxus species was used by 
American tribes for the treatment of some noncancerous conditions.62 However, despite their 
clinical success, the efficacy of microtubule binding agents is often limited by the emergence of 
resistant tumour cells. One of the most studied mechanism is the multidrug restistance (MDR) 
phenotype that is associated with reduced drug accumulation because of drug efflux.63 Therefore, 
novel microtubule binding agents are being investigated to offer more effective therapeutic options. 
One rationale for the continued development of novel agents is the potential of improving drug 
activity by exploiting the differences in mechanism of action.64 
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Figure 10: Structures and binding-sites of different microtubule-binders. Vinblastine (29, Vin) binds to the plus end of 
microtubules. Colchicine (30, Col) binds unpolymerised tubulin at the α/β-tubulin interface near the α-tubulin GTP-binding site 
and is then incorporated into microtubules. The binding of either 29 or 30 to the microtubule plus-end decreases microtubule 
dynamics. At higher concentrations, binding of these drugs along the length of microtubules disrupts lateral contacts between 
protofilaments, resulting in microtubule depolymerisation. Paclitaxel (Tax, 31) binds to the interior lumen of microtubules, 
resulting in decreased dynamics at low concentrations and microtubule bundling at higher concentrations.59,65  
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2 Aims 
Tetrahydroisoquinolines (THIQs) are an interesting class of compounds enriched with diverse 
bioactivities. The natural product noscapine (21) has shown potent effects in the treatment of 
cancers by modulating tubulin. Inspired by the underlying THIQ scaffold of the mentioned natural 
product, a focused library of THIQs was considered for synthesis.  
The large group of benzyl isoquinoline alkaloids (e.g. norlaudanosine 32) feature a benzyl group in 
α position to the nitrogen as they originate from the amino acid tyrosine. As due to biosynthetic 
pathways, substitution in the 1-position is quite frequent among tetrahydroisoquinoline natural 
products (Figure 11) and a certain degree of rigidity also seems to be beneficial, an alkyne 
function should be introduced in this position. This alkynylated THIQ core scaffold could now be 
decorated on the aromatic positions (R1), the alkyne (R2) or the nitrogen (R3). According to the 
principles of BIOS, a limited set of compounds should be sufficient to explore chemical space and 
thereby aid in the detection of biologically active compounds. The library should then be evaluated 
towards modulating tubulin polymerisation. 
Microtubule-binding agents have been part of anticancer therapy for decades and continue to be 
an important treatment option for various cancer types. Structurally new compounds are therefore 
of great value. 
 
Figure 11: Outline for THIQ library. 
More specifically, the library of alkynylated THIQs was outlined to consist of two conceptually 
different library parts: a natural product inspired (A) and natural product derived (B) part. In the 
latter case the cotarnine (23) core was chosen as prevalidated THIQ core that could be decorated 
by alkynylation and optional quaternisation. Such compound collections obtained by means of 
modification of a given scaffold are referred to as natural product derived.22 If during synthesis the 
scaffold is built up, compound collections obtained by means of this approach are referred to as 
32                                                                                                                                                    21                                                        
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natural product inspired. In this process different functional groups and substituents are introduced 
not necessarily at the sites of substitution found in the guiding natural product.22  
 
Figure 12: Library of alkynylated THIQs. The library consists of a natural product inspired part (A) and a natural product 
derived part (B) on the basis of the cotarnine (23) scaffold.  
23 
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3 Results and Discussion 
3.1 Library Synthesis 
Readily accessible substituted phenylethylamines (33, 34, 35) were chosen as starting point. 
Reaction with ethyl chloroformate yielded the corresponding carbamates (36, 37, 38) and 
subsequent dehydrative cyclization (using P2O5, POCl3) led to the substituted 3,4-
dihydroisoquinolin-1(2H)-ones (39, 40, 41).66,67 Deprotonation of these lactams with base (n-BuLi 
or NaH or DMAP/Et3N) and subsequent N-acylation with Boc2O afforded N-Boc lactams (42, 43, 
44, 45) (Figure 13).  
 
 
 
Figure 13: Synthesis of the protected core scaffold. a) ClO2CEt, Et2O; b) P2O5/POCl3; c) 1. NaH or n-BuLi or DMAP/Et3N; 2. 
Boc2O; d) 1.TIPS-acetylene, n-BuLi, BF3·Et2O, –78 °C, 2. DIBAL-H, e) TBAF, THF, 0 °C. 
In 1983 Yamaguchi et al. described a one-pot alkynylation protocol to access alkynyl 
azacyloalkanes by the coupling reaction of alkynyl boranes and aliphatic lactams.68 Alkynyl 
boranes were generated in situ from lithium acetylide and boron trifluoride etherate in 
tetrahydrofuran at –78 °C and treated with the corresponding lactam. In all cases, the lactam was 
used as the N-alkylated derivative. The resulting adducts were then reacted with lithium aluminium 
hydride to afford alkynyl azacycloalkanes.68 When adopting this protocol for the alkynylation of the 
simple N-methylated aromatic lactam 46, double alkynylation (47) and only traces of the desired 
mono-alkynylated product 48 were observed (Figure 14). Only reducing the equivalents of the 
alkynyl borane resulted in the single-alkynylated product 48, though in low yield.  
33 R = 4’-OMe 
34 R = 3’-OMe, 4’-OMe 
35 R = 4’-Br 
36 R = 4’-OMe (93%) 
37 R = 3’-OMe, 4’-OMe (65%) 
38 R = 4’-Br (97%) 
 
39 R = 7-OMe (49%) 
40 R = 6-OMe, 7-OMe (40%) 
41 R = 7-Br (41%) 
42 R = H (80%) 
43 R = 7-OMe (89%) 
44 R = 6-OMe, 7-OMe (70%) 
45 R = 7-Br (57%) 
50 R = H (73%) 
51 R = 7-OMe (62%) 
52 R = 6-OMe, 7-OMe (17%) 
53 R = 7-Br (72%) 
54 R = 7-OMe (86%) 
55 R = 6-OMe, 7-OMe (86%) 
56 R = 7-Br (88%) 
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In order to destabilize the proposed intermediate N-acyl iminium species (49), the methyl group of 
the lactam was exchanged for the electron withdrawing Boc-group (42, 43, 44, 45) (Figure 13). 
Using the above described alkynylation protocol and employing DIBAL-H as reducing agent 
yielded the desired alkynylated tetrahydroisoquinoline core scaffold (50, 51, 52, 53). Yields 
indicated that this reaction strongly depends on the electronic properties of the lactam. While 
goods yields could be obtained for simple (50) or moderately activated lactams (51, 53), low yield 
was obtained for the rather electron rich dimethoxy-substituted lactam (52). Finally, TIPS-
deprotection with tetrabutyl ammonium fluoride69 yielded terminal alkynes (54, 55, 56), constituting 
a fundamental scaffold and starting point for further library expansion. Overall this alkynylation 
procedure constitutes an efficient one-pot protocol to access alkynylated tetrahydroisoquinolines; 
especially secondary THIQs that are rather difficult to access otherwise can be synthesised via this 
route. 
N
O
a
N
TIPS TIPS
b
N
TIPS
36%
37%
N
R2
R1
R3
X
 
Figure 14: Lactam-alkynylation. a) 1. TIPS-acetylene (3 equiv.), n-BuLi, BF3·Et2O, –78 °C, 2. LiAlH4, –78 to –10 °C; b) TIPS-
acetylene (1 equiv.), n-BuLi, BF3·Et2O, –78 °C, 2. LiAlH4, –78 to –10 °C. 
Terminal alkynes open up a wide range of possible reactions for the decoration of the core scaffold 
and the design of a structurally diverse THIQ library (Figure 15). Sonogashira coupling70 of 
terminal alkynes with assorted aryl iodides and subsequent acidolytic Boc deprotection led to 
secondary amines as the corresponding hydrochlorides (73-90). Furthermore, employing a 
protocol by Maier and co-workers,69 Cu(I)-catalysed Huisgen [2+3] cycloaddition71 of terminal THIQ 
alkynes with various azides, followed by Boc deprotection afforded different triazoles (64-72). Of 
note is that a range of benzylic and phenylic azides reacted smoothly under these conditions 
(Table 2).  
 
46 
47 
48 
49 
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Figure 15: Decoration of terminal alkynes. a) (1) Pd(PPh3)4, CuI, Et3N, THF, RT, R2I, (2) HCl/MeOH; b) (1) CuSO4, Na-ascorbate, 
EtOH/H2O, R2N3, (2) HCl/MeOH. 
In general, the reaction of carbanion equivalents with imines constitutes a useful procedure for the 
formation of carbon-carbon bonds in the α position of a nitrogen atom. Consequently, the base-
mediated alkynylation of iminium-salts was explored as an alternative access to alkynylated 
THIQs. The necessary 3,4-dihydroisoquinolines (5772, 58, 5973) were therefore readily accessible 
from either the corresponding lactam (39) or phenylethylamines (60, 34) (Figure 16). 
 
 
Figure 16: Synthesis of 3,4-dihydroisoquinolines. Reduction of lactam 39, followed by oxidation resulted in 58. Bischler-
Napieralski cyclization yielded 5772 and 59.73 
In order to alkynylate the 3,4-dihydroisoquinolines in the α position of the nitrogen atom, an 
activation as iminium salt is necessary. While the use of N-methylated iminium salts is described in 
60 57 
39 58 
34 59 
54-56 
73-90  
64-72 
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literature quite frequently,74 reagents that activate the imine by quaternisation and are 
subsequently readily removable are quite rare. In this respect, trimethylsilyl 
trifluoromethanesulphonate (TMS-OTf) appeared as optimal choice as it fulfilled these demands. 
The usefulness of trimethylsilyl triflate as a removable activating group in imine chemistry has 
initially been demonstrated by Holland and co-workers.75  
Using TMS-OTf as reagent gave iminium salts as heavy precipitates formed in situ. Subsequent 
alkynylation with acetylides and TMS-group removal upon aqueous work-up satisfyingly yielded 
alkynylated THIQs (Figure 17). This protocol constitutes a versatile alternative to the above 
described synthetic route via Sonogashira coupling. Especially, alkynylated THIQ cores that were 
challenging to obtain via lactam alkynylation could be synthesised more efficiently using the 
iminium route. 
 
Figure 17: Alkynylation of TMS-iminium salts.  
The compound library of alkynylated THIQs should not only consist of library members with 
secondary amines but also N-alkylated derivatives. As mentioned above, N-methylated iminium 
salts are used quite frequently for the installation of C-C bond in the α position of the nitrogen 
atom. Such N-methyl iminium salts were readily formed by refluxing the corresponding imines with 
methyl iodide to give air stable salts (61, 62, 63). In addition to the synthesised iminium salts, 
commercially available cotarnine (23) could also be derivatized by means of base-mediated 
alkynylation, opening access to a diverse set of N-methylated alkynylated THIQs with an 
underlying natural product inspired or natural product derived core. Further treatment of these 
tertiary amines with methyl iodide yielded the quaternised THIQs (Figure 18). 
57-59 73-90 
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Figure 18: Synthesis of alkynylated N-methylated THIQs. 
 
Table 1: Overview of synthesised THIQs via [3+2] cycloaddition. Yields over two steps from alkyne 54 using general 
procedure XI. 
 
 
cpd R Yield [%] 
64 Benzyl 64 
65 o-Methoxyphenyl 63 
66 m-Methoxyphenyl 54 
67 m-Methoxybenzyl 71 
68 o-Bromobenzyl 73 
69 m-Bromobenzyl 75 
70 p-Bromobenzyl 60 
71 Pyridine-2-yl-methyl 64 
72 (1,3-Benzodioxol-5-yl)methyl 75 
 
 
57 R1 = H 
58 R1 = 7-OMe 
59 R1 = 6,7-OMe 
61 R1 = H (54%) 
62 R1 = 7-OMe (69%) 
63 R1 = 6,7-OMe (78%) 
23 R1 = 6,7-OCH2O, 8-OMe 
 
 
 
91-103, 105-119 121-130 
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Table 2: Overview of synthesised THIQs. A Synthesis via general procedure V: Sonogashira coupling and Boc-deprotection. B 
Synthesis via general procedure VI: alkynylation of TMS-iminium salt.  
cpd 
 
R1 R2 R3 R4 Yield [%] 
73 H m-Methoxyphenyl H H 16B 
74 7-OMe H H H 99B 
75 7-OMe Phenyl H H 41B 
76 7-OMe o-Methoxyphenyl H H 43B 
77 7-OMe m-Methoxyphenyl H H 95A 
78 7-OMe p-Trifluoromethylphenyl H H 72A 
79 7-OMe 3-Thiophene H H 46A 
80 7-OMe Pyridine-3-yl H H 46A 
81 6,7-OMe H H H 47B 
82 6,7-OMe Phenyl H H 35B 
83 6,7-OMe o-Methoxyphenyl H H 10B 
84 6,7-OMe m-Methoxyphenyl H H 90B 
85 6,7-OMe p-Trifluoromethylphenyl H H 71A 
86 6,7-OMe Thiophene-3-yl H H 68B 
87 6,7-OMe m-Diethylene glycol monomethyl phenyl H H 16B 
88 Br Phenyl H H 45A 
89 Br m-Methoxyphenyl H H 32A 
90 Br p-Trifluoromethylphenyl H H 59A 
91 H Phenyl Me H 83 
92 H o-Methoxyphenyl Me H 73 
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cpd 
 
R1 R2 R3 R4 Yield [%] 
93 H m-Methoxyphenyl Me H 85 
94 H 3-Thiophene Me H 99 
95 7-OMe H Me H 81 
96 7-OMe Phenyl Me H 99 
97 7-OMe o-Methoxyphenyl Me H 88 
98 7-OMe m-Methoxyphenyl Me H 71 
99 7-OMe 3-Thiophene Me H 89 
100 7-OMe Pyridine-3-yl Me H 67 
101 6,7-OMe H Me H 61 
102 6,7-OMe Phenyl Me H 41 
103 6,7-OMe o-Methoxyphenyl Me H 89 
104 6,7-OMe m-Methoxyphenyl Allyl H 72 
105 6,7-OMe 3-Thiophene Me H 40 
106 6,7-OCH2O, 8-OMe H Me - 76 
107 6,7-OCH2O, 8-OMe Phenyl Me - 95 
108 6,7-OCH2O, 8-OMe o-Methoxyphenyl Me - 39 
109 6,7-OCH2O, 8-OMe m-Methoxyphenyl Me - 99 
110 6,7-OCH2O, 8-OMe p-Methoxyphenyl Me - 91 
111 6,7-OCH2O, 8-OMe p-Trifluoromethylphenyl Me - 99 
112 6,7-OCH2O, 8-OMe 3-Thiophene Me - 74 
113 6,7-OCH2O, 8-OMe Pyridine-3-yl Me - 23 
114 6,7-OCH2O, 8-OMe Naphthalene-1-yl Me - 69 
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cpd 
 
R1 R2 R3 R4 Yield [%] 
115 6,7-OCH2O, 8-OMe o-Chlorophenyl Me - 48 
116 6,7-OCH2O, 8-OMe m-Chlorophenyl Me - 37 
117 6,7-OCH2O, 8-OMe m,m-Dimethoxyphenyl Me - 13 
118 6,7-OCH2O, 8-OMe m-Diethylene glycol monomethyl phenyl Me - 39 
119 6,7-OCH2O, 8-OMe Cyclopropane Me - 16 
120 6,7-OCH2O, 8-OMe CH2O-(4-F-Ph) Me - 99 
121 6,7-OCH2O, 8-OMe H Me Me 88 
122 6,7-OCH2O, 8-OMe Phenyl Me Me 99 
123 6,7-OCH2O, 8-OMe m-Methoxyphenyl Me Me 99 
124 6,7-OCH2O, 8-OMe p-Methoxyphenyl Me Me 99 
125 6,7-OCH2O, 8-OMe p-Trifluoromethylphenyl Me Me 99 
126 6,7-OCH2O, 8-OMe Thiophene-3-yl Me Me 99 
127 6,7-OCH2O, 8-OMe CH2O-(4-F-Ph) Me Me 97 
128 7-OMe o-Methoxyphenyl Me Me 93 
129 7-OMe m-Methoxyphenyl Me Me 76 
130 6,7-OMe Phenyl Me Me 99 
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Especially for further structure-activity-relationship studies the reduction of the alkynylated THIQs 
was evaluated using Pd/C and H2. Overall the alkyne reduction proved to proceed quite smoothly 
under mild conditions. Secondary THIQ 77, tertiary THIQ 109 and propargylic tertiary THIQ 120 
were readily converted into their reduced analogues (131-133) (Table 3). 
N
R3
R1
R2
N
R3
R2
R1
Pd/C, H2
ethyl acetate, RT
 
 
Table 3: Reduction of alkynylated THIQs. 
cpd R1 R2 R3 Yield [%] 
131 7-OMe m-Methoxyphenyl H 95 
132 6,7-OCH2O, 8-OMe m-Methoxyphenyl Me 54 
133 6,7-OCH2O, 8-OMe CH2O-(4-F-Ph) Me 91 
 
Overall, efficient synthetic protocols were thus developed that allowed the implementation of a 
focused THIQ library that was subsequently used for biological studies (see section III3.3 
Microtubule Inhibition). 
77, 109, 120 131-133 
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3.2 Enantioselective Synthesis 
In order to get access to enantiomerically pure or highly enantio-enriched analogues of alkynylated 
THIQs the addition of terminal alkynes to isolated alkylisoquinoliniums (the natural product 
derivative cotarnine 23 was chosen as model substrate), catalysed by copper bromide and a chiral 
ligand, was investigated. Various chiral phosphine ligands were screened, like Josiphos derivates 
(Figure 20), different BINAP analogs and QUINAP (Figure 21). While Josiphos derived ligands 
(136-143) resulted in almost no stereoinduction, QuinoxP (144) and BINAP (148) led at least to an 
enantiomeric excess of 50%. The best ligand proved to be QUINAP76 (152) resulting in quantitative 
yields and efficient stereoinduction (ee: 98%) (Table 4). 
Overall Josiphos derivatives (Figure 20) resulted in low stereoinduction. Generally speaking most 
P,P-ligands (140, 141, 143) gave slight stereoinduction while almost no induction could be 
observed for P,N-ligands (137-139). Remarkable was the effect of exchanging Josiphos’ (143) 
phenyl-groups to cyclohexyl-groups (142) that resulted in extinguishing the slight stereoinduction of 
Josiphos. 
When comparing the stereoinduction by BINAP derivatives and structurally related ligands (147-
150) enantioselectivity dramatically decreased with increasing steric crowding and electron-rich 
substituents on the phosphorous atom from phenyl (148) to toluene (149), xylene (150) or 
trimethoxyphenyl (147). Most likely the catalytically active species of the CuBr/BINAP and 
CuBr/QUINAP system is a tetrahedral dinuclear copper(I) complex with bridging bromine 
counterions (134, 135) (Figure 19).77,78 Introducing more electron rich substituents on the 
phosphorus could stabilize the CuBr/ligand complex and steric crowding prevents substrate 
coordination, both effects could lead to a decrease in ee. 
Ph2
P
P
Ph2
P
Ph2
Ph2
P
Cu
Br
Br
Cu
N
PPh2
N
Ph2P
Cu
Br
Br
Cu
 
 
Figure 19: Proposed CuBr/BINAP and CuBr/QUINAP complexes. 
Most beneficial proved to be the change from the bidentate P,P-ligand BINAP (148) to the less 
sterically demanding bidentate hemilabile P,N-ligand QUINAP (152). Probably the more labile 
nitrogen coordination facilitates the coordination of the iminium substrate and the following 
conversion.  
CuBr/BINAP complex            CuBr/QUINAP complex 
134 135 
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Table 4: Ligand Screening. Various different ligands were screened for the alkynylation of cotarnine employing reaction 
conditions as published by Taylor and Schreiber.76 
Ligand yield [%] ee [%] 
136 99 2 
137 25 4 
138 56 4 
139 99 2 
140 15 12 
141 26 10 
142 99 0 
Josiphos (143) 42 10 
(R)-QuinoxP (144) 99 50 
145 41 6 
(R)-Phanephos 146 99 18 
147 52 8 
(R)-BINAP (148) 99 50 
(R)-TolBINAP (149) 73 16 
(R)-XylBINAP (150) 61 22 
(R)-MonoPhos (151) 53 4 
(S)-QUINAP (152) 99 98 
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Figure 20: Josiphos derivatives. 
 
 
Figure 21: Assorted chiral ligands. 
 
136 137 138 
139 140 
141  142 Josiphos (143) 
QuinoxP (144) 145 
Phanephos (146) 
147 
148 R = Ph 
149 R = Tol 
150 R = Xyl 
151  152 
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The QUINAP/CuBr system reported by Taylor and Schreiber gave the highest enantiomeric excess 
(Table 4). The absolute configuration of the major enantiomer was assigned by assuming that the 
stereochemical course of the reactions proceeds by analogy to the results of Taylor and Schreiber 
They employed the CuBr/(S)-QUINAP alkynylation as key step for the synthesis of (S)-(–)-
homolaudanosine, an isoquinoline-based natural product.76 
A possible mechanism could be proposed in analogy to reports by Knochel and coworkers (Figure 
22 and Figure 23).77-79 The chiral, dimeric copper(I) complex 13579 could coordinate an alkyne 
under formation of a side-on complex 153. Base-mediated deprotonation results in an end-on 
copper-acetylide with a coordinated iminium ion 154. The addition of the acetylide to the iminium 
ion within the coordination sphere of the chiral copper(I) complex 155 and the regeneration of the 
catalyst yields the chiral alkynylated THIQ 156 (Figure 22). 
The postulated transition state 157 (Figure 23) could consist of two QUINAP molecules creating a 
chiral sphere that facilitates the side-on coordination of the iminium ion to the copper(I) center. The 
methoxy groups of the THIQ might in addition be involved in the copper chelation, especially the 
8-OMe. Shown in Figure 23 is a dimeric copper(I) complex consisting of two (S)-QUINAP 
molecules, end-on coordinated phenylacetylene and side-on coordinated cotarnine (23). 
Different iminium species were used for the investigation of the CuBr/QUINAP catalysed 
alkynylation reaction (Table 5). The simple imine 7-methoxy-3,4-dihydroisoquinoline (58) (entry 1) 
could not be converted to the corresponding alkynylated product. Also in situ generated TMS-
iminium salts (entry 2) did only result in recovered starting materials. This might be due to the 
rather labile TMS-group. Activation with a methyl or allyl group (entry 3 and 4) resulted in high to 
moderate ee. The rather bulky and electron withdrawing carboxybenzyl group (entry 5) gave low 
conversion without any enantioselectivity. The loss of selectivity might either be due to steric 
hindrance or to disfavoured side-on coordination of the imine caused by the electron withdrawing 
carbamate. Quite remarkable is the effect of the methoxy groups. While no methoxy group (entry 
6) gave 83% ee, just the installation of one methoxy group in 8-position enhanced the selectivity to 
99% ee (entry 7). This might be due to additional copper chelating effects and therefore enhanced 
stereoinduction. In accordance with the proposed transition state (Figure 23) additional 
substituents on the aromatic iminium salt in 6- or 7-position do not cause steric crowding and are 
therefore tolerated (entry 8). 
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Figure 22: Postulated mechanism for CuBr/QUINAP catalysed alkynylation of tetrahydroisoquinoline iminium salts. 
 
Figure 23: Postulated transition state of (S)-QUINAP/CuBr complex with end-on copper acetylide and side-on cotarnine 
coordination. Figure generated with Marvin Sketch80 and Ball View.81,82 
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Table 5: CuBr-catalysed addition of 3-ethynylanisole to different iminium salts. a) 1 equiv Et3N, DCM, –55 °C, 5 mol% CuBr, 5.5 
mol% QUINAP. *prepared in situ. 
entry R1 R2 cpd yield [%] ee [%] 
1 7-OMe - - - - 
2 7-OMe TMS* - - - 
3 7-OMe Me 98 99 91 
4 6,7-OMe Allyl 104 78 82 
5 6,7-OMe Carboxybenzyl* 159 34 0 
6 H Me 93 99 83 
7 8-OMe Me 160 99 99 
8 6,7-OCH2O, 8-OMe Me 109 92 99 
 
  
61-63, 158, 242  
93, 98, 104, 109, 159, 160 
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Various different alkynes were evaluated using the CuBr/QUINAP system. The system proved to 
give excellent ee values and viable yields of various substituted phenylacetylenes (Table 6, entries 
1-4), as well as alkynes carrying a heterocyclic (Table 6, entry 5) or an aliphatic substituent (Table 
6, entries 6, 8). For a more flexible propargylic ether the ee values decreased (Table 6, entry 7). 
 
Table 6: CuBr-catalysed addition of terminal alkynes to cotarnine iodide 23. a) 1 equiv Et3N, DCM, –55 °C, 5 mol% CuBr, 5.5 
mol% (S)-QUINAP. 
entry R cpd yield [%] ee [%] 
1 Phenyl 107 99 98 
2 m-Methoxyphenyl 109 92 99 
3 p-Methoxyphenyl 110 88 99 
4 p-Trifluoromethylphenyl 111 95 97 
5 3-Thiophene 112 99 99 
6 Cyclopropane 119 75 99 
7 CH2O-(4-F-Ph) 120 83 63 
8 1-Cyclohexene 161 58 97 
 
  
23 
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As the enantioselective alkynylation with a flexible propargylic ether appeared to be challenging 
(Table 6, entry 7) a further ligand screening was performed. Ligands that gave stereoinduction in 
the first screen were employed for the synthesis of 120. However, none of the ligands resulted in 
improved yields or ee in comparison with the CuBr/QUINAP system (Table 7). 
 
Table 7: Ligand Screening. Different ligands were screened for the alkynylation of cotarnine using a propargylic alkyne under 
CuBr/QUINAP conditions. 
Ligand yield [%] ee [%] 
(R)-QuinoxP (144) 46 10 
(R)-BINAP (148) 16 14 
(R)-TolBINAP (149) 40 4 
(R)-XylBINAP (150) 30 22 
(S)-QUINAP (152) 83 63 
 
In summary, a highly efficient enantioselective access to alkynylated tetrahydroisoquinolines could 
be established facilitating further structure-activity-relationship studies.  
23 120 
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3.3 Microtubule Inhibition 
Screening and further biological studies of the compounds synthesised as described in the 
previous chapters were performed by Dr. Sayantani Roy. 
The synthesised THIQs were complemented by 6 commercial compounds (322-327, see 
Appendix for details) in order to give a library of 103 compounds (see experimental section for 
exact composition). According to their origin, compounds were clustered in three categories: (1) 
natural product derived THIQs were synthetic derivatives of the natural product noscapine (21), 
mainly obtained via alkynylation of the iminium salt cotarnine (23); (2) natural product inspired 
THIQs exhibit a THIQ core that was built up synthetically; (3) fragments or building blocks (e.g. 6,7-
dimethoxy-1,2,3,4-tetrahydroisoquinolinium chloride 162) (Figure 24). 
 
Figure 24: THIQ library tested on tubulin modulation. 103 THIQs were sorted according to their origin. 
The described compound collection was screened at a concentration of 30 µM for phenotypic 
changes associated with microtubule cytoskeleton and mitotic arrest in BSC-1 and HeLa cells after 
treatment for 24h. Chromosomes were stained with DAPI and anti-tubulin antibody coupled to 
FITC (fluorescein isothiocyanate) was used to detect tubulin. From the 103 compounds tested, 7 
compounds (including noscapine 21) induced phenotypic changes, such as accumulation of round-
shaped cells with condensed DNA, which are indicative of mitotic arrest. For the three compounds 
causing the strongest effects (107, 109, 117), both enantiomers were tested. While the (S)-
enantiomer was inactive, the (R)-enantiomer proved to be the active component of the racemic 
mixture initially screened. The identified hit compounds clearly occupy a distinct niche within the 
THIQ library. Only natural product derived compounds, containing the noscapine THIQ core were 
found as actives. The best compound (R)-109 features a phenyl acetylene function with one 
methoxy group in the meta position and (R)-configuration of the only stereocenter. Loss of the 
triple bond, aliphatic alkyne residues, bulky meta substituents or quaternisation of the nitrogen led 
to complete loss of activity (Figure 25). 
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Table 8: Structure-activity relationship (SAR) of selected THIQs in a phenotypic HeLa-cell based screen. HeLa-cells were 
incubated with 30 µM compound for 24h and cells in mitotic arrest were counted. The percentage of mitotic versus normal 
cells was determined. 
 
 
 
cpd R1 R2 R3 R4 % of mitotic cells 
93 H m-Methoxyphenyl Me H 7 
98 7-OMe m-Methoxyphenyl Me H 4 
106 6,7-OCH2O, 8-OMe H Me H 4 
107 6,7-OCH2O, 8-OMe Phenyl Me H 65 
108 6,7-OCH2O, 8-OMe o-Methoxyphenyl Me H 26 
109 6,7-OCH2O, 8-OMe m-Methoxyphenyl Me H 67 
110 6,7-OCH2O, 8-OMe p-Methoxyphenyl Me H 11 
116 6,7-OCH2O, 8-OMe m-Chlorophenyl Me H 11 
117 6,7-OCH2O, 8-OMe m,m-Dimethoxyphenyl Me H 46 
122 6,7-OCH2O, 8-OMe Phenyl Me Me 4 
123 6,7-OCH2O, 8-OMe m-Methoxyphenyl Me Me 3 
Noscapine (21) 
    56 
DMSO     6 
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Figure 25: Structure-activity relationship for THIQs tested on HeLa cells. Compounds were ranked “active” if they significantly 
(more than 10% mitotic versus normal cells) increased mitotic arrest (see Table 8). 
Screening efforts led to structurally simplified (one stereocenter versus two in the natural product) 
noscapine related microtubule inhibitors (Figure 25). 
The identified hit compounds were subjected to concentration dependent measurements (30 µM, 
15 µM, 7.5 µM) on HeLa and BSC-1 cells. As depicted in Figure 26 a clear dose responsiveness 
was observed. The most potent compound (R)-109 was compared to noscapine (21), that was 
known to arrest cells in mitosis. Treatment of HeLa and BSC-1 cells resulted in rounded cell shape 
with highly condensed DNA content, suggesting their arrest in mitosis. This phenotype was 
observed upon treatment of HeLa cells with (R)-109 even at 7.5 µM, while noscapine appeared to 
be less potent at the same concentration (Figure 26). Comparable phenotypes were caused by 
incubation of BSC-1 cells with (R)-109 and 21. However, the consequences were less pronounced 
and higher concentrations of compound were required to cause comparable effects as in HeLa 
cells. Thus, as a general trend BSC-1 cells seemed to be less affected by (R)-109 than HeLa cells 
(Figure 26). 
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Figure 26: Influence of (R)-109 and 21 on A) HeLa and B) BSC-1 cells treated either with different concentrations of (R)-109 and 
21 or 0.3% DMSO for 24h. Chromosomes were stained with DAPI and anti-α-tubulin-FITC antibody was used to detect tubulin. 
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As noscapine (21) is a known tubulin binder, experiments investigating the influences of the 
identified noscapine related alkynylated THIQs on in vitro tubulin polymerisation were performed. 
The polymerisation of isolated porcine tubulin was thus induced with GTP and monitored.83 The 
anti-neoplastic agent nocodazole (163) is known to inhibit tubulin polymerisation strongly and is 
therefore frequently used in cell biology to synchronize cells. In this experiment 163 was 
consequently used as control for the inhibition of tubulin polymerisation. In comparison with the 
natural product 21 the synthesised compound (R)-109 showed a much stronger inhibition of tubulin 
polymerisation (Figure 27).  
 
Nocodazole (163) 
Figure 27: In vitro tubulin polymerisation assay. Tubulin polymerisation was monitored by fluorescence measurement at 
excitation/emission 370/460 nm. After tubulin polymerisation was induced with GTP, polymerisation was monitored by means 
of enhanced DAPI fluorescence upon binding to microtubules. 
The most potent compounds were subjected to a microtubule re-growth assay. In this experiment 
the time-dependent microtubule re-polymerisation in BSC-1 cells upon re-warming after cold 
treatment is studied. When cells are cooled down microtubules depolymerise. Examining the time-
dependent re-growth of microtubules upon re-warming with and without tubulin modulators is a 
widely accepted approach to elucidate a compound’s impact on cells (Figure 27). In DMSO treated 
cells, microtubule-organizing centers (MTOCs) reappeared just 2 min after re-warming and the 
microtubule cytoskeleton had recovered after 10 min. In contrast (R)-109 and 21 partially inhibited 
microtubule regrowth as up to 10 min and recovering after 15 min.  
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Figure 28: Re-growth of microtubules in BSC-1 cells. Cells were treated with 0.3% DMSO, 15 µM of each 21 and (R)-109. After 
cold treatment on ice and re-warming at 37 °C microtubule re-growth was studied at the given time points after fixation and 
staining. DNA was stained with DAPI (blue) and tubulin was detected using anti-α-tubulin antibody coupled to FITC and 
secondary antibody coupled to Alexa. Size bar: 20 µm. 
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Fluorescence activated cell sorting (FACS) of HeLa cells treated with (R)-109 and stained for DNA 
with propidium iodide, confirmed the compounds’ ability to efficiently arrest cells in the G2/M phase 
(A, Figure 29). Staining of cells with anti-PhosphoHistoneH3 antibody and propidium iodide 
revealed that at 15 µM (R)-109 37% of the cells were in mitosis, while only 14% of mitotic cells 
were observed after treatment with parent compound noscapine (21) at the same concentration (B, 
Figure 29). In comparison DMSO treated cells showed 3% mitotic cells. 
 DMSO (R)-109 Noscapine (21) 
A 
 
 
 
 
   
B 
 
 
 
 
Figure 29: Cell cycle analysis of HeLa cells treated with (R)-109 and noscapine (21). A) Cells were incubated for 24h with 15 µM 
(R)-109 and noscapine (21) and 0.3% DMSO as control prior to staining with propidium iodide and FACS. The percentage of 
cells in the G1 and G2/M phase is shown in the figure. B) FACS analysis to determine the amount of mitotic cells. Cells were 
treated with 15 µM of (R)-109, noscapine (21) and anti-PhosphoHistoneH3 antibody (mitotic marker) overnight and stained with 
propidium iodide (PI) to measure the DNA content. 
Although several efforts were made to determine the binding site for noscapine on tubulin, so far in 
literature there is no direct evidence for binding to the well-characterized colchicine and vinca 
sites.84 For the brominated noscapine derivative, Br-noscapine (22), a binding to the colchicine site 
has been reported.85 
In order to explore the possible binding site of (R)-109 on tubulin, competition experiments using 
colchicine (30) or the vinblastine (29) derivative BODIPY ® FL-vinblastine were performed. The 
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fluorescence of both compounds increases significantly upon binding to tubulin. After preincubation 
of the two probes with tubulin, (R)-109 was added at different concentrations and the change in 
fluorescence upon replacement of the probes observed. In a control experiment known competitors 
(vincristine for the vinblastine binding site and nocodazole for the colchicine binding site) were 
added. However, similarly to noscapine, (R)-109 could neither displace colchicine nor vinblastine 
and therefore does not bind to one of these two well-characterized binding sites (Figure 30). 
 
Figure 30: Competition experiments for binding site determination of (R)-109 on tubulin. A) Vinblastine competition assay 
using BODIPY ® FL-vinblastine. The tubulin-vinblastine-test compound or tubulin-vinblastine-vincristine complex was formed 
by incubating 5 µM tubulin with 5 µM BODIPY-FL-vinblastine and different concentrations of (R)-109 or vincistine for 1h at RT. 
Fluorescence readings (ex/em 470/514 nm) were performed in black 96 well plates using SAFIRE II plate reader (Tecan, Grödig, 
Austria). Blank values were substracted from all sample values. Values were normalized to the DMSO control. B) The tubulin-
colchicine-test compound or tubulin-colchicine-nocodazole complex was formed by incubating 5 µM tubulin with 50 µM 
colchicine and different concentrations of (R)-109 or nocodazole for 1h at RT. Fluorescence readings (ex/em 365/435 nm) were 
performed in black 96 well plates using SAFIRE II plate reader. Blank values were subtracted from all sample values. Values 
were normalized to the DMSO control. 
  
0 10 20 30 40 50
0,4
0,5
0,6
0,7
0,8
0,9
1,0
1,1
1,2
1,3
1,4
Fl
u
or
e
sc
e
n
ce
 
In
te
n
si
ty
 
(F
L/
F0
)
Concentration (µM)
 Nocodazole
 TZ85+
0 10 20 30 40 50
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
1,1
1,2
1,3
1,4
EC50 9,1675 +/- 0,874
FL
/F
0
Concentration (µM)
 Vincristine
 (R)-11d
Concentration [µM] Concentration [µM]
Fl
u
o
re
sc
e
n
ce
In
te
n
sit
y[
 
]
Fl
u
o
re
sc
e
n
ce
In
te
n
sit
y[
 
]
A B Vincristine )-109 ocodazole (R)-109 
Tetrahydroisoquinolines (THIQs) 47 
 
4 Summary and Conclusion 
Using the principles of biology-oriented synthesis a library of alkynylated tetrahydrosioquinolines 
was synthesised. This library was based on the biologically prevalidated core scaffold of 
tetrahydroisoquinoline, a structural backbone occurring in various natural products of diverse 
origin, exerting numerous biological effects. This collection of THIQs was applied to the biological 
application of microtubule inhibition.  
The designed library with limited structural diversity around the THIQ core consisted of two 
theoretically distinct parts. On the one side the natural product cotarnine, an N-methyl iminium salt, 
was readily alkynylated using various acetylides, thus resulting in a natural product derived 
collection of alkynylated THIQs. Further modifications included the quaternisation with methyl 
iodide or reduction of the triple bond. The second part of the library – natural product inspired – 
was built up from various phenylethylamines that were cyclized to result in the corresponding 
lactam. These lactams were then alkynylated using a modified protocol by Yamaguchi et al.68 that 
yielded alkynylated THIQs. On the basis of the fully protected THIQ core various modifications 
were possible. Library generations however, focused on triazole derivatives generated by click 
chemistry and diverse alkynylated THIQs available via Sonogashira coupling. As the one-pot 
alkynylation reaction proved to be challenging, especially for electron rich dimethoxy lactams, an 
alternative approach via the alkynylation of TMS-triflate precipitated imines was developed. In most 
cases this approach resulted in enhanced yields for the synthesis of electron rich alkynylated 
THIQs. Together with the lactam alkynylation a very efficient methodology platform was 
established in order to access numerous secondary THIQs, that are challenging to obtain 
otherwise.  
Further investigations concentrated on CuBr-catalysed enantioselective alkynylation reactions of 
iminium salts. Extensive ligand screening efforts led to a very efficient method giving high ee and 
almost quantitative yields. The absolute stereochemistry of the obtained alkynylated THIQs could 
be assigned in analogy to reports published by Taylor and Schreiber.76 
A library of 103 THIQs was tested in a phenotypic screen on cancer cell lines (HeLa and BSC-1) 
and led to the identification of small molecule microtubule inhibitors. Quite interestingly, only 
compounds closely related to the natural product noscapine were identified. In contrast to 
noscapine that contains two stereocenters, the identified compounds comprised only one 
stereocenter with the same (R)-stereochemistry at the carbon in the α position to the nitrogen. A 
clear structure activity relationship could be drawn, yielding compounds that were more potent than 
noscapine. As new microtubule inhibitors due to tumor resistance are in urgent need and 
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noscapine and its derivatives recently have drawn scientific interest due to favourable toxicity and 
superior in vivo activity, these structurally related, simplified small molecules could be of great 
interest. 
The need for new suitable small molecules applicable as protein ligands lies at the heart of 
chemical biology. The BIOS approach is a tool to explore well-defined parts of drug-like chemical 
space. As natural products can be regarded as evolutionary pre-validated structures by nature, 
these scaffolds are used as guideline for the generation of chemical diversity. Being metabolites of 
plant, animal, fungal or bacterial origin, natural products were in contact with many proteins during 
their biosynthesis, and consequently have inherent potential to bind to proteins. In the search for 
molecules that interact with proteins, natural substances can therefore serve as a model. A 
hierarchical classification of known natural products allows to trace back complex natural products 
to their underlying core structures. The performed studies for the generation of a focused 
compound collection inspired by the natural product noscapine and its underlying THIQ-core prove 
the power of the BIOS concept to generate along the lines of biological prevalidation, high content 
small molecule libraries with exalted hit rates. 
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1 Introduction 
1.1 Small Molecule Microarray Technology 
The discovery of small molecule modulators of a protein of interest can enable not only the 
functional analysis of the protein but also the development of drugs targeting human disease 
related proteins. Within the past decade the development of high-throughput screening (HTS) 
methods using microarray technologies has led to major advances in modern chemical biology 
research. In a single step, thousands of biochemical interactions can be analysed simultaneously, 
diverse biomolecules including DNA/RNA and oligonucleotides, proteins, peptides, carbohydrates, 
small molecules, tissue and live cells.86 Small molecule microarrays were first described by 
MacBeath et al. in 1999. In this approach small molecules containing carboxylic acid functions 
were immobilized on maleimide-derivatized glass slides.87 In the following years various 
applications especially combining diversity-oriented-synthesis (DOS) strategies with consecutive 
compound immobilization were developed. However, a serious limitation to all of these approaches 
was that library members must possess some functional group that is able to react predictably and 
chemoselectively with another functional group on the substrate surface. Consequently, this 
technique is not suitable for high-throughput-immobilization of complex, synthesis intense, small 
molecules or isolated natural products.86 
Osada and co-workers therefore developed an approach towards “non-selective” and functional-
group-independent immobilization using a photoinduced cross-linking reaction to anchor small 
molecules on glass slides88,7 or gold surfaces.89 This approach relies on reactive carbene species 
generated from trifluoromethyl aryldiazirine upon UV irradiation. After spotting small molecules on 
glass or gold surfaces coated with diazirin-based photo-affinity linkers, covalent immobilization is 
initiated via UV irradiation. The in-situ generated carbene-species react with proximate small 
molecules in a functional-group-independent manner. With this method there is no need for the 
incorporation of certain reactive groups amongst library members and therefore it is especially 
suited for natural product derived compound libraries. Furthermore, this technique allows various 
facets of the immobilized compound to be exposed for interaction.7 Osada and co-workers could 
demonstrate that the immobilized small molecules retained their ability to interact with their binding 
protein by immobilization of small molecules with known protein binding partners and detection of 
their binding affinity.89  
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A  B   
Figure 31: A) Trifluoromethyl aryldiazirine attached to a glass slide via PEG linker. UV irradiation generates reactive carbene 
species that react with small molecules in a “non-selective” manner, resulting in immobilization. B) Overview of a systematic 
chemical array screening method. Genes of interest are cloned and can be expressed as RFP-fused proteins in the 
mammalian cell line HEK293T. After transfection, cell lysates are prepared for incubation with glass slides. Hit compounds are 
detected via merged display analysis.90,6 
Further improvements to array screening using small molecules that were immobilized in a 
functional-group-independent manner allowed the screening of cell lysates. Protein lysates of cells 
that express the protein of interest fused with red fluorescent protein (RFP) can be used and 
merged display analysis with lysate from RFP-only expressing cells removes false positive signals 
(Figure 1B). For example, this technique was used to detect novel inhibitors of carbonic anhydrase 
II that could serve as antiglaucoma drugs.90,6 
 
Figure 32: Different options for the detection of proteins bound to small molecule microarray. a) Cy3 or Cy5 labelled protein, b) 
target protein conjugated with fluorescent protein (e.g. mCherry), c) antibody detection of protein, d) antibody detection of 
protein-tag (e.g. His-tag, GST-tag). 
For small molecule microarrays on glass slides, either fluorescently labelled or tagged proteins 
(e.g. His- or GST-tag) are essential. Furthermore, small molecule microarrays have to be washed 
and dried before scanning the fluorescence and relatively weak small molecule-protein interactions 
might be susceptible to the washing process. Therefore alternative platforms not requiring protein 
labeling and allowing in-situ observation of binding are of interest. Such methods could be used to 
supplement and validate primary screening using glass slides. Osada and co-workers successfully 
applied their photo-cross-linking protocol to Surface Plasmon Resonance imaging (SPR) of 
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immobilized small molecules on gold surfaces. Proteins that bind to the immobilized small 
molecules on the gold surface change the local index of refraction and therefore alter the 
resonance conditions of the surface plasmon waves. Such SPR binding assays can be performed 
under wet conditions in real time with untagged protein. This technique therefore constitutes an 
ideal supplement to glass slide array screening (Figure 33).89,91,92  
 
Figure 33: SPR imaging of immobilized small molecules on a gold surface.93 
1.2 Glass Slide Preparation 
A major benefit of small molecule microarrays is the inexpensive preparation of array slides; 
however, precise microprinting technology needs to be available. Photo affinity linker-coated 
(PALC) glass slides were prepared by covalent attachment of photoaffinity linkers to an activated 
glass surface. Typically such a photoaffinity linker (PAL) consists of a UV sensitive head (e.g. 
trifluoromethyl aryldiazirine) and a flexible polyethylene glycol tail terminating with a functional 
amine group for covalent immobilization. PAL1 (164) and PAL2 (165) were synthesised from 
readily available trifluoromethyl aryldiazirine 166 and mono-protected diamine 167. EDC-coupling 
and Boc-deprotection gave 164 and successive coupling with Fmoc-(Pro)9-OSu followed by Fmoc-
deprotection resulted in 165 (Linker synthesis was performed by K. Honda). 
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Figure 34: Synthesis of photoaffinity linker PAL1 (164) from trifluoromethyl aryldiazirine 166 and mono-protected bis-amine 
167. PAL2 (165) was synthesised from 164 via peptide coupling with Fmoc-(Pro)9-OSu followed by deprotection. 
In order to immobilize PEG-linkers, amine-coated (AC) glass slides were treated with N,N’-
disuccinimidyl carbonate (DSC) and base in order to give highly reactive O-succinimidyl 
carbamate-coated slides. Covalent attachment of photoaffinity linkers (PAL) containing amine 
groups (e.g. photoaffinity linker PAL1 and PAL2, Figure 34) and blocking of free binding sites with 
ethanolamine gave photo affinity linker-coated (PALC) slides (Figure 35).7 
 
Figure 35: Preparation of PALC slides. PAL1 (n = 0), PAL2 (n = 9). 
Using high-precision printing robots, compounds as DMSO stock solutions were spotted on the 
surface of PAL-coated slides. After the evaporation of the solvent, the slides were irradiated with 
UV light, followed by several washing steps. Typically 3,500 compounds were spotted in dublicates 
on a single glass slide. 
166 167 
164 165 
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1.3 Gold Chip Preparation 
Self assembled monolayers (SAMs) on gold are commonly used for immobilizing organic 
molecules on gold surfaces, thus generating ordered and oriented layers. SAMs offer the 
opportunity to modify surfaces with controlled morphology and reactivity. Especially thiols have 
been extensively studied for SAM anchoring on gold surfaces.94,95 
In order to investigate small molecule protein interactions via SPR measurements, Osada and co-
workers employed SAMs of alkanethiolate photoaffinity linkers on gold. Thus UV irradiation 
enabled functional-group-independent immobilization of small molecules on SPR chips.92,93 
Synthesis of thiol photoaffinity linker (PAL3, 168) was performed according to literature procedures 
from PAL1 (164) and alcohol 169 (linker synthesis by K. Honda).93 In order to improve the SPR-
signal a mixture of 168 and dummy linker 170 was always used to prepare SAMs. After coating 
such an SPR chip with PAL3, compounds were spotted and immobilized using a similar protocol 
as for the preparation of glass slides. 
 
Figure 36: Synthesis of photoaffinity-thiol linker PAL3 (168) from PAL1 (164) and aldehyde 169.93 
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1.4 Targeting Ras-Depalmitoylation 
The oncogene involved in the Harvey virus causing sarcoma tumor in rats was identified in the 
1980s and therefore named H-Ras for Harvey rat sarcoma.96,97 Two additional oncogenic Ras 
isoforms were identified in Kirsten sarcoma viruses and in human Neuroblastoma and named 
respectively as K-Ras and N-Ras.96,98 The Ras subfamily comprising the H-Ras, N-Ras and K-Ras 
(K-Ras4A and K-Ras4B) proteins forms a group of 21 kDa GTP-regulated molecular switches 
cycling between a GDP-bound “OFF” and a GTP-bound “ON” state. Ras proteins bind GDP/GTP 
with high affinity and in the presence of a GTPase-activating protein (GAP) display high GTP-
hydrolyzing activity.99 Once activated, Ras proteins signal through various cell-signalling pathways 
involved in cell proliferation (e.g. MAPK).100,101 Oncogenic forms of Ras contain point mutations 
that incapacitate the proteins with respect to GTP hydrolysis.102 Consequently, the cycling of the 
switch is inhibited; Ras accumulates in the active form and contributes to tumor formation, due to 
constant signalling with subsequent gene expression in the nucleus. As many other genes involved 
in the Ras signal transduction pathway are also found as oncogenes in human or animal tumors, 
Ras itself and the Ras pathway are thus considered to be prime targets for antitumor therapy.99 
Indeed, Ras gene mutations occur in 20-30% of all cancers, with K-Ras most frequently mutated 
(~85%), followed by N-Ras (~15%) and H-Ras (<1%). Ras-mutations have a significant 
consequence, exemplified by K-Ras mutations found in 90% of all pancreatic cancers.100 
 
Figure 37: Schematic illustration of the dynamic processes that regulate the localization of Ras isoforms. The 
acylation/deacylation cycle maintains the specific plasma membrane/Golgi localization of palmitoylated H-Ras or N-Ras.103 
Small Molecule Microarrays 57 
 
Members of the Ras superfamily have turned out to be precisely regulated in their cellular 
localization.103 De- and re-palmitoylation,104,105 consisting of the reversible removal and attachment 
of palmitic acid from and to cysteines at the C-terminus of the H- and N-Ras GTPases, manage 
their membrane anchoring and thus maintain their specific subcellular localization and 
activity.106,107 The cycle of membrane tethering of Ras isoforms by palmitoylation on the Golgi, 
relocalization to the plasma membrane by the secretory pathway and ubiquitous depalmitoylation 
counteracts unspecific distribution of H/N-Ras over all intracellular membranes by continuous 
redirection to the Golgi system.103 This dynamic cycle accounts for the specific localization of 
palmitoylated Ras isoforms to the plasma membrane and Golgi apparatus and drives the rapid 
exchange of both protein pools.107  
Pertubation of the dynamic palmitoylation/depalmitoylation process might provide a new means for 
the modulation of local Ras activity with potential therapeutic relevance to unregulated signalling in 
tumors containing mutations in the Ras-encoding gene. Up to now, only three depalmitoylating 
enzymes have been described: protein palmitoylthioesterase-1 (PPT1), acyl protein thioesterase 1 
(APT1) and acyl protein thioesterase 2 (APT2).  
PPT1 was first isolated from bovine brain extract, later on also cloned and expressed.108,109 It was 
found important in lysosomal protein degradation by depalmitoylation110 exemplified by PPT1 
mutations causing fatal lysosomal storage diseases such as infantile neuronal ceroid lipofuscinosis 
(INCL).111,112 
 
Figure 38: Crystal structure of hAPT1 (PDB-code: ifj2). View of the electrostatic surface potential of APT1. Positively charged 
regions are shown in blue and negative regions in red. Residues of the catalytic site: Ser114, Asp169, and His210.113 
Human APT1 is a 25 kDa cytosolic114 protein that was originally described as a lysophospholipase 
(LYPLA1) involved in the hydrolysis of lysophospholipids.115,116 Lysophospholipids are detergent-
58 Small Molecule Microarrays 
 
 
like intermediates of phospholipid metabolism, whose in vivo levels must be strictly regulated for 
proper cell function and survival.117 Recently LYPLA1 was identified as an enzyme with PLA1 
activity that is released from human platelets during blood clotting.118 As demonstrated by Duncan 
and Gilman, this protein preferentially employs thioacylated proteins as substrates and its name 
was therefore changed to acyl protein thioesterase 1 (hAPT1).114 In 2000, the crystal structure was 
solved displaying the tertiary fold of a typical α/β hydrolase with the catalytic site consisting of 
Ser114, His203 and Asp169, with Ser114 as the nucleophilic residue. hAPT1 shows a distinct 
negative surface potential surrounding its active site, which is a common feature among esterases 
and lipases to expulse negatively charged hydrolysis products like palmitic acid (Figure 38).113  
 hAPT1  hAPT2 
A 
 
B 
 
C 
 
D 
 
Figure 39: Surface potential of hAPT1 and hAPT2. A/B) Surface potential of hAPT1/hAPT2 monomer. C/D) Surface potential of 
hAPT1/hAPT2 dimer. Positively charged regions are shown in blue and negative regions in red (work by M. Bürger). 
In addition, hAPT1 appears to be dimeric with its active site obstructed by the dimer interface, 
suggesting the requirement of enzyme dissociation to interact with its substrates. In vitro APT1 was 
found to depalmitoylate a variety of substrates like H-Ras, diverse heterotrimeric G protein α 
subunits, eNOs, RGS4, SNAP-23, Ghrelin and platelet proteins.114,119-123 It was described, 
therefore, as “the first bona fide player” in the regulated thioacylation of intracellular proteins.114 
Results by Rocks et al.124 suggested that no primary consensus sequence at the palmitoylation site 
of Ras is needed, as a farnesylated/palmitoylated protein with D-amino acids at the palmitoylation 
site resulted in the natural spatiotemporal pattern of Ras-localization. This finding raises the 
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question how a cytosolic protein like APT1 recognizes membrane-embedded thioesters and could 
explain the broad substrate tolerance of APT1 from soluble proteins like the eNOs to 
transmembrane proteins like SNAP-23.124,125 Yet, depalmitoylation does not occur without any 
discrimination as caveolin was not affected by APT1 in conditions used for eNOs deacylation.126,123 
Acyl protein thioesterase 2 (APT2) or lysophopholipase 2 (LYPLA2) was purified from pig 
stomach,127 afterwards cloned and expressed.128 With 66% sequence identity and especially a 
conserved catalytic triad hAPT2 is a close homologue of hAPT1. Like APT1, APT2 is dimeric with 
its catalytic site occluded by the dimer interface (Figure 39). The superimposition of the APT1 and 
APT2 crystal structure visualizes the similarity of the two proteins (Figure 40). However, the 
electrostatic potential reveals significant differences between the two proteins. In close proximity of 
their active sites, APT2 is substantially more hydrophobic than APT1 (Figure 39). 
 
Figure 40: Superimposition of hAPT1 and hAPT2. A) Crystal structure overlay of APT1 and APT2 nonomers. Green: hAPT2, 
blue: hAPT1. B) Crystal structure overlay of APT1 and APT2 dimers, with their catalytic site obstructed by the dimer interface. 
Green/red: hAPT2, blue: hAPT1 (work by M. Bürger). 
Tomatis et al. observed increased depalmitoylation of GAP-43 (growth-associated protein 43) in 
APT2 overexpressing cells, indicating that APT2 may be involved in GAP-43 depalmitoylation, 
while no effect was perceived with cells overexpressing APT1. Furthermore, the authors suggest 
the involvement of APT2 in H-Ras depalmitoylation.129 However, in vivo proof for the participation 
of APT2 in Ras depalmitoylation is still lacking. 
Initially, based on a reverse chemical genetics approach, Waldmann and co-workers designed 
inhibitors antagonizing the biological function of APT1. As human H-Ras protein is a substrate for 
APT1 in vitro, inhibitors were designed to mimic the C-terminus of the natural protein. A 
A                                                        B 
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peptidomimetic benzodiazepinedione core was chosen as the underlying scaffold and equipped 
with a hydrolysis-stable sulfonamide to mimic the transient tetrahedral intermediate of thioester 
hydrolysis. However, no in vivo effects could be observed for this class of inhibitors.130,131 
In a more recent study, protein structure similarity clustering (PSSC)25,30 exploiting the highly 
conserved character of APT1,114 was used to develop APT1 inhibitors as chemical biology tools to 
investigate the role of APT1 and its relevance to Ras depalmitoylation. In analogy to the known 
gastric lipase inhibitor tetrahydrolipstatin a compound library was synthesised harbouring an 
electrophilic β-lactone core in order to trap the nucleophilic catalytic serine residue. Extensive 
screening efforts led to the development of potent inhibitors like palmostatin B (171) (Figure 41). 
 
Figure 41: Structure of Palmostatin B (171). (IC50 = 670 nM). The IC50 value was obtained employing a colorimetric assay using 
4-nitrophenyl octanoate (PNPO) as substrate (APT1: 75 nM, PNP: 600 µM, 30 min inhibitor pre-incubation).132  
Dekker et al. could show that the inhibition of cellular thioesterase activity, which accounts for 
depalmitoylation, causes an entropy-driven loss of the precise steady-state localization of 
palmitoylated Ras proteins and, as a consequence, down-regulates rather than impairs the down-
stream signalling activity of oncogenic Ras. Additionally, after treatment of cells with palmostatin B 
(171), a partial phenotypic reversion was induced in H-RasG12V-transformed MDCK-F3 cells with 
restoration of E-cadherin expression at the cell-cell interfaces, while K-Ras transformed control 
cells were unaffected. The authors thus proposed APT1 inhibition as a potential strategy for the 
development of new anti-cancer drugs.132  
 
 
 
171 
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2 Aims 
According to their amino acid sequence identities the human acyl protein thioesterases APT1, 
APT2 and the protein lysophospholipase-like 1 (LYPLAL1) belong to two different subclasses of 
the lysophospholipase family, which is in turn a subclass of the α/β hydrolases superfamily.133 A 
BLAST (Basic Local Alignment Search Tool) search with LYPLAL1 finds acyl protein thioesterases 
as closest relatives. All three proteins possess a catalytic triad consisting of a serine, an aspartate 
and a histidine. The overlay of the crystal structures of the three proteins illustrates the very similar 
fold of the proteins (Figure 42). While APT1 has been identified as prime regulator of Ras 
palmitoylation,132 the biological function of APT2128 (lysophopholipase II) and especially LYPLAL1 
remain essentially unknown. 
 
Figure 42: Superimposition of the crystal structures of hAPT1, hAPT2, and hLYPLAL1 (PDB code: 3U0V).134 The structures are 
shown as cartoon representations. APT1 is colored in red, APT2 in blue, and LYPLAL1 in yellow (work by M. Bürger). 
The tight relationship between the LYPLAL1 and APT1 families, the presence of the catalytic triad 
and the very similar fold of the proteins implicate a cellular function of LYPLAL1 comparable to 
APT1. However, LYPLAL1 was also suggested to act as a triglyceride lipase in adipose tissue;135 
some studies revealed a link between the lyplal1 gene locus and the waist-hip ratio of study 
participants,136,137 others indicated an involvement in fat distribution138 and non-alcoholic fatty liver 
disease.139 So far, neither the biological function of LYPLAL1, nor any small molecule inhibitors for 
this protein have been investigated.  
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In summary, the three proteins APT1, APT2 and LYPLAL1 constitute an interesting group of 
proteins and small molecule inhibitors would provide a highly desirable tool box, both for chemical 
biology ventures as well as for medicinal purposes. Small molecule microarray screening of 
immobilized structurally diverse natural products and derivatives could provide a high-throughput 
chemical profiling of the three proteins by the means of finding small molecules that show high-
affinity binding.  
Chemical array screening should first be validated using known inhibitors (for APT1 and 2) and 
screening conditions optimized. Therefore a “validation array” (referred to as MPI array) had to be 
constructed containing known β-lactone inhibitors140 (nanomolar inhibitors of APT1 and 2). Finally 
proteins were subjected to a structurally diverse library of compounds. As natural products portray 
a very prominent field in total chemical space, the chemical library “RIKEN Natural Products 
Depository (RIKEN NPDepo)” including approximately 13,000 compounds mainly consisting of 
secondary metabolites isolated from actinomycetes, fungi, plants and other organisms was 
chosen.141 Microarray screening was performed with tagged protein (GST-tag) and in order to 
validate screening results, SPR imaging was used to observe protein-ligand interaction with tag-
free protein in real time. As follow-up experiments APT1 and APT2 binders were subjected to a 
biochemical functional analysis in an enzymatic test system. For LYPLAL1 such a test system had 
to be developed first. 
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3 Results and Discussion 
Microarray experiments were performed at the RIKEN Advanced Science Institute in Wako, Japan 
under supervision of Prof. Dr. H. Osada with the help of Dr. Yasumitsu Kondoh, Kaori Honda and 
Motoko Uchida.  
3.1 Array Validation and Optimization 
In order to validate the array screening results, known inhibitors were included on the “MPI array” 
(about 500 compounds from the MPI Dortmund), that was used for the optimization of screening 
conditions. Palmostatin B (171)132 and four other second generation β-lactone inhibitors (Figure 
43) were chosen as they are nanomolar inhibitors with equal potency for APT1 and 2.142,140  
 
  
Figure 43: Palmostatin B and second generation β-lactone inhibitors. 
For the first optimization round, standard PEG-slides (coated with PAL1 linker, 164) and two 
different APT1 protein concentrations, 5 nM (concentration of enzymatic APT1 assay) and 1 µM 
were used for protein incubation. Two different incubation methods were examined; the cover slide 
method and the Agilent chamber incubation method. In the cover slide method the array slide was 
covered by a glass slide and incubated using 50 µL of protein solution in buffer. In contrast, 
employing the chamber method, the array glass slide was covered by an Agilent Technologies 
Gasket slide using 500 µL of protein solution. The covered array slide was then incubated in a 
special chamber that allowed the rotation of the slide. 
 
Bound proteins were visualized by an antibody detection system. As GST labelled proteins were 
used throughout, firstly - after protein incubation and washing - array slides were treated with an 
anti-GST antibody from rabbit. As second antibody a species specific (anti-rabbit) Cy5 labelled 
antibody was used. Consequently protein bound to the small molecule microarray resulted in a 
Palmostatin B (171) 
 
X = SO2, NMe2 
n = 4, FD241 (172) 
n = 5, FD243 (173) 
 
 
X = SO2, NMe3+I- 
n = 4, FD253 (174) 
n = 5, FD255 (175) 
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fluorescent signal (670 nm) after excitation at 650 nm (for a visualization of this detection method 
see Figure 32d). 
The immobilized β-lactones (Figure 43) could be detected at either protein concentration, though 
the level of fluorescence was rather low in the case of 5 nM protein. Further, the influence of the 
used linker (PAL2 linker, 165) and the protein incubation method (Agilent chamber incubation) was 
evaluated, but none of the conditions led to further improvements. PEG-slides (PAL1 linker, 164) 
with cover slide incubation of APT1 (1 µM) was selected as method of choice as it resulted in 
nicely analysable data with high signal-to-noise ratio. The same conditions were used for APT2 
and LYPLAL1. As illustrated in Figure 44 and Figure 45, β-lactone derivatives show almost equal 
binding affinity for APT1 and 2 on the chemical array. In order to compare the fluorescence signal 
of the three proteins, the signal was referenced to the glutathione signal. As immobilized 
glutathione binds to the GST-tag of the proteins its fluorescence therefore reflects a distinct signal 
for each protein and viable reference point. The equal potency of the β-lactone inhibitors for APT1 
and 2140 on the enzymatic level is also reflected in the fluorescent values of array binding affinity. 
The fluorescent values of LYPLAL1 show, in comparison to APT1 and 2, at least one order of 
magnitude lower affinity for the β-lactones. Very remarkably is the selectivity of Palmostatin B, 
which does not bind to LYPLAL1 at all. As demonstrated in this validation experiments, the chosen 
screening conditions are able to identify known inhibitors as potent protein binders. For further 
screening experiments these conditions were thus applied. 
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Figure 44: Picture of fluorescent spots at PMT-gain: 200. Compounds were spotted in double spots from left to right (172, 173, 
174, 175, 171). After incubation with GST-protein, array slides were treated with anti-GST antibody from rabbit, followed by 
species specific (anti-rabbit) Cy5 labelled antibody. Cy5 labelled antibody was visualized by excitation at 650 nm and emission 
at 670 nm. 
 
Figure 45: Comparison of GST-APT1, GST-APT2 and GST-LYPLAL1. Fluorescent values (fluorescence of Cy5 labelled 
antibody) were averaged from four spots on MPI array and referenced to Glutathione. Protein concentration: 1 µM, PMT-gain: 
200. 
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3.2 Screening of NPDepo 
Compounds of RIKEN Natural Products Depository (NPDepo) were immobilized on PAL1 (164) 
coated glass slides in duplicates. In total, 12,356 compounds from NPDepo (slides A+B: 6,884; 
G+H: 5,472) were screened on the three GST-proteins using a GST-specific antibody for detection 
of bound protein.  
After incubating the glass arrays with the corresponding protein, slides were successively treated 
with first (GST-specific) and secondary (species specific) Cy5 labelled antibodies. The dried slides 
were then scanned using a fluorescence scanner. For data analysis the fluorescence intensity of 
each spot was corrected by the local background and by a blank control. After analysis of the 
screening data, frequent hitters (showing binding affinity in more than 5% of the so far at RIKEN 
screened proteins) were removed. Data analysis revealed several hits. In order to fingerprint the 
chemical binding profile of the corresponding protein, all selected hit compounds from primary 
NPDepo screening were spotted on a single PALC-slide and binding of GST-protein was detected 
with an anti-GST and secondary antibody. Initial screening hits (from NPDepo slides A, B, G, H) 
were complemented by representative borinic acid derivatives (176-180) that were selected from 
31 hits found on NPDepo slide F (compounds from RIKEN Brain Science Institute143) and three 
boronic acids (190-192) with known micromolar APT1 inhibitory activity. As control compound 
glutathione was selected as it allows referencing the fluorescence intensity of each protein 
(fluorescence was set to 1000). The fingerprint of the three proteins reflects the similarity of APT1 
and 2 with almost identical binding profiles and LYPLAL1 with a distinctly different binding pattern 
(Figure 46). 
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Figure 46: Comparison of GST-APT1, GST-APT2 and GST-LYPLAL1 binding profiles. Compounds were spotted on PALC-glass 
microarray in two different layouts (layout A and B). Protein concentration: 1 µM, PMT-gain: 300. 
As depicted in Figure 47 various small molecules binding to GST-APT1 and GST-APT2 could be 
identified. Representatives of bis-borinic acids and bis-borinate esters bound APT1 and APT2 
rather strongly (176, 177, 178, 179, 180). The pancreatic lipase inhibitor tetrahydrolipstatin (181) – 
a known obesity drug – that served as lead compound for the development of β-lactone APT1 
inhibitors132 – was also identified with strong APT1 and 2 binding but minor LYPLAL1 binding 
(primary screen). Further microarray binders include 182, nizatidine (183), 184 and analogues of 
the APT1 and 2 fluorescent substrates (185, 186). 
For LYPLAL1 a rather limited amount of compounds was detected on chemical array. In addition, 
the detected fluorescence was rather low. Nevertheless, besides pipemidic acid (187), 188, 4,4'-
[1,3-phenylenebis(oxy)]diphthalic acid (189), also three boronic acids (190, 191, 192), that were 
not detected with APT1 and 2, showed binding activity (Figure 48). 
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Figure 47: APT1 and APT2 binders. Small molecule binders of GST-APT1 and GST-APT2. Number in brackets indicates 
position on array. 
176 (C03) 177 (C05) 
182 (C01) 
R = H 178 (C04) 
R =                              179 (C02) 
R =                              180 (C06) 
Tetrahydrolipstatin (181) 
Nizatidine (188, A02) 184 (B03) 
R = H   185 (B09) 
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Figure 48: LYPLAL1 binders. Structures of small molecules binding to GST-LYPLAL1. 
 
 
Figure 49: Binding profile of GST-proteins. Fluorescence values referenced to glutathione. 
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3.3 Boron Compounds as APT1 and 2 Inhibitors 
Compounds that were detected upon small molecule microarray screening using GST-tagged 
proteins were also subjected to SPR-analysis with GST-free protein. SPR binding assays on gold 
chips can detect protein small molecule interaction in real time and therefore are often used to 
supplement and validate results from chemical arrays. All hits from the primary screen of NPDepo 
were printed with identical layout on glass array and SPR-chip to directly compare the two 
methods. Figure 50 depicts the hit validation using SPR-analysis. The control compounds, the 
known β-lactone inhibitors palmostatin B (171), FD241 (172) and tetrahydrolipstatin (181) could as 
expected be confirmed as APT1 and APT2 binders in both microarray and SPR-analysis. 
 
Figure 50: Validation of Microarray Hits using SPR-Analysis. A and D: Small molecule microarray data of GST-APT1 and GST-
APT2. B and E: SPR-Analysis of APT1 and APT2. C and F: SPR-Signal of APT1 and APT2. Known β-lactone inhibitors 171, 172 
and 181 were identified as APT1 and APT2 binders in both microarray and SPR-analysis. Bis-boron compounds (176-179) 
could also be confirmed upon SPR-analysis. 
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Out of the already limited number of APT1 and APT2 binders (Figure 47) an even smaller number 
of compounds could also be identified on SPR-chip. Interestingly, the bis-boron compounds (176-
179) that already displayed rather strong binding signals on chemical array (see Figure 50 A and 
D) could likewise be detected on SPR-chip (see Figure 50 B, C and E, F). The detected bis-borinic 
acids and borinate esters (176-179) are cell penetrating143 small molecules that were originally 
synthesised to inhibit store-operated calcium entry (SOCE), that is an important mechanism for 
replenishing intracellular calcium stores and sustaining calcium signalling.143 
In order to test if the small molecules identified upon microarray screening experiments impair the 
enzymatic activity of APT1 and APT2 a fluorometric assay detecting the release of 6,8-difluoro-4-
methylumbelliferol (DiFMU) from 6,8-difluoro-4-methylumbelliferyl octanoate (DiFMUO) was 
applied. For APT1 the previously known conditions could be used (5 nM APT1, 15 µM 
substrate),140 but for APT2 the assay conditions had to be adapted due to the lower catalytic 
efficiency of APT2 towards the substrate (50 nM APT2, 15 µM substrate) (Table 9).  
Table 9: Kinetic data for human APT1 and APT2. Data determined in a fluorescent assay with DiFMUO as substrate. Protein 
concentration was chosen to be 5 nM (APT1) and 50 nM (APT2). 
Kinetic Data APT1 APT2 
Km [µM] 6.1 ± 0.8 2.1 ± 0.6 
vmax [nmol/s] 
Kcat [s-1] 
1.3 ± 0.05 
0.26 
0.7 ± 0.05 
0.014 
Kcat/Km [s-1mM-1] 43 6.7 
 
All identified microarray APT1 and APT2 binders (Figure 47) were tested towards their inhibitory 
potency in the above described enzymatic assay at 50 µM (note: out of the bis-boron compounds 
only 179 could be provided from RIKEN for biochemical studies). However, from these compounds 
only compound 179 did show an inhibitory effect at 50 µM. Further measurements revealed an IC50 
for both proteins in the low micromolar range (Table 10). 
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Table 10: IC50 of APT1 and APT2 inhibitors. 
compound IC50 [nM] APT1 IC50 [nM] APT2 
palmostatin B (171) 5.37 ± 0.38 19.58 ± 0.87 
FD241 (172) 2.13 ± 0.13 36.74 ± 2.35 
tetrahydrolipstatin (181) 549 ± 171 408 ± 211 
179 3,300 ± 200 979 ± 58 
 
In order to investigate the inhibition mode of 179, Lineweaver-Burk analysis was performed. This is 
a double-reciprocal presentation of the Michaelis-Menten equation (Equation 1) where the 
reciprocal velocity of the reaction is plotted as a function of the reciprocal substrate concentration. 
The graph therefore intersects the x-axis at -1/Km (negative reciprocal Michaelis-Menten constant 
Km) and the y-axis at 1/vmax (reciprocal maximal reaction velocity), which can be read directly from 
the graphical plot. In the competitive inhibition substrate and inhibitor compete for the active site of 
the enzyme. Therefore the affinity between substrate and enzyme at a certain inhibitor 
concentration appears to be lower and therefore Km is higher while the maximum velocity does not 
change. In the double-reciprocal presentation competitive inhibition is consequently reflected in 
intersecting lines on the y-axis. 
v = vmax
S
Km  S
 
vmax: maximal velocity 
[S]: substrate concentration 
Km: Michaelis-Menten constant 
Equation 1: The Michaelis-Menten equation 
Equation 1 is converted to: 
1
v
 = 
Km+[S]
vmax[S]
=
Km
vmax
1
[S]
+
1
vmax
 
Equation 2: Linearized Michaelis Menten equation. 
Lineweaver-Burk analysis of 179 on APT1 (Figure 53) and APT2 (Figure 53) revealed a 
competitive inhibition mode, the same mechanism already observed for other boron compounds 
that had been shown to inhibit β-hydrolases like porcine pancreatic lipase, presumably through 
complex formation with the active site serine residue.144 Thus the Ki-values for 179 were 
determined to be 0.99 ± 0.13 µM for APT1 and 0.73 ± 0.20 µM for APT2 (Table 11). These values 
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are in the same magnitude as when calculated with non-linear curve fitting (APT1: 1.53 ± 0.34 µM 
and APT2: 1.10 ± 0.30 µM). (Figure 51) 
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Figure 51: Non-linear curve fitting using different concentrations of compound 179. 
 
 
Figure 52: Lineweaver-Burk analysis of bis-boron compound 179 on APT1. 
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Figure 53: Lineweaver-Burk analysis of bis-boron compound 179 on APT2. 
 
Table 11: Calculation of Ki. 
APT1 KM [µM] Ki [µM] mean Ki [µM] 
1 µM 17.86 0.88 0.99 ± 0.13 
3 µM 35.71 0.91  
5 µM 43.48 1.18  
 
APT2 KM [µM] Ki [µM] mean Ki [µM] 
0.75 µM 6.75 0.45 0.73 ± 0.20 
2 µM 9.62 0.83  
3 µM 13.51 0.91  
 
Acyl Protein Thioesterase 1 (APT1) is an α/β-hydrolase113 containing an active serine in the 
catalytic site that was shown to be irreversibly targeted by β-lactones.132 Another way of reversibly 
trapping nucleophilic residues in enzyme catalytic sites and hence impairing the enzymatic function 
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involves the use of boronic acids. Boronic acids were reported to inhibit β-hydrolases like porcine 
pancreatic lipase. Garner reported that boronic acids are potent inhibitors of lipase action at 
substrate-water interfaces, presumably through complex formation with the active center serine.144 
A classical example for a boronic acid used in the clinic is the first approved proteasome inhibitor 
Bortezomib - a tripeptide where leucine contains a boronic acid function instead of a carboxylic 
acid function. The boron atom binds the catalytic site of the 26S proteasome with high affinity and 
specificity.145 Inspired by the finding of bis-boron compound 179 as a low micromolar inhibitor of 
APT1 and APT2 various simple, sterically less demanding, small aliphatic and aromatic boronic 
acids were screened on APT1 using the fluorescent activity assay. Therefore, a set of simple 
aliphatic and aromatic boronic acids of commercial and synthetic origin (kindly provided by Prof. 
Dr. Dennis Hall) was assembled and screened on APT1.140 
As shown in Table 13 phenyl boronic acids with electron withdrawing groups (e.g. 190,  191 or 
192) and therefore increasing electrophilicity of the nucleophile trapping boron atom did show the 
most potent inhibition of APT1. Less electron rich unsubstituted phenyl boronic acid 202 did inhibit 
less, or in the case of bulky phenylboronic acids 203 and 204, not at all. Testing the boronic acids 
on APT2 showed similar inhibition patterns as that for APT1. Some boronic acids even inhibited in 
the low nanomolar range (192-194). 
Table 12: Kinetic solubility, as determined by a direct LC/MS based measurement (assay wall: 50 µM). Cell permeability, as 
determined by a parallel artificial membrane permeability assay (PAMPA). Flux [%] denotes concentration (test 
well)/concentration (control well) × 100. Data measured by the Lead Discovery Center, Dortmund. 
compound Solubility [µM] PAMPA flux [%] 
190 42.3 64.5 
 191 37.6 60.7 
192 32.0 20.6 
 
Physicochemical studies, including parallel artificial membrane permeability assays (PAMPA)146 
revealed that boronic acids possess moderate (192) to excellent cell permeability (190,  191) and 
favourable solubility properties (Table 12). 
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Table 13: IC50 values for different phenylboronic acids. 
Cpd ID Structure IC50 [µM] APT1 IC50 [µM] APT2 
190 BA4 
 
0.51 ± 0.03 1.97 ± 0.10 
192 BA23 
 
1.1 ± 0.2 0.138 ± 0.013 
 191 BA22 
 
1.4 ± 0.1 0.418 ± 0.013 
193 BA13 
 
2.3 ± 0.1 0.529 ± 0.133 
194 BA74 
 
3.2 ± 0.2 0.238 ± 0.025 
195 BA37 
 
3.7 ± 0.4 2.95 ± 0.15 
196 BA14 
 
3.9 ± 1.0 2.87 ± 0.63 
197 BA05 
 
4.6 ± 0.4 4.18 ± 0.77 
198 BA36 
 
6.3 ± 0.5 2.16 ± 0.17 
199 BA62 
 
10.2 ± 1.0 1.98 ± 0.09 
200 BA49 
 
13.5 ± 1.4 11.3 ± 4.0 
201 BA03 
 
14.7 ± 1.6 25.1 ± 1.41 
202 BA16 
 
16.9 ± 1.5 
 
3.55 ± 0.40 
203 BA35 
 
> 50 > 50 
204 BA29 
 
> 50 > 50 
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Table 14: Graphical representation of IC50 values for APT1, APT2 and selected yAPT1 values. 
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Although several APT inhibitors131,130,132,142,140 are known, no structural data elucidating the exact 
binding of the small molecule inhibitors has been obtained. Indeed, several attempts to obtain co-
structures of APT1 with small molecule inhibitors (work by Marco Bürger) have not been successful 
and, so far, other groups did not present APT1 co-crystal structures either. These issues most 
likely originate from the solvent-inaccessible active site that is totally shielded by the dimer 
interface.147 The venture for a suitable crystallographic model system for APT1 led Marco Bürger, 
Arthur T. Porfetye and Dr. Ingrid R. Vetter to the identification of APT1 from Saccharomyces 
cerevisiae, which possesses a completely accessible active site, but possesses a fold that is highly 
identical to its human relative. Furthermore, it could be demonstrated that yeast APT1 has 
comparable biochemical properties to human APT1 and is also able to depalmitoylate human 
N-Ras in vitro (shown by Dr. Kristina Görmer). Of interest is that boronic acids identified via 
enzymatic screening on human APT1 did inhibit yeast APT1 to comparable extent (significant 
abberations for 190 and  191). Arthur T. Porfetye succeeded in co-crystallizing the identified 
inhibitors with yAPT1, confirming the proposed mode of action. 
Table 15: Comparison of yAPT1 and hAPT1. IC50 data for the bis-boron compound 179, boronic acids 192, 194, 195, 193 were 
measured for both yAPT1 and hAPT1. Data for yAPT1 were obtained by Arthur T. Porfetye. 
Compound IC50 yAPT1 [µM] IC50 hAPT1 [µM] 
192 2.7 ± 0.1 1.1 ± 0.2 
194 3.3 ± 0.1 3.2 ± 0.2 
179 3.3 ± 0.2 3.3 ± 0.2 
195 4.3 ± 0.1 3.7 ± 0.4 
193 4.7 ± 0.1 2.3 ± 0.1 
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Figure 54: Crystal structures of yAPT1 with bound boronic acid. Resolution of SLS data sets: 193: 1.9 Å, 192: 1.85 Å, 195: 2.00 
Å, 194: 1.75 Å (work by Arthur T. Porfetye).  
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Figure 55: Proposed binding model for boronic acid inhibition. 
According to the crystal structures (Figure 54) boronic acid inhibitors form a tetrahedral complex 
with serine 119 and histidine 207, thus inactivating the enzyme’s active site. However, these 
enzyme-inhibitor complexes are in equilibrium with the free boronic acid (Figure 55). These 
compounds therefore constitute a class of covalent, but reversible, inhibitors. This feature renders 
boron compound very promising, as the known β-lactone APT1 and APT2 inhibitors that likewise 
covalently bind to the catalytic serine 119 are destroyed upon hydrolysis. Therefore, the inhibitory 
effect is diminished either by auto-hydrolysis of the β-lactones in aqueous media or by enzyme 
192 
194 
193 
195 
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hydrolysis, while for boron compounds such an inactivation does not take place. To further 
characterize these inhibitors, an in vitro inhibition assay was performed by Dr. Kristina Görmer 
using boron compound 179, APT1 as a deacylating enzyme and palmitoylated N-Ras as a 
substrate. Briefly, after incubation of the inhibitor with N-Ras and APT1, the release of fatty acid 
was monitored with ADIFAB which in the presence of free fatty acid changes its fluorescent 
spectrum, thereby allowing the calculation of free palmitic acid.148 Indeed, N-Ras depalmitoylation 
by APT1 was inhibited completely at 50 µM of 179, indicating the potent in vitro inhibition of APT1. 
In an LDH-toxicity test none of the tested boron compounds did exert toxic effects at 50 µM or 
below. Furthermore, MDCK cells were subjected to boron compounds and the inhibition of 
downstream ERK-phophorylation was checked. Compound 179 displayed a complete inhibition of 
ERK-phosphorylation at 30 and 15 µM (work by Nancy E. Martinez). 
 
Figure 56: A: Amount of palmitic acid detected after incubation of N-Ras with APT1 (50 nM) and ADIFAB (200 nM) in absence 
(dark red) or in the presence of 50 µM 179 (light red) (work by Dr. Kristina Görmer). B: LDH-toxicity test for boron compounds 
179, 190-192. C: ERK-phosphorylation blot of MDCK cells treated with 30 or 15 µM of boron compounds 179, 190-192 and 
control UO126 (work by Nancy E. Martinez). 
In conclusion, by small molecule microarray screening a bis-boron compound could be identified 
that potently inhibited APT1 and APT2. Further experiments with simple phenyl boronic acids 
highlighted the potency of boron compounds to be non-toxic and effective APT1 and APT2 
inhibitors.  
179 
untreated   LDH(+)       179      190       192       191 
190    191   192  179  UO126  190    191   192  179 UO126                
Small Molecule Microarrays 81 
 
3.4 Identification of LYPLAL1 Inhibitors 
Regardless of the relatively low sequence identity of human lysophospholipase-like protein 1 
(hLYPLAL1) of 33% to hAPT1 and hAPT2, LYPLAL1 is detected as the most similar fold in the 
protein database by a DALI search. Like APT1 and APT2, LYPLAL1 belongs to the protein 
superfamily of α/β hydrolases. The 1.72 Å crystal structure of human LYPLAL1134 showed a typical 
α/β hydrolase fold with the classical catalytic triad of serine, aspartate and histidine. A structural 
feature of LYPLAL1 is that unlike acyl protein thioesterases, the hydrophobic tunnel that 
accommodates the lipid part of the substrate is closed. Therefore LYPLAL1 lacks the structural 
prerequisites for the delipidation of large substrates like palmitoylated proteins, as well as long 
chain lipid degradation in general. In fact, follow-up experiments in order to develop an enzymatic 
assay for LYPLAL1 confirmed that LYPLAL1 is neither able to hydrolyze long-chain esters (see 
below); nor to depalmitoylate N-Ras protein in vitro148 so that a potential induced-fit mechanism is 
very unlikely. Besides the fact that LYPLAL1 exhibits a closed substrate tunnel two striking 
differences in comparison with APT1 and 2 are obvious: on the one hand the electrostatic surface 
potential around the active site shows distinct positive charge in the immediate vicinity of the 
catalytic serine (opposite charge as compared with APT1 and APT2) and on the other hand 
LYPLAL1 crystallizes as monomer. Hence, even though LYPLAL1 has the most similar folds to 
APT1 among all known PDB structures, the structure features an open, solvent-accessible active 
site reminiscent of α/β hydrolases that hydrolyze smaller substrates. The activity assays described 
in the following section confirmed this hypothesis. 
 
Figure 57: Crystal structure of LYPLAL1. A: Crystal structure of LYPLAL1 (green) superimposed on APT1 (blue). The tunnel-
closing loop is highlighted by an arrow. B: 4-nitro-phenyl acetate docked into the active site of LYPLAL1. The surface is 
colored according to the electrostatic potential. Positively charged regions are shown in blue and negative regions in red.134 
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In order to investigate whether the small molecules identified as LYPLAL1 binders on chemical 
array were capable to also inhibit the enzyme activity, an enzymatic assay had to be developed. 
So far no activity assay has been published and information about possible LYPLAL1 substrates 
was also rather vague. As LYPLAL1 was originally proposed to be a phospholipase, LYPLAL1 was 
subjected to activity tests for the four different types of phospholipases A1, A2, C and D (Invitrogen 
EnzChek phospholipase assays). However, as already implicated by the thorough analysis of the 
crystal structure, LYPLAL1 did not display measurable phospholipase activity. In addition 
commercial substrates sensing triacylglycerol lipase and lipase activity in general (Table 17, 
experimental section) did not result in any observable enzymatic activity. Consequently, in line with 
the knowledge from the crystallographic data various 4-nitrophenyl esters (215, 216, 217, 218, 
219, 220), differing in length were tested. 4-Nitrophenyl acetate (215, PNPA) turned out to be most 
efficiently hydrolyzed by LYPLAL1, confirming the already suspected preference for small 
substrates. Consistent with the shallow shape of the active site substrates with increasing chain 
length showed reduced activity. Interestingly, 4-nitrophenyl propionate (216) constituted an 
exception to that rule, and showed less hydrolysis than 4-nitrophenyl butyrate (217) by the 
enzyme.  
 
Figure 58: Hydrolysis of different 4-nitrophenyl esters by hLYPLAL1. Free 4-nitrophenol was detected by absorbance at 410 
nm over a time period of 40 min. Measurements were carried out at 300 nM protein and 500 µM substrate. Each data point 
represents the average value of three independent wells. Background caused by auto hydrolysis of the substrate was 
subtracted from the data. 
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Figure 59: Normalized hydrolysis of different 4-nitrophenyl esters by hLYPLAL1. Regression line slopes of the above 
measurements were calculated and normalized against the slope of the most efficient substrate PNPA. 
As the colorimetric PNPA-assay had to be performed using high concentrations of substrate (1.2 
mM), a more sensitive assay employing lower substrate concentrations and therefore higher 
sensitivity was developed. PNPA (215) was substituted by 6,8-difluoro-4-methylumbelliferol acetate 
(221, DiFMUA) in the activity assay. DiFMUA was synthesised from literature known 6,8-difluoro-4-
methylumbelliferol (222, DIFMU)149,142 (kindly provided by Dr. Marion Rusch) by way of acetylation 
with acetylchloride in 65% yield.  
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Figure 60: Synthesis of 6,8-difluoro-4-methylumbelliferol acetate (DiFMUA, 221). 
Michaelis-Menten kinetics showed that LYPLAL1 hydrolyzed DiFMUA (221) with the same catalytic 
efficiency (kcat/Km) as PNPA (215).  
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Table 16: Comparison of the two LYPLAL1 substrates PNPA (215) and DiFMUA (221). 
Kinetic Data 
(300 nM LYPLAL1) 
PNPA (215) DiFMUA (221) 
 
 
 
 
Km [µM] 782 ± 130 12.6 ± 5.6 
vmax [nmol/s] 168 2.72 
½ vmax [nmol/s] 84 1.36 
Kcat = vmax/[E0] [s-1] 0.56 0.009 
Kcat/Km [s-1mM-1] 0.7 0.7 
Assay conditions 1.2 mM 40 µM 
 
 
Figure 61: A) Microarray Analysis of LYPLAL1. Chemical array showing that compound 188 binds to GST-LYPLAL1. B) IC50 
value determination of LYPLAL1 inhibition by compound 188. 
 
188 
IC50: 43 ± 3 µM 
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The analysis of the identified microarray binders for LYPLAL1 in the DiFMUA-assay resulted in one 
compound (188) with an IC50 below 50 µM. Compound 188 is a successful example of microarray 
screening and constitutes a novel scaffold that could serve as starting point for the development of 
more potent inhibitors for LYPLAL1. Such inhibitors could help to elucidate the role of LYPLAL1 in 
obesity and be of interest for further pharmaceutical developments. 
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4 Summary and Conclusion 
Small molecule microarray screening was evaluated as a technique to identify compounds binding 
to APT1, APT2 and LYPLAL1. All these proteins share high structural similarities and are members 
of the enzyme superfamily of the α/β-hydrolases. Using chemical array technology and known 
high-affinity inhibitors suitable conditions for microarray screening of thousands of natural products 
and natural product derivatives from RIKEN NPDepo could be found. After initial screening of 
NPDepo on the three GST-tagged proteins, hit compounds were selected and subjected to further 
validation efforts aiming to create a unique fingerprint binding profile for every protein. As already 
indicated by thorough analysis of the crystal structures of the proteins (structures were solved in 
the course of the project by Marco Bürger) the high similarity of APT1 and APT2 was also reflected 
in almost identical binding profiles, while LYPLAL1 interacted with completely different compounds. 
For follow-up experiments APT1/APT2 binders were investigated separately from LYPLAL1 
binders.  
Enzymatic screening of the identified APT1/APT2 binders did only reveal the compound class of 
bis-borinic esters and bis-borinate compounds. This rather low success rate of the screening of a 
compound library enriched with thousands of natural products, or derivatives thereof, at the same 
time points out the weak points of small molecule microarray screening. As only binding of a small 
molecule to the protein of interest is detected the proteins enzymatic activity is not necessarily 
perturbed. In the case of APT1 and APT2, microarray screening is maybe even less suitable due to 
the strong tendency of the proteins to form dimers. For further evaluation of microarray screening 
as tool to find inhibitors a monomeric model system like yAPT1 might be a valid strategy. However, 
microarray screening led to the identification of bis-boron compounds as potent APT1 and APT2 
modulators not just on glass array and SPR-chip but also on the enzymatic level. The identified 
compound showed competitive behaviour towards the assay substrate, pointing out the potent 
effect of boron as the most important moiety of the molecule. In order to investigate the role of 
boron in more details, simple phenyl boronic acids were screened on the proteins revealing a 
potent inhibitory effect. Together with the crystallographic data obtained for co-crystals of boronic 
acids with monomeric yAPT1, that could be used as model system for human APT1, it could be 
concluded that the boron moiety is most likely involved in the blocking of the catalytic serine of 
APT1. Surprisingly, none of the boron compounds did show toxic effects on cells. For bis-boron 
compounds even potent in vitro and in vivo inhibition of the Erk pathway could be observed, that 
could be caused by APT1 and APT2 inhibition. However, further biological studies are needed. 
Small Molecule Microarrays 87 
 
The crystallographic analysis of LYPLAL1 combined with the results from biochemical substrate 
screening uncovered a rather unexpected substrate preference compared to the highly homologue 
APT1; namely LYPLAL1 has a shallow active site, whereas APT1 features a large hydrophobic 
tunnel that most likely accommodates the large lipid substituents of its natural substrates. In 
addition, it does neither cleave thioester bonds of prenylated N-Ras, nor exhibit any phospholipase 
activity in contradiction to initial assumptions.135 An enzymatic assay was developed in order to 
investigate the potency of LYPLAL1 protein binders on chemical array to functionally inhibit the 
protein’s enzymatic activity. During this study small nitrophenyl esters were found to be readily 
hydrolyzed. In substituting PNPA (215) by DiFMUA (221) the sensitivity of the assay could be 
improved without influencing the hydrolysis efficiency. This implicates that the fluorophore does not 
sterically obstruct the hydrolysis of the ester bond, or at least not more than the p-nitrophenyl 
group. Testing the identified microarray binders for their inhibition potential all binders showed 
inhibitory activity, with one small molecule showing an IC50 below 50 µM and therefore constituting 
the first known LYPLAL1 inhibitor. This compound features a carboxyl group that could potentially 
interact with the positive patch in the active site. Using the identified compound as lead for further 
development of a high affinity inhibitor the investigation of the still unknown physiological role of 
LYPLAL1 could be uncovered, e.g. by applying the small molecule to adipocyte cell cultures or 
whole organisms. 
In summary, small molecule microarray screening was used for the high-throughput determination 
of modulators for three human proteins of medical interest. Microarray screening constitutes a 
method with rather low hit rates as it completely relies on small molecule binding. Consequently, 
compounds with high affinity but, for example, fast off-rate are not detected in such a system, thus 
resulting in significant numbers of false negative results. Nevertheless, this screening technology 
benefits from its inexpensive and highly time-efficient realisation. During this study microarray 
screening results successfully led to the identification of structurally new inhibitors. 
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V Experimental Section 
1 Assay Procedures 
1.1 Enzymatic Assay Protocol for APT1 and APT2 
Human acyl protein thioesterase 1 (APT1) was expressed and purified as described previously.113 
APT2 was produced under the same conditions as already described for APT1, with the following 
changes: the apt2 gene (cDNA clone IRATp970G0114D, imaGenes, Berlin) was cloned into a 
pGEX expression vector by means of the Gateway system and modified to contain a PreScission 
protease recognition sequence between the apt2 and the gst gene. The construct was then 
expressed as GST-APT2 fusion protein in E. coli BL21 (DE3) Codon+ RIL cells at 20 °C for 16 
hours. The fusion protein was loaded on a GSH column and APT2 was separated from GST by 
overnight incubation of the column with PreScission protease, and finally purified to homogeneity 
by gel filtration. Proteins were provided by Marco Bürger. 
APT1-Assay142 
The enzymatic activity was determined by measuring the release of fluorescent 6,8-difluoro-4-
methylumbelliferone (222, DiFMU) from 6,8-difluoro-4-methylumbelliferyl octanoate (223, DiFMUO) 
by APT1 hydrolysis using a Tecan Infinite M200 microplate reader in a 96 well format. The assay 
was performed in buffer containing 20 mM HEPES, 150 mM NaCl, which was titrated to pH 7.53-
7.55 using 2 N HCl solution. The final enzyme concentration was 5 nM and the final substrate 
concentration was 15 µM. In the assay, 30 µL inhibitor solution (at varying concentrations) in buffer 
containing 0.01% (v/v) Triton-X100 was mixed with 50 µL APT1 solution (10 nM) in buffer 
containing 0.01% (v/v) Triton-X100. The mixture was incubated for 20 min. at 37 oC. Subsequently, 
20 µL of a solution of 223 (75 µM) in buffer containing 0.09% (v/v) Triton-X100 was added to the 
reaction mixture and after 2 min. lag time the formation of fluorescent DiFMU (222) was recorded 
(λex = 358 nm, λem = 455 nm) over 40 min at 60 s intervals at 37 oC. The substrate solution was 
prepared by dissolving 2.43 mg of 223 in 100 µL DMSO. Then, 900 µL assay buffer containing 
10% (v/v) Triton-X100 was added and the mixture was stirred vigorously (Vortex). The resulting 
mixture was added to 99 mL assay buffer to give a solution containing 100 µM DiFMUO (223) and 
0.09% (v/v) Triton-X100. During the incubation and in between measurements the reaction mixture 
was shaken. The reaction rate was determined by linear regression analyses (r2 ≥ 0.98) of the 
fluorescence emission increase over time. The background reaction rate with no enzyme present 
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was subtracted and the reaction rates were normalized to the reaction rate with no inhibitor present 
(100%).  
APT2-Assay140 
As described for APT1, the enzyme activity was determined by measuring the release of 
fluorescent 6,8-difluoro-4-methylumbelliferone (222, DiFMU) from 6,8-difluoro-4-methylumbelliferyl 
octanoate (223, DiFMUO). The final enzyme concentration was 50 nM and the final substrate 
concentration 15 µM. Besides that, the same protocol as for APT1 was followed. 
 
Steady state enzyme kinetics (APT1 and APT2) 
Parameters of steady state kinetics were measured at a final concentration of 5 nM APT1 and 50 
nM APT2. Increase of fluorescence intensity at 358/455 nm (excitation/emission) with final 
DiFMUO (223) concentrations ranging from 45 µM to 0.7 µM in assay buffer were recorded at 
37 °C over 40 min at 30 s intervals. The resulting fluorescence was referenced to a linear DiFMU 
fluorescence-concentration relationship.  
Km and vmax values for APT1 and APT2 were obtained by nonlinear least square fitting of 
Michaelis-Menten equation parameters to the data using XL Fit. The determined constants are for 
APT1: Km = 6.1 ± 0.8 µM and vmax = 1.3 ± 0.05 nmol s-1 and for APT2: Km = 2.1 ± 0.6 µM and vmax = 
0.7 ± 0.05 nmol s-1 (Figure 62). 
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Figure 62: Michaelis-Menten plot for DiFMUO hydrolysis. The solid line represents the fitted Michaelis-Menten equation with 
the given constants. A) 5 nM APT1; Km = 6.1 ± 0.8 µM and vmax = 1,300 ± 45 pmol s-1. B) 50 nM APT2; Km = 2.1 ± 0.6 µM and vmax = 
700 ± 5 pmol s-1. 
  
From the vmax value and the enzyme concentration (APT1: 5 nM, APT2: 50 nM) the turnover 
number (Kcat) for the 6,8-difluoro-4-methylumbelliferyl octanoate (DiFMUO) hydrolysis by 
APT1/APT2 (APT1: 0.26 s-1, APT2: 0.014 s-1) and the enzyme efficiency (Kcat/Km) were determined 
(APT1: 43 s-1 mM-1, APT2: 6.7 s-1 mM-1). 
Concentration dependent inhibition of APT1/APT2 was measured using 10 different concentrations 
around the IC50 value resulting from two-fold dilution series. Reaction progress at every 
concentration of inhibitor was measured in triplicate. Linear regression analysis was performed 
with Microsoft Excel and IC50 values were calculated using 4-parameter logarithmic fits with XL Fit 
curve fitting software (www.idbs.com). Linear regression analysis was performed with Microsoft 
Excel and IC50 values were calculated using 4-parameter logarithmic fits with XL Fit curve fitting 
software (www.idbs.com) for Excel according to: 
y =
(A1-A2)
1+(x/x0)
p +A2 
Equation 3: Equation used for IC50 evaluation. 
y is the reaction rate at the inhibitor concentration x, A1 is the minimum reaction rate (no enzyme 
present), A2 the maximum reaction rate (no inhibitor present), p is the Hill-slope and x0 is the IC50. 
The fitted IC50 parameter represents the relative IC50 value, and is defined as the concentration 
giving a response half way between the fitted top (A2) and bottom (A1) of the curve. 
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1.2 Enzymatic Assay for LYPLAL1 
Human lyplal1 cDNA (imaGenes clone IRAUp969E0370D) was used as a template for PCR 
amplification. The lyplal1 full-length gene was cloned into a pGEX 4T1 expression vector (GE 
Healthcare) by means of the Gateway system, with modified primer to encode a PreScission 
protease cleavage site immediately upstream to the lyplal1 start codon, leaving the two amino 
acids GP preceeding the N-terminal start methionine as cloning artifact. E. coli BL21 Codon +RIL 
cells were transformed using the cloned construct and the overexpressed LYPLAL1 was 
purified.134 Protein was provided by Marco Bürger. 
Substrate Screening 
Different substrates were screened for their ability to be hydrolysed by LYPLAL1. Therefore 
different lipase substrates (224-228) in assay buffer (20 mM Hepes, 150 mM NaCl, pH 7.53-7.55, 
0.01% (v/v) Triton-X100) were incubated at varying concentrations with different concentrations of 
LYPLAL1 and detected at the appropriate wavelengths. However no enzymactic activity could be 
observed. In addition EnzChek® Phospholipase kits A1, A2, C and D purchased from Invitrogen 
were used for the detection of LYPLAL1 phospholipase activity. However, LYPLAL1 did not exhibit 
phospholipase activity. Finally a series of various p-nitrophenol (PNP) esters (216-220) was 
subjected to LYPLAL1 hydrolysis. LYPLAL1 activity was determined by measuring the release of 
coloured p-nitrophenol (PNP) using a Tecan Infinite M200 microplate reader at 410 nm. The 
substrate screening was performed at 300 nM LYPLAL1 and 500 µM of the PNP-ester in assay 
buffer. Parameters of steady state kinetics were measured at a final concentration of 300 nM 
LYPLAL1 using either a colorimetric (PNP-acetate, 215) or fluorimetric detection (6,8-difluoro-4-
methylumbelliferyl acetate, DiFMUA, 221). In the colorimetric assay, the release of yellow PNP 
from 215 with final concentrations ranging from 2400 µM to 37.5 µM in assay buffer was monitored 
by recording the increase of absorbance at 410 nm at 37 °C over 40 min at 30 s intervals. The 
resulting absorbance was referenced to a linear PNP absorbance-concentration relationship. In the 
fluorimetric assay, the increase of fluorescence intensity at 358/455 nm (excitation/emission) with 
final DiFMUA (221) concentrations ranging from 60 µM to 0.94 µM in assay buffer were recorded 
at 37 °C over 40 min at 30 s intervals. The resulting fluorescence was referenced to a linear 
DiFMU fluorescence-concentration relationship. Km and vmax values were obtained by nonlinear 
least square fitting of Michaelis-Menten equation parameters to the data using XL Fit. The 
determined constants were: PNPA-assay (Km = 782 ± 130 µM; vmax = 168 nmol s-1; Kcat = 0.56 s-1; 
Kcat/Km = 0.7 s-1mM-1) and DiFMUA-assay (Km = 12.6 ± 5.6 µM; vmax = 2.72 nmol s-1; Kcat = 0.009 
s-1; Kcat/Km = 0.7 s-1mM-1). 
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Table 17: Substrates tested on LYPLAL1. 
ID Substrates 
224 Resorufin oleate 
223 6,8-Difluoro-4-methylumbelliferyl octanoate (DiFMUO) 
225 4-(Trifluoromethy)umbelliferyl oleate 
226 8-Octanoyloxypyrene-1,3,6-trisulfonic acid 
227 1,2-Dioleoyl-3-(pyren-1-yl)decanoyl-rac-glycerol 
228 Dansyl-11-aminoundecanoic acid 
229 Substrate for phospholipase A1: Glycero-phosphoethanolamine derivative (dye-
labelled at the acyl chain sn-1 position, quencher at the glycerophosphoethanolamine 
head group, non-cleavable ether linkage in the sn-2 position), full name: N-((6-(2,4-
DNP)amino)hexanoyl)-1-(BODIPY® FL C5)-2-hexyl-sn-glycero-3-phosphoethanolamine 
230 Substrate for phospholipase A2: Glycero-phosphocholine derivative (red/green dye-
labelled at the acyl chain sn-1 and sn-2 positions, non-cleavable ether linkage in the sn-
1 position) full name: 1-O-(6-BODIPY® 558/568-aminohexyl)-2-BODIPY® FL C5-sn-
glycero-3-phosphocholine 
231 Substrate for phospholipase C: Glycero-phosphoethanolamine derivative (dye-
labelled at the acyl chain sn-2 position, proprietary substrate) 
232 Substrates for phospholipase D: Phosphatidylcholine, Cholin oxidase and Amplex 
Red® 
215 4-nitrophenyl acetate (v = 65.5 ± 2.1 nmol/s, Km = 782 µM, kcat = 0.56 s-1, vmax = 168 
nmol/s) 
216 4-nitrophenyl propionate (v = 8.9 ± 1.4 nmol/s) 
217 4-nitrophenyl butyrate (v = 25.5 ± 0.7 nmol/s) 
218 4-nitrophenyl valerate (v = 18.7 ± 0.5 nmol/s) 
219 4-nitrophenyl hexanoate (v = 9.2 ± 0.2 nmol/s) 
220 4-nitrophenyl octanoate (v = 2.4 ± 0.2 nmol/s) 
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LYPLAL1 Assay134 
The enzyme activity was determined by measuring the release of fluorescent DIFMU (222) by 
LYPLAL1 hydrolysis of DiFMUA (221) in a Tecan Infinite M200 microplate reader in a 96 well 
format. The final enzyme concentration was 300 nM and the final substrate concentration was 40 
µM. In the assay, 30 µL inhibitor solutions (at varying concentrations) in assay buffer were mixed 
with 20 µL LYPLAL1 solution (1.5 µM) in assay buffer. The mixture was incubated for 20 min at 
37 °C. Subsequently, 50 µL of a solution of 221 (80 µM) in assay buffer was added to the reaction 
mixture and after 2 min lag time the formation of fluorescent 222 was recorded (λex = 358 nm, λem = 
455 nm) over 40 min at 60 s intervals at 37 °C. During the incubation and in between 
measurements the reaction mixture was shaken. The reaction rate was determined by linear 
regression analyses (r2 ≥ 0.98) of the fluorescence emission increase over time. The background 
reaction rate with no enzyme present was subtracted and the reaction rates were normalised to the 
reaction rate with no inhibitor present (100%). 
Concentration dependent inhibition of LYPLAL1 was measured using 10 different concentrations 
around the IC50 value resulting from two-fold dilution series. Reaction progress at every 
concentration of inhibitor was measured in triplicate. Linear regression analysis was performed 
with Microsoft Excel and IC50 values were calculated using 4-parameter logarithmic fits with XL Fit 
curve fitting software (www.idbs.com). Linear regression analysis was performed with Microsoft 
Excel and IC50 values were calculated using 4-parameter logarithmic fits with XL Fit curve fitting 
software (www.idbs.com) for Excel according to Equation 3. The fitted IC50 parameter represents 
the relative IC50 value, and is defined as the concentration giving a response half way between the 
fitted top (A2) and bottom (A1) of the curve. 
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2 Microarrays on Glass Slides 
2.1 Preparation of Photo-Crosslinked Chemical Arrays 
The slides were prepared according to the literature.7,89 A solution of the compounds (dissolved in 
DMSO) was spotted onto PALC slides with a high-precision arrayer using a head with 16-micro-
spotting pins. Then the slides were exposed to UV irradiation of 4 J/cm2 at 365 nm using a CL-
1000L UV crosslinker (UVP, CA). Slides were washed with DMSO, DMF, acetonitrile, THF, DCM, 
ethanol and MilliQ water (3 × 5 min in an ultrasonicator). Finally the slides were spin dried and 
stored at –20 °C until use. Compounds of NPDepo arrays were spotted with a 24 pin head at 2.5 
mg/mL and compounds of the MPI array with a 16 pin head at 10 mM. 
 
Figure 63: Layout of MPI-slide. 
Compounds were spotted in blocks by 144 compounds. Whereas every block started with one row 
of standard compounds (most frequently used compounds on NPDepo arrays are shown in Table 
18) and the corners of each block were marked by a position marker. 
 
16 blocks
duplicate
Library member
Marker (Cy5 = 100µM, Cy3 = 10 µM)
Standard 
1 block = 12 x 12 spots (Library member)
1 multi block = 12 x 12 x 16 = 2304 spots
Center-to-center distance = 345 µm
Double spots per 1 compound
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Table 18: Control compounds spotted on NPDepo-arrays and known binding partners. 
Compound Name Known binder(s) 
Biotin Streptavidin 
Cyclosporine A Cyclophilin A 
Glutathione Glutathion-S-transferase 
His peptide His antibody 
FLAG peptide FLAG antibody 
SB203580 p38 MAP-kinase 
MTX Dihydrofolate hydrogenase (DHFR) 
Staurosporine Kinases 
 
2.2 Screening of Microarray Slides 
The same buffer as for the APT1 and 2 enzymatic assay was used (20 mM Hepes, 150 mM NaCl, 
pH = 7.53-7.55). The slides were incubated in buffer containing 1% skim milk for one hour at RT 
with gentle shaking, washed with buffer (3 × 5 min on shaker) and dried for 1 min using a spin 
dryer (Waken, model 2350, spindryer-mini). For protein and antibody incubation either cover slide 
or chamber method were used.  
In the cover slide method the array slide was covered by a glass slide from Matsunami Glass Ind., 
Ltd. (micro cover glass, 24 × 60 mm) and incubated using 50 µL of protein solution in buffer 
containing 1% skim milk at 30 °C for 1 h. In the chamber method, the glass slide was covered by 
an Agilent Technologies Gasket slide using 500 µL of protein solution. The covered slide is 
incubated at 30 °C for 1 h in a hybridization oven using an Agilent G2534A Microarray 
Hybridization Chamber. Using chamber incubation, no spin drying of array slides after intermediate 
washing is necessary. Only after final wash, spin drying is essential. 
Array slides were incubated with anti-GST antibody (rabbit lgG fraction, Invitrogen, 30 µg/mL) in 
buffer containing 1% skim milk at 30 °C for 1 h using one of the above mentioned incubation 
methods. This incubation was followed by another wash step (buffer: 3 × 5 min on shaker, spin dry: 
1 min) and incubation with second antibody (Millipore, Gt X Rb lgG Cy5 anti-rabbit, 50 µg/mL) at 
30 °C for 1 h. After the final wash step (assay buffer: 3 × 5 min on shaker, spin dry: 1 min) slides 
were scanned at 635 nm on a GenePix 4200AL microarray scanner (Molecular Devices). The 
fluorescence signals were quantified using GenePix 6.1 software with local background 
subtraction. From every slide two copies were used, one was treated with assay buffer containing 
1% skim milk as control and the other one with GST labelled target protein in assay buffer 
containing 1% skim milk. The two resulting pictures were coloured green and red respectively 
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using Photoshop 5.5 software. Then, the colored figures were merged. The false positive signals 
caused by binding of ligands to antibody or by autofluorescent signals of the ligand itself were 
detected as yellow signals. For data analysis fluorescent signal for every compound in both 
multiblocks was corrected by the local background subtraction and the fluorescence intensity of the 
corresponding control slide (Equation 4).  
∆I = Isample-Ireference 
Equation 4: Calculation of fluorescence intensity. 
For hit-analysis a relative ranking was used (Equation 5). 
∆I =	∆I  + n · SD 
relative ranking: n ≥ 1: +; n ≥ 2: ++; n ≥ 3: +++ 
I: Fluorescence Intensity of compound spot 
SD: standard deviation  
∆I : mean fluorescence intensity of all compound spots 
Equation 5: Relative ranking of fluorescence. 
The hits from screening of NPDepo slides (A, B, G, H) were complemented by known nanomolar 
APT1/APT2 inhibitors (β-lactones) and borinic acids, that were found upon screening of 
compounds from RIKEN BSI (array F). The chosen layout was spotted on two SPR chips (version 
A and B) on a single glass slide in order to compare glass array and SPR screening. While for SPR 
chips as position marker Sennoside B (frequent protein binder) was used, for glass slides a mixture 
of Cy5 and Cy3 was employed. 
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Figure 64: Array layout for SPR chip and glass slides.  
 
  
Array  version A
ID Compound Name M A01 A09 B05 A04 A12 C11 A07 B03 A02 A10 M
A01 Leucomycin A1 A02 A10 B06 A05 B01 D02 A08 B04 A03 A11 D02
A02 NPD2612 A03 A11 C10 A06 B02 A01 A09 B05 A04 A12 B06
A03 NPD2826 M A04 A12 C11 A07 B03 A02 A10 B06 A05 B01 C10
A04 NPD3976 A05 B01 D02 A08 B04 A03 A11 C10 A06 B02 C11
A05 NPD4355 A06 B02 A01 A09 B05 A04 A12 C11 A07 B03 D02
A06 Pipemidic acid A07 B03 A02 A10 B06 A05 B01 D02 A08 B04 D02
A07 Spiramycin I M A08 B04 A03 A11 C10 A06 B02 A01 A09 B05 M
A08 4,4'-[1,3-phenylenebis(oxy)]diphthalic acid M: Sennoside B (SPR chip), Cy3/Cy5 (glass slide)
A09 Captopril(CAP) D02: DMSO
A10 Nizatidine(NIZ)
A11 NP214 Array version B
A12 NP223 M B07 C03 C11 B10 C06 B05 C01 C09 B08 C04 M
B01 NP275 B08 C04 C12 B11 C07 D02 C02 C10 B09 C05 D02
B02 NP387 B09 C05 D01 B12 C08 B07 C03 C11 B10 C06 C12
B03 NP513 B10 C06 B05 C01 C09 B08 C04 C12 B11 C07 D01
B04 NPD3383 M B11 C07 D02 C02 C10 B09 C05 D01 B12 C08 B05
B05 NPD3397 B12 C08 B07 C03 C11 B10 C06 B05 C01 C09 D02
B06 NPD3936 C01 C09 B08 C04 C12 B11 C07 D02 C02 C10 D02
B07 NPD4020 M C02 C10 B09 C05 D01 B12 C08 B07 C03 C11 M
B08 NPD6047 M: Sennoside B (SPR chip), Cy3/Cy5 (glass slide)
B09 NPD6048 D02: DMSO
B10 NPD7112
B11 NPD7330 Array version A
B12 NPD8335 Array version B
C01 NP558 SPR chip ver. A & B as positive control
C02 RBSI-B3003-C Array version A & B as negative control or marker
C03 RBSI-B6057-5
C04 RBSI-B4045-26
C05 RBSI-B6055-4
C06 RBSI-B2133-C
C07 TZ-BA4
C08 TZ-BA22
C09 TZ-BA23
C10 FD241 Arrangement on glass slide
C11 PalmB
C12 AGWI000564-1
D01 AGWI000566-1
D02 DMSO
M: Sennoside B
A B
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3 SPR Imaging 
3.1 Preparation of Photo-Crosslinked Chemical Arrays 
Gold-coated glass chips (TOYOBO, Japan) were incubated in ethanol containing photoaffinity 
linker 168 (0.1 mM) and dummy linker 170 for 12h. The chip was rinsed successively with ethanol 
and dried in air. DMSO solutions (10 mM) of small molecules were spotted on the gold-coated 
glass chip using an automated spotter (TOYOBO, Japan). After evaporation of DMSO chips were 
exposed to UV irradiation of 4 J/cm2 at 365 nm using a CL-1000L UV crosslinker (UVP, CA). The 
chips were then washed with DMSO, water and ethanol, according to literature procedures.92 
3.2 SPR Measurement 
The photo-cross-linked SPR chip was placed in an SPR imaging instrument (TOYOBO, Japan) 
and SPR signals were obtained in running buffer (10 mM Hepes, 150 mM NaCl, pH = 7.4). The 
running buffer and the protein samples were applied to the chip surface at 0.1 mL/min. After 
washing with running buffer, a solution of the corresponding protein (10 µM) was injected to the 
chip surface and incubated for 10 min. All SPR experiments were performed at 30 °C. SPR images 
and signal data were collected with an SPR analysis program (TOYOBO, Japan) and SPR 
difference images were constructed using a Scion Image (Scion, MD) program. 
4 Immobilization of Small Molecules on Chemical Beads 
In order to immobilize selected small molecules on chemical beads for further experiments like 
pull-down and target identification, photoaffinity linker-coated beads were prepared by covalent 
attachment of photoaffinity linkers to N-hydroxysuccinimide (NHS) activated sepharose beads. The 
photoaffinity linker was synthesised according to previous reports93 from readily available mono-
protected diamine (233) and trifluoromethyl aryldiazirine (234). EDC-coupling and Boc-deprotection 
resulted in photoaffinity linker 235 (synthesis performed by K. Honda). Before the immobilization of 
compounds their UV-stability (4 J/cm2 at 365 nm) was confirmed by LC-MS analysis of UV 
irradiated sample and non-UV irradiated sample. 
The following compounds were immobilized on chemical beads: 
Microtubules project: 106 (negative control), (R)-107, (R)-109, 120 (negative control) 
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Figure 65: Synthesis of photoaffinity linker 235 from trifluoromethyl aryldiazirine 234 and mono-protected bis-amine 233. 
NHS-activated Sepharose 4 Fast Flow beads were obtained from GE Healthcare as suspension in 
100% isopropanol. Compounds were immobilized to 15 nmol/µL bead suspension. Therefore 400 
µL of sepharose bead suspension was centrifuged at 1,500 rpm for 1 min and the supernatant 
discarded. Beads were washed (3 × 400 µL) with 1 mM HCl and 0.1 M NaHCO3 in (1:1) 
dioxane/water (3 × 400 µL). Photoaffinity linker 235 (3 equiv.) was dissolved in 0.1 M NaHCO3 in 
(1:1) dioxane/water (400 µL) and beads were incubated for 2h at 37 °C in the linker solution with 
gentle rotation, followed by washing with 0.1 M NaHCO3 in (1:1) dioxane/water (3 × 400 µL). In 
order to block residual binding sites, beads were treated with 1 M ethanolamine in Tris-HCl buffer 
(0.1 M, pH = 8.0) (1 mL) and incubated for 1h at 37 °C with gentle rotation. 
Bead suspension was then transferred to a spin column (Scan Column) and washed with water (3 
× 400 µL) followed by methanol (3 × 400 µL). Dry beads were then transferred to a glass vial and 
the compound added dissolved in methanol (400 µL). Solvents were evaporated in vacuo and 
beads exposed to UV irradiation of 4 J/cm2 at 365 nm using a CL-1000L UV crosslinker (UVP, CA). 
Beads were then transferred to a spin column with methanol followed by successive washing with 
methanol (15 × 400 µL) and PBS-buffer (3 × 400 µL). Finally beads were suspended in 1 mM 
NaN3-PBS-buffer, pH = 7.4 (400 µL) and stored at 4 °C.  
 
 
 
    234                                               233                                                                             235 
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5 Synthetic Procedures 
5.1 General 
Unless otherwise noted, all reactions were performed in oven-dried glassware. Petroleum ether 
with a boiling range of 40–60 °C was used. Reactions were generally run under argon atmosphere. 
All commercially available compounds (Acros, Aldrich, Fluka, Merck, ABCR) were used without 
purification. Cotarnine iodide was purchased from ZereneX Molecule Ltd. Additional cotarnine 
derivatives were purchased from InterBioScreen Ltd. 1H and 13C NMR: Varian Mercury 400 (1H-, 
400 MHz; 13C-, 101 MHz) or Bruker Avance DRX 500 (1H-, 500 MHz; 13C-, 126 MHz) Varian Unity 
Inova 600 (1H-, 600 MHz; 13C-, 126 MHz), spectra were recorded at 295 K; chemical shifts are 
calibrated to the residual proton and carbon resonance of the solvent: CDCl3 (δH 7.26, δC 77.0 
ppm), CD3OD (δH 3.31, δC 49.0 ppm), DMSO-d6 (δH 2.50, δC 39.5 ppm). Data are represented as 
follows: chemical shift (multiplicity [br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet], integration, coupling constants in Hz). Preparative chiral HPLC was conducted using a 
Dionex HPLC system (UltiMate 3000 preparative) with a Chiralpak® IC column (cellulose tris(3,5-
dichlorophenylcarbamate) immobilized on 5 µm silica gel). Melting points: Büchi Melting Point B-
450, uncorrected. HRMS (ESI): LTQ Orbitrap with flow injection (H2O/MeCN = 1:1, 0.1% HCO2H, 
flow rate: 250 µL/min) Flash chromatography: Acros silica gel 35–70 µm. Thin-layer 
chromatography: Merck silica gel 60 F254 on aluminium plate. Optical rotations: Schmidt + Haensch 
Polartronic HH8, sodium D line (589 nm), c = g per 100 mL.  
5.2 Synthesis  
General procedure I: preparation of substituted phenethylcarbamates  
To a solution of phenylethylamine (1 equiv) and Hünigs base (1 equiv) in dry diethyl ether (40 mL) 
was added dropwise and under ice-cooling a solution of ethyl chloroformate (1 equiv) in diethyl 
ether (10 mL). A white precipitate formed immediately. After vigorous stirring for 2h at RT, the 
solution was filtered and the solvent was removed under reduced pressure. The colourless 
crystalline residue was redissolved in ether (50 mL) and extracted with water (50 mL), brine (50 
mL) and dried with MgSO4, filtered and evaporated to dryness. 
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Ethyl 4-methoxyphenethylcarbamate (36) 
 
According to general procedure I, 4-methoxyphenethylamine 33 (4.84 mL, 33.0 mmol, 1 equiv) 
yielded 36 as a colourless solid (6.89 g, 93%). Rf = 0.35 (petroleum ether/ethyl acetate, 3:1); m. p. 
49-50 °C; 1H-NMR (400 MHz, CDCl3): δ = 1.21 (t, 3H, J = 7.3, OCH2CH3), 2.73 (t, 2H, J = 6.8, 
PhCH2), 3.38 (m, 2H, CH2NH), 3.77 (s, 3H, OMe), 4.08 (q, 2H, J = 7.3, OCH2CH3), 4.70 (br s, 1H, 
NH), 6.80 (d, 2H, J = 8.5, CHar), 7.09 (d, 2H, J = 8.5, CHar); 13C-NMR (101 MHz, CDCl3): δ = 14.6 
(OCH2CH3), 35.2 (PhCH2), 42.2 (CH2NH), 55.2 (OMe), 60.6 (OCH2CH3), 113.9 (2C, CHar), 129.6 
(2C, CHar), 130.7 (Cq), 156.5 (CO), 158.2 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for C12H18O3N 
224.12812, found 224.12807. 
Ethyl 3,4-dimethoxyphenethylcarbamate (37) 
 
According to general procedure I, 3,4-dimethoxyphenethylamine 34 (4.58 mL, 27.6 mmol, 1 equiv) 
yielded 37 as a yellow oil (4.52 g, 65%). Rf = 0.43 (petroleum ether/ethyl acetate, 1:1); 1H-NMR 
(400 MHz, CDCl3): δ = 1.31 (t, 3H, J = 7.3, OCH2CH3), 2.67 (t, 2H, J = 7.0, PhCH2), 3.30 (m, 2H, 
CH2NH), 3.76 (s, 3H, OMe), 3.77 (s, 3H, OMe), 4.01 (q, 2H, J = 7.3, OCH2CH3), 4.89 (br s, 1H, 
NH), 6.65-6.63 (m, 2H, CHar), 6.70-6.73 (m, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 14.4 
(OCH2CH3), 35.4 (PhCH2), 42.0 (CH2NH), 55.5 (OMe), 55.6 (OMe), 60.3 (OCH2CH3), 111.0 (CHar), 
111.6 (CHar), 120.4 (CHar), 131.1 (Cq), 147.3 (Cq-OMe), 148.6 (Cq-OMe), 156.4 (CO); HRMS (ESI): 
[M+H]+ calculated for C13H20O4N 254.13868, found 254.13869. 
Ethyl 4-bromophenethylcarbamate (38)  
 
According to general procedure I, 4-bromophenethylamine 35 (3.88 mL, 25.0 mmol, 1 equiv) 
yielded 38 as a colourless solid (6.58 g, 97%). Rf = 0.71 (petroleum ether/ethyl acetate, 1:2); m.p. 
77–78 °C; 1H-NMR (400 MHz, CDCl3): δ = 1.21 (t, 3H, J = 7.0, OCH2CH3), 2.76 (t, 2H, J = 6.8, 
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PhCH2), 3.40 (m, 2H, CH2NH), 4.09 (q, 2H, J = 7.0, OCH2CH3), 4.62 (br s, 1H, NH), 7.06 (d, 2H, J 
= 8.0, CHar), 7.42 (d, 2H, J = 8.0, CHar); 13C-NMR (101 MHz, CDCl3): δ = 14.6 (OCH2CH3), 35.6 
(PhCH2), 41.9 (CH2NH), 60.8 (OCH2CH3), 120.3 (Cq-Br), 130.5 (2C, CHar), 131.6 (2C, CHar), 137.8 
(Cq), 156.5 (CO); HRMS (ESI): [M+H]+ calculated for C11H15O2NBr 272.02807, found 272.02841. 
Analytical data were in accordance with literature.150 
General procedure II: preparation of substituted dihydroisoquinolinones (GP2) 
To a solution of the phenethylcarbamate (1 equiv) in POCl3 (1 g starting material in 5 mL POCl3) 
P2O5 (2 equiv) was added. The solution was heated to reflux for 2h. The reaction was quenched by 
slowly pouring into ice water (vigorous reaction!). The resulting mixture was basified with KOH and 
extracted with ethyl acetate. The combined organic phases were washed with water, brine and 
dried with MgSO4, filtered and the solvent was evaporated in vacuo. The crude product was 
absorbed on silica gel and purified via flash chromatography. 
7-Methoxy-3,4-dihydroisoquinolin-1(2H)-one (39) 
 
According to general procedure II, ethyl 4-methoxyphenethylcarbamate 36 (13.5 g, 60.5 mmol, 
1 equiv) yielded 39 as a colourless solid (5.2 g, 49%). Flash chromatography (petroleum 
ether/ethyl acetate, 1:2). Rf = 0.39 (ethyl acetate); m.p. 113-114 °C; 1H-NMR (400 MHz, CDCl3): δ 
= 2.93 (t, 2H, J = 6.8, PhCH2), 3.54 (dt, 2H, J1 = 6.8, J2 = 2.8, CH2N), 3.84 (s, 3H, OMe), 5.98 (br s, 
1H, NH), 7.00 (dd, 1H, J1 = 8.3, J2 = 3.0, 6-H), 7.12 (d, 1H, J = 8.3, 5-H), 7.58 (d, 1H, J = 3.0, 8-H); 
13C-NMR (101 MHz, CDCl3): δ = 26.9 (PhCH2), 39.8 (CH2N), 55.1 (OMe), 110.7 (CHar), 119.1 
(CHar), 128.1 (CHar), 129.5 (Cq), 130.9 (Cq), 158.3 (Cq-OMe), 166.7 (CO); HRMS (ESI): [M+H]+ 
calculated for C10H12O2N 178.08626, found 178.08603. Analytical data were in accordance with 
literature.151 
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6,7-Dimethoxy-3,4-dihydroisoquinolin-1(2H)-one (40) 
 
According to general procedure II, ethyl 3,4-dimethoxyphenethylcarbamate 37 (5.00 g, 19.7 mmol, 
1 equiv) yielded 40 as a colourless solid (1.64 g, 40%). Flash chromatography (petroleum 
ether/ethyl acetate, 1:4). Rf = 0.42 (acetone); m.p. 169-171 °C; 1H NMR (400 MHz, CDCl3): δ = 
2.82 (t, 2H, J = 6.8, PhCH2), 3.45-3.49 (m, 2H, CH2N), 3.83 (s, 6H, OMe), 6.59 (s, 1H, CHar), 7.35 
(br s, 1H, NH), 7.46 (s, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 27.7 (PhCH2), 40.1 (CH2N), 
55.8 (OMe), 55.8 (OMe), 109.4 (CHar), 109.7 (CHar), 121.2 (Cq), 132.5 (Cq), 147.6 (Cq-OMe), 151.8 
(Cq-OMe), 166.6 (CO); HRMS (ESI): [M+H]+ calculated for C11H14O3N 208.09682, found 
208.09674. Analytical data were in accordance with literature.152 
7-Bromo-3,4-dihydroisoquinolin-1(2H)-one (41) 
 
According to general procedure II, ethyl 4-bromophenethylcarbamate 38 (4.00 g, 14.7 mmol, 
1 equiv) yielded 41 as a slightly yellow solid (1.37 g, 41%). Flash chromatography (petroleum 
ether/ethyl acetate, 1:2). Rf = 0.36 (petroleum ether/ethyl acetate, 1:3); m.p. 47-49 °C; 1H-NMR 
(400 MHz, CDCl3): δ = 2.91 (t, 2H, J = 6.5, PhCH2), 3.54 (dt, 2H, J1 = 6.5, J2 = 3.0, CH2N), 7.08 (d, 
1H, J = 8.0, 5-H), 7.52 (dd, 1H, J1 = 8.0, J2 = 2.3, 6-H), 7.68 (br s, 1H, NH), 8.15 (d, 1H, J = 2.3, 8-
H); 13C-NMR (101 MHz, CDCl3): δ = 27.6 (PhCH2), 39.8 (CH2N), 120.8 (Cq-Br), 129.0 (CHar), 130.6 
(Cq), 130.7 (CHar), 134.9 (CHar), 137.6 (Cq), 165.5 (CO); HRMS (ESI): [M+H]+ calculated for 
C9H9BrNO 225.98620, found 225.98636. 
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tert-Butyl 1-oxo-3,4-dihydroisoquinoline-2(1H)-carboxylate (42) 
 
A solution of 3,4-dihydroisoquinolin-1(2H)-one66 (0.89 g, 6.05 mmol, 1 equiv) in anhydrous THF (18 
mL) was cooled to –78 °C and n-butyllithium (1.6 M in hexane, 3.80 mL, 3.40 mmol, 1 equiv) was 
added dropwise. After 30 min a solution of di-tert-butyl dicarbonate (1.32 g, 6.05 mmol, 1 equiv) in 
THF (3 mL) was added dropwise, and the reaction mixture was stirred at –78 °C until the reaction 
was complete as monitored via TLC (3h). The reaction was quenched with saturated aq. NH4Cl 
and the organic phase extracted with diethyl ether (3 × 50 mL), dried with MgSO4, filtered and the 
solvents were evaporated in vacuo to give the crude product, which was purified via flash 
chromatography (petroleum ether/ethyl acetate, 9:1) to afford 42 as a colourless solid (1.20 g, 
80%). Rf = 0.29 (petroleum ether/diethyl ether, 4:1); m.p. 69-71 °C; 1H-NMR (400 MHz, CDCl3): δ = 
1.49 (s, 9H, Boc-(CH3)3), 2.98-3.01 (m, 2H, PhCH2), 3.97-4.00 (m, 2H, CH2N), 7.19-7.21 (m, 1H, 
CHar), 7.32-7.36 (m, 1H, CHar), 7.44-7.48 (m, 1H, CHar), 8.15 (dd, 1H, J1 = 7.9, J2 = 1.5, CHar); 13C-
NMR (101 MHz, CDCl3): δ = 28.0 (Boc-(CH3)3), 28.2 (PhCH2), 44.3 (CH2N), 83.0 (Boc-Cq), 127.1 
(CHar), 129.2 (CHar), 128.5 (CHar), 132.7 (CHar), 139.4 (2C, Cq), 153.0 (Boc-CO), 163.8 (CO); 
HRMS (ESI): [M+H]+ calculated for C14H18O3N 248.12812, found 248.12824. 
tert-Butyl 7-methoxy-1-oxo-3,4-dihydroisoquinoline-2(1H)-carboxylate (43) 
 
A solution of 7-methoxy-3,4-dihydroisoquinolin-1(2H)-one (39) (50 mg, 28.0 mmol, 1 equiv) in THF 
(4 mL) was cooled to 0 °C and NaH (60% oil suspension, 12.4 mg, 31.0 mmol, 1.1 equiv) was 
added portion wise. The reaction mixture was stirred for 1h at this temperature and a solution of di-
tert-butyl dicarbonate (62 mg, 28.0 mmol, 1 equiv) in THF (1 mL) was added dropwise. The 
reaction mixture was warmed to RT overnight. Water was added and the aqueous phase was 
extracted with diethyl ether (3 × 30 mL). The combined organic fractions were washed with brine 
(30 mL), dried with MgSO4, filtered and the solvents were removed in vacuo. Flash 
chromatography (petroleum ether/diethyl ether, 4:1) yielded 43 as a colourless oil (70 mg, 89%). Rf 
= 0.45 (petroleum ether/ethyl acetate, 4:1); 1H-NMR (400 MHz, CDCl3): δ = 1.49 (s, 9H, Boc-
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(CH3)3), 2.82 (t, 2H, J = 6.3, PhCH2), 3.71 (s, 3H, OMe), 3.84-3.87 (m, 2H, CH2N), 6.91 (dd, 1H, J1 
= 8.3, J2 = 2.8, 6-H), 7.00 (d, 1H, J = 8.3, 5-H), 7.55 (d, 1H, J = 2.8, 8-H); 13C-NMR (101 MHz, 
CDCl3): δ = 27.1 (PhCH2), 27.8 (Boc-(CH3)3), 44.5 (CH2N), 55.1 (OMe), 82.8 (Boc-Cq), 111.9 
(CHar), 120.4 (CHar), 128.1 (CHar), 129.8 (Cq), 131.6 (Cq), 152.9 (Boc-CO), 158.4 (Cq-OMe), 163.6 
(CO); HRMS (ESI): [M+H]+ calculated for C15H20O4N 278.13868, found 278.13881. 
tert-Butyl 6,7-dimethoxy-1-oxo-3,4-dihydroisoquinoline-2-carboxylate (44) 
 
To a 0.5 M solution of 40 (76 mg, 0.37 mmol, 1 equiv) in DCM was added triethylamine (102 µL, 
0.73 mmol, 2 equiv), 4-dimethylaminopyridine (160 mg, 0.73 mmol, 2 equiv) and di-tert-butyl 
dicarbonate (160 mg, 0.73 mmol, 2 equiv), and the mixture was stirred at RT overnight. The 
solvents were evaporated in vacuo. Column purification (petroleum ether/ethyl acetate, 3:1) yielded 
44 as a colourless solid (79 mg, 70%). Rf = 0.33 (petroleum ether/ethyl acetate, 2:1); m.p. 116-119 
°C; 1H-NMR (400 MHz, CDCl3): δ = 1.54 (s, 9H, Boc-(CH3)3), 2.89 (t, 2H, J = 6.3, PhCH2), 3.86 (s, 
3H, OMe), 3.88 (s, 3H, OMe), 3.92-3.95 (m, 2H, CH2N), 6.60 (s, 1H, CHar), 7.60 (s, 1H, CHar); 13C-
NMR (101 MHz, CDCl3): δ = 27.9 (PhCH2), 28.0 (Boc-(CH3)3), 44.6 (CH2N), 55.9 (OMe), 82.9 (Boc-
Cq), 109.0 (CHar), 111.1 (CHar), 121.6 (Cq), 133.8 (Cq), 148.0 (Cq), 152.8 (Cq), 153.3 (Boc-CO), 
163.8 (CO); HRMS (ESI): [M+H]+ calculated for C16H22O5N 308.14965, found 308.14925. Analytical 
data were in accordance with literature.153 
tert-Butyl 7-bromo-1-oxo-3,4-dihydroisoquinoline-2(1H)-carboxylate (45) 
 
To a 0.5 M solution of 41 (176 mg, 0.78 mmol, 1 equiv) in DCM was added triethylamine (114 µL, 
0.82 mmol, 1.05 equiv), 4-dimethylaminopyridine (100 mg, 0.82 mmol, 1.05 equiv) and di-tert-butyl 
dicarbonate (178 mg, 0.82 mmol, 1.05 equiv), and the mixture was stirred at RT overnight. The 
solvents were evaporated in vacuo. Column purification (petroleum ether/diethyl ether, 4:1) yielded 
45 as a yellow solid (146 mg, 57%). Rf = 0.50 (petroleum ether/ethyl acetate, 4:1); m.p. 97-99 °C; 
1H-NMR (400 MHz, CDCl3): δ = 1.53 (s, 9H, Boc-(CH3)3), 2.92 (t, 2H, J = 6.1, PhCH2), 3.91-3.94 
(m, 2H, CH2N), 7.06 (d, 1H, J = 8.0, 5-H), 7.50-7.52 (m, 1H, 6-H), 8.21-8.22 (m, 1H, 8-H); 13C-NMR 
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(101 MHz, CDCl3): δ = 27.7 (PhCH2), 27.9 (Boc-(CH3)3), 44.1 (CH2N), 83.3 (Boc-Cq), 120.9 (Cq-Br), 
128.8 (CHar), 130.9 (Cq), 132.2 (CHar), 135.5 (CHar), 138.1 (Cq), 152.6 (Boc-CO), 162.4 (CO); 
HRMS (ESI): [M+H]+ calculated for C14H17O3NBr 326.03863, found 326.03879. 
2-Methyl-3,4-dihydroisoquinolin-1(2H)-one (46) 
 
To a solution of 3,4-dihydroisoquinolin-1(2H)-one66 (0.21 g, 1.42 mmol, 1 equiv) in anhydrous DMF 
(15 mL), sodium hydride (60% oil suspension; 60 mg, 1.49 mmol, 1.05 equiv) was added, the 
suspension stirred for 30 min at RT and methyl iodide (90 µL, 1.49 mmol; 1.05 equiv) was added 
dropwise to yield a clear solution immediately. The reaction mixture was stirred at RT overnight. 
The reaction was quenched by adding water (40 mL) and the aquous phase was extracted with 
ethyl acetate (3 × 20 mL). The combined organic fractions were dried with MgSO4, filtered and the 
solvent evaporated in vacuo to give the crude product, which was purified via flash 
chromatography (petroleum ether/ethyl acetate, 2:1) to afford 46 as a slightly yellow oil (146 mg, 
64%). Rf = 0.38 (petroleum ether/ethyl acetate, 1:2); 1H-NMR (400 MHz, CDCl3): δ = 2.84-2.87 (m, 
2H, PhCH2), 3.01 (s, 3H, NCH3), 3.40-3.43 (m, 2H, CH2N), 7.02-7.04 (m, 1H, CHar), 7.17-7.29 (m, 
2H, CHar), 7.95-7.97 (m, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 27.5 (PhCH2), 34.8 (NCH3), 
47.7 (CH2N), 126.6 (2C, CHar), 127.6 (CHar), 129.0 (Cq), 131.2 (CHar), 137.7 (Cq), 164.4 (CO); 
HRMS (ESI): [M+H]+ calculated for C10H12ON 162.09134, found 162.09100. 
2-Methyl-1,1-bis[(triisopropylsilyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline (47) 
 
By analogy to the literature68 to a solution of TIPS-acetylene (270 µL, 1.21 mmol, 3 equiv) in THF 
(1.5 mL) at –78 °C a solution of n-butyllithium (1.6 M in hexane, 0.76 mL, 1.21 mmol, 3 equiv) was 
added dropwise. After 10 min stirring, boron trifluoride etherate (0.33 mL, 1.21 mmol, 3 equiv) was 
added and stirring was continued for 10 min. Then a solution of 46 (75 mg, 0.47 mmol, 1 equiv) in 
THF (1 mL) was added to react for 30 min at that temperature. The reaction mixture was treated 
with lithium aluminiumhydride (18.5 mg, 0.49 mmol, 1.05 equiv) elevating the temperature to –10 
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°C over 2h. The reaction was quenched by adding a small amount of ethanol and the aluminium 
salts were precipitated by adding a saturated aqueous solution of sodium sulfate (5 mL). The water 
layer was extracted with diethyl ether (3 × 50 mL), the combined organic layers were washed with 
brine, dried with MgSO4, filtered and the solvents were evaporated under reduced pressure. Flash 
chromatography (petroleum ether/ethyl acetate, 12:1) yielded 47 as a colourless oil (56 mg, 37%). 
Rf = 0.40 (petroleum ether/ethyl acetate, 19:1); 1H-NMR (400 MHz, CDCl3): δ = 1.05 (s, 42H, TIPS-
CH(CH3)2), 2.71 (s, 3H, NCH3), 2.89-2.90 (m, 4H, PhCH, CH2N), 7.02-7.04 (m, 1H, CHar), 7.12-
7.19 (m, 2H, CHar), 7.73-7.76 (m, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 11.3 (TIPS-
CH(CH3)2), 18.6 (TIPS-CH(CH3)2), 28.7 (PhCH2), 41.2 (NCH3), 47.6 (CH2N), 58.5 (Cq), 85.6 (Cq 
alkyne), 106.2 (Cq alkyne), 125.8 (CHar), 127.0 (CHar), 128.4 (CHar), 128.5 (CHar), 133.4 (Cq), 137.3 
(Cq); HRMS (ESI): [M+H]+ calculated for C32H54NSi2 508.37893, found 508.37807. 
2-Methyl-1-[(triisopropylsilyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline (48) 
 
By analogy to the literature68 to a solution of TIPS-acetylene (108 µL, 0.49 mmol, 1.05 equiv) in 
THF (1.5 mL) at –78 °C a solution of n-butyllithium (1.6 M in hexane, 0.31 mL, 0.49 mmol, 1.05 
equiv) was added dropwise. After 10 min stirring, boron trifluoride etherate (0.13 mL, 0.49 mmol, 
1.05 equiv) was added and stirring was continued for 10 min. A solution of 46 (75 mg, 0.47 mmol, 
1 equiv) in THF (1 mL) was added and stirring was continued for 30 min at that temperature. The 
reaction mixture was treated with lithium aluminiumhydride (18.5 mg, 0.49 mmol, 1.05 equiv) 
elevating the temperature to –10 °C over 2h. The reaction was quenched by adding a small 
amount of ethanol and the aluminium salts were precipitated by adding a saturated aq. solution of 
sodium sulfate (5 mL). The water layer was extracted with diethyl ether (3 × 50 mL), the combined 
organic layers were washed with brine, dried with MgSO4, filtered and the solvents were 
evaporated in vacuo. Flash chromatography (petroleum ether/ethyl acetate, 12:1) yielded 47 as a 
colourless oil (56 mg, 37%). Flash chromatography (petroleum ether/ethyl acetate, 12:1) yielded 56 
mg (37%) of the target compound as a colourless oil. Rf = 0.29 (petroleum ether/diethyl ether, 4:1); 
1H-NMR (400 MHz, CDCl3): δ = 1.04 (s, 21H, TIPS-CH(CH3)2), 2.57 (s, 3H, NCH3), 2.64-2.99 (m, 
4H, PhCH2, CH2N), 4.52 (s, 1H, CH), 7.07-7.09 (m, 1H, CHar), 7.13-7.15 (m, 2H, CHar), 7.30-7.32 
(m, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 11.2 (TIPS-CH(CH3)2), 18.6 (TIPS-CH(CH3)2), 28.8 
(PhCH2), 43.6 (NCH3), 48.6 (CH2N), 57.2 (CH), 86.8 (Cq alkyne), 105.4 (Cq alkyne), 125.7 (CHar), 
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126.7 (CHar), 127.5 (CHar), 128.7 (CHar), 133.2 (Cq), 135.3 (Cq); HRMS (ESI): [M+H]+ calculated for 
C21H34NSi 328.24550, found 328.24517. 
General procedure III: preparation of alkynylated tetrahydroisoquinolines  
By analogy to the literature68 to a solution of TIPS-acetylene (3 equiv) in THF (1.5 mL) at –78 °C a 
solution of n-butyllithium (1.6 M in hexane, 3 equiv) was added dropwise. After 10 min stirring, 
boron trifluoride etherate (0.13 mL, 0.49 mmol, 1.05 equiv) was added and stirring was continued 
for 10 min. Then a solution of the corresponding lactam (1 equiv) in THF (1 mL) was added and 
stirring was continued for 30 min at that temperature. The excess alkynyl borane was quenched by 
addition of ethanol (2.5 equiv). The reaction mixture was treated with diisobutylaluminium hydride 
solution (1 M in toluene, 2.7 equiv), stirred for 1h at –78 °C and then 1h at –10 °C. The reaction 
was quenched by adding a saturated aqueous solution of Rochelle’s salt (5 mL) and allowed to 
warm to RT overnight. The water layer was extracted with diethyl ether (3 × 50 mL), the combined 
organic layers were washed with brine, dried with MgSO4, filtered and the solvents were 
evaporated in vacuo. 
tert-Butyl 1-[(triisopropylsilyl)ethynyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate (50) 
 
According to general procedure III, lactam 42 (200 mg, 0.81 mmol, 1 equiv) yielded 50 as a 
colourless oil (245 mg, 73%). Flash chromatography (petroleum ether/ethyl acetate, 49:1). Rf = 
0.43 (petroleum ether/ethyl acetate, 19:1); 1H-NMR (400 MHz, CDCl3): δ = 1.03 (s, 21H, TIPS-
CH(CH3)2), 1.51 (s, 9H, Boc-(CH3)3), 2.73-2.77 (m, 1H, PhCH), 2.86-2.96 (m, 1H, PhCH), 3.23-
3.36 (m, 1H, CHN), 4.06-4.30 (m, 1H, CHN), 5.77-5.95 (m, 1H, CH), 7.08-7.19 (m, 3H, CHar), 7.29-
7.31 (m, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 11.1 (TIPS-CH(CH3)2), 18.5 (TIPS-CH(CH3)2), 
28.4 (Boc-(CH3)3), 28.6 (PhCH2), 37.7 (CH2N), 47.7 (CH), 80.3 (Cq alkyne), 83.3 (Boc-Cq), 107.1 
(Cq alkyne), 126.2 (CHar), 126.9 (CHar), 127.5 (CHar), 128.9 (CHar), 133.9 (Cq), 146.5 (Cq), 154.2 
(Boc-CO); HRMS (ESI): [M+H]+ calculated for C20H40O2NSi 414.28222, found 414.28228. 
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tert-Butyl 7-methoxy-1-[(triisopropylsilyl)ethynyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(51) 
 
According to general procedure III, lactam 43 (285 mg, 1.03 mmol, 1 equiv) yielded 51 as a 
colourless oil (282 mg, 62%). Flash chromatography (petroleum ether/ethyl acetate, 49:1). Rf = 
0.47 (petroleum ether/ethyl acetate, 9:1); 1H-NMR (400 MHz, CDCl3): δ = 1.02 (s, 21H, TIPS-
CH(CH3)2), 1.49 (s, 9H, Boc-(CH3)3), 2.65-2.71 (m, 1H, PhCH), 2.80-2.88 (m, 1H, PhCH), 3.31-
3.17 (m, 1H, CHN) 3.76 (s, 3H, OMe), 4.16-4.29 (m, 1H, CHN), 5.75-5.91 (m, 1H, CH), 6.75 (dd, 
1H, J1 = 8.4, J2 = 2.5, 6-H), 6.84 (s, 1H, 8-H), 7.00 (d, 1H, J = 8.4, 5-H); 13C-NMR (101 MHz, 
CDCl3): δ = 11.1 (TIPS-CH(CH3)2), 18.5 (TIPS-CH(CH3)2), 27.8 (PhCH2), 28.3 (Boc-(CH3)3), 37.9 
(CH2N), 47.8 (CH), 55.2 (OMe), 80.3 (Cq), 83.0 (Boc-Cq), 107.0 (Cq alkyne), 111.4 (CHar), 114.2 
(CHar), 126.0 (Cq), 129.8 (CHar), 135.0 (Cq), 154.2 (Boc-CO), 157.9 (Cq-OMe); HRMS (ESI): [M+H]+ 
calculated for C26H42O3NSi 444.29285, found 444.29308. 
tert-Butyl 6,7-dimethoxy-1-[(triisopropylsilyl)ethynyl]-3,4-dihydroisoquinoline-2(1H)-
carboxylate (52) 
 
According to general procedure III, lactam 44 (79 mg, 0.26 mmol, 1 equiv) yielded 52 as a 
colourless oil (21 mg, 17%). Flash chromatography (petroleum ether/ethyl acetate, 9:1). Rf = 0.33 
(petroleum ether/ethyl acetate, 3:1); 1H-NMR (400 MHz, CDCl3): δ = 0.97 (s, 21H, TIPS-CH(CH3)2), 
1.46 (s, 9H, Boc-(CH3)3), 2.57-2.61 (m, 1H, PhCH), 2.77-2.85 (m, 1H, PhCH), 3.09-3.19 (m, 1H, 
CHN), 3.80 (s, 6H, OMe), 4.19-4.28 (m, 1H, CHN), 5.66-5.82 (m, 1H, CH), 6.53 (s, 1H, CHar), 6.76 
(s, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 10.9 (TIPS-CH(CH3)2), 18.4 (TIPS-CH(CH3)2), 28.1 
(PhCH2), 28.2 (Boc-(CH3)3), 37.5 (CH2N), 47.2 (CH), 55.6 (2C, OMe), 80.2 (Cq), 82.8 (Boc-Cq), 
94.7 (Cq), 107.2 (Cq), 109.8 (CHar), 111.0 (CHar), 125.7 (Cq), 147.5 (Cq-OMe), 147.8 (Cq-OMe), 
154.2 (Boc-CO); HRMS (ESI): [M+H]+ calculated for C27H44O4NSi 474.30341, found 474.30283. 
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tert-Butyl 7-bromo-1-[(triisopropylsilyl)ethynyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(53) 
NBoc
Br
TIPS
5
6
8
 
According to general procedure III, lactam 45 (145 mg, 0.44 mmol, 1 equiv) yielded 53 as a 
colourless oil (158 mg, 72%) of the target compound. Flash chromatography (petroleum ether/ethyl 
acetate, 49:1). Rf = 0.46 (petroleum ether/ethyl acetate, 9:1); 1H-NMR (400 MHz, CDCl3): δ = 1.01 
(s, 21H, TIPS-CH(CH3)2), 1.49 (s, 9H, Boc-(CH3)3), 2.69-2.73 (m, 1H, PhCH), 2.80-2.88 (m, 1H, 
PhCH), 3.28-3.38 (m, 1H, CHN), 4.08-4.21 (m, 1H, CHN), 5.73-5.92 (m, 1H, CH), 6.97 (d, 1H, 
J = 8.4, 5-H), 7.27 (dd, 1H, J1 = 8.5, J2 = 1.8, 6-H), 7.44 (s, 1H, 8-H); 13C-NMR (101 MHz, CDCl3): 
δ = 11.0 (TIPS-CH(CH3)2), 18.5 (TIPS-CH(CH3)2), 28.1 (PhCH2), 28.3 (Boc-(CH3)3), 37.4 (CH2N), 
47.2 (CH), 80.5 (Cq), 84.1 (Boc-Cq), 106.2 (Cq alkyne), 119.7 (Cq-Br), 130.1 (CHar), 130.3 (CHar), 
130.5 (CHar), 132.8 (Cq), 136.3 (Cq), 154.0 (Boc-CO); HRMS (ESI): [M+H]+ calculated for 
C25H39O2NBrSi 492.19280, found 492.19232. 
General procedure IV: TIPS-deprotection 
To a solution of TIPS-protected alkynylated tetrahydroisoquinoline in THF (5 mL) at 0 °C was 
added a solution of tetra-n-butylammonium fluoride (1 M in THF, 1.1 equiv) dropwise. The reaction 
mixture was stirred at RT for 20 min, after which saturated NaHCO3 solution was added and the 
aqueous phase was extracted with diethyl ether (3 × 30 mL). The combined organic fractions were 
washed with brine, dried with MgSO4, filtered and the solvent was removed in vacuo. Flash 
chromatography yielded the desired alkyne. 
tert-Butyl 1-ethynyl-7-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (54) 
 
According to general procedure IV, TIPS-protected alkynylated tetrahydroisoquinoline 51 (563 mg, 
1.27 mmol, 1 equiv) yielded 54 as a colourless oil (313 mg, 86%). Flash chromatography 
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(petroleum ether/ethyl acetate, 9:1). Rf = 0.34; 1H-NMR (400 MHz, CDCl3): δ = 1.49 (s, 9H, Boc-
(CH3)3), 2.31 (d, 1H, J = 2.5, CH alkyne), 2.67-2.72 (m, 1H, PhCH), 2.81-2.89 (m, 1H, PhCH), 3.18-
3.47 (m, 1H, CHN), 3.79 (s, 3H, OMe), 4.00-4.30 (m, 1H, CHN), 5.74-5.94 (m, 1H, CH), 6.76-6.82 
(m, 2H, CHar), 7.04 (d, 1H, J = 8.5, CHar); 13C-NMR (101 MHz, CDCl3): δ =27.6 (PhCH2), 28.4 (Boc-
(CH3)3), 38.7 (CH2N), 46.5 (CH), 55.3 (OMe), 70.9 (CH alkyne), 80.5 (Cq), 83.2 (Boc-Cq), 111.8 
(CHar), 114.1 (CHar), 126.0 (Cq), 130.0 (CHar), 134.7 (Cq), 154.1 (Boc-CO), 158.1 (Cq-OMe); HRMS 
(ESI): [M+H]+ calculated for C17H22O3N 288.15942, found 288.15955. 
tert-Butyl 1-ethynyl-6,7-dimethoxy-3,4-dihydroisoquinoline-2-carboxylate (55) 
 
According to general procedure IV, TIPS-protected alkynylated tetrahydroisoquinoline 52 (144 mg, 
0.30 mmol, 1 equiv) yielded 55 as a colourless oil (83 mg, 86%). Flash chromatography (petroleum 
ether/ethyl acetate, 9:1). Rf = 0.46 (petroleum ether/ethyl acetate, 2:1); 1H-NMR (400 MHz, CDCl3): 
δ = 1.48 (s, 9H, Boc-(CH3)3), 2.31 (d, 1H, J = 2.4, CH alkyne), 2.61-2.66 (m, 1H, PhCH), 2.80-2.88 
(m, 1H, PhCH), 3.18-3.40 (m, 1H, CHN), 3.82 (s, 3H, OMe), 3.85 (s, 3H, OMe), 4.05-4.29 (m, 1H, 
CHN), 5.67-5.87 (m, 1H, CH), 6.57 (s, 1H, CHar), 6.74 (s, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ 
= 27.9 (PhCH2), 28.3 (Boc-(CH3)3), 39.0 (CH2N), 45.6 (CH), 70.8 (CH alkyne), 80.4 (Cq), 83.3 (Boc-
Cq), 109.8 (CHar), 111.4 (CHar), 125.4 (Cq), 135.7 (Cq), 154.1 (Boc-CO); HRMS (ESI): [M+H]+ 
calculated for C18H24O4N 318.16998, found 318.17012. 
Alternatively 55 could also be synthesised from 81. To a solution of the free amine 81 (96 mg, 
0.44 mmol, 1 equiv) in DCM (7 mL) triethylamine (123 µL, 0.88 mmol, 2 equiv), 
4-dimethylaminopyridine (108 mg, 0.88 mmol, 2 equiv) and di-tert-butyl dicarbonate (193 mg, 0.88 
mmol, 2 equiv) were added. The mixture was stirred at RT overnight. The solvents were 
evaporated in vacuo. Flash chromatography afforded 55 as a colourless oil (75 mg, 53%).  
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tert-Butyl 1-ethynyl-7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate (56) 
 
According to general procedure IV, TIPS-protected alkynylated tetrahydroisoquinoline 53 (266 mg, 
0.54 mmol, 1 equiv) yielded 56 as a colourless solid (159 mg, 88%). Flash chromatography 
(petroleum ether/ethyl acetate, 9:1). Rf = 0.40; m.p. 129-130 °C; 1H-NMR (400 MHz, CDCl3): δ = 
1.48 (s, 9H, Boc-(CH3)3), 2.33 (d, 1H, J = 2.5, CH alkyne), 2.68-2.74 (m, 1H, PhCH), 2.80-2.88 (m, 
1H, PhCH), 3.15-3.40 (m, 1H, CHN), 4.05-4.29 (m, 1H, CHN), 5.74-5.93 (m, 1H, CH), 6.99 (d, 1H, 
J = 8.0, CHar), 7.30 (dd, 1H, J1 = 8.0, J2 = 1.8, CHar), 7.43 (d, 1H, J2 = 1.8, CHar); 13C-NMR (101 
MHz, CDCl3): δ = 27.9 (PhCH2), 28.3 (Boc-(CH3)3), 38.1 (CH2N), 45.9 (CH), 71.6 (CH alkyne), 80.8 
(Cq), 82.5 (Boc-Cq), 119.9 (Cq-Br), 130.2 (CHar), 130.4 (CHar), 130.7 (CHar), 132.9 (Cq), 135.6 (Cq), 
154.0 (Boc-CO); HRMS (ESI): [M+H]+ calculated for C16H19O2NBr 336.05937, found 336.05960. 
7-Methoxy-3,4-dihydroisoquinoline (58) 
 
A solution of lithium aluminium hydride in THF (1 M, 13.0 mmol, 14.7 mL, 1.3 equiv) was slowly 
added to a solution of 7-methoxy-3,4-dihydroisoquinolin-1(2H)-one 39 (2.00 g, 10.0 mmol, 1 equiv) 
in anhydrous THF (50 mL). The mixture was heated to reflux for 2h and subsequently quenched by 
sequential addition of water (20 mL) and 3 N NaOH (20 mL). The reaction mixture was filtered and 
the residue was washed with acetone (2 × 50 mL) and diethyl ether (2 × 50 mL). The combined 
organic/aqueous mixture was concentrated to 1/3 of the volume under reduced pressure and 
acidified using 3 N HCl. The mixture was washed with diethyl ether (2 × 30 mL) and basified with 
solid KOH. The basic aqueous fraction was extracted with diethyl ether (5 × 50 mL). The combined 
organic fractions were washed with brine (30 mL), dried with MgSO4, filtered and the solvents were 
removed in vacuo to give 1.4 g (8.6 mmol). Without further purification the residue was dissolved in 
DCM (45 mL) and N-bromosuccinimide (1.68 g, 9.4 mmol, 1.1 equiv) was added portion wise over 
20 min. After the addition was complete, the mixture was allowed to react for 30 min. Aq. NaOH 
(15 mL of a 30% aqueous solution) was added and stirring was continued for 1h at RT. The 
organic layer was separated, washed with water (20 mL) and the product was extracted with 4N 
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HCl (2 × 20 mL). The combined acidic extracts were washed with DCM and basified (pH = 9) with 
concentrated ammonia solution and the aqueous phase was extracted with DCM. The combined 
organic fractions were washed with brine (30 mL), dried with MgSO4, filtered and the solvents were 
removed in vacuo to give 58 as a yellow oil (1.10 g, 68%). Rf = 0.30 (dichloromethane/methanol, 
19:1); 1H-NMR (400 MHz, CDCl3): δ = 2.68-2.72 (m, 2H, PhCH2), 3.77-3.81 (m, 2H, CH2N), 3.84 (s, 
3H, OMe), 6.85 (d, 1H, J = 2.5, 8-H), 6.95 (dd, 1H, J1 = 8.2, J2 = 2.5, 6-H), 7.09 (d, J = 8.2, 5-H), 
8.33 (s, 1H, H-imine); 13C-NMR (101 MHz, CDCl3): δ = 23.9 (PhCH2), 47.6 (CH2N), 55.1 (OMe), 
112.0 (CHar), 116.4 (CHar), 127.9 (Cq), 128.0 (CHar), 128.8 (Cq), 158.4 (Cq-OMe), 159.9 (C-imine); 
HRMS (ESI): [M+H]+ calculated for C10H12ON 162.09134, found 162.09140. 
6-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3,4-dihydroisoquinoline (236) 
 
To a solution of 7-hydroxy-6-methoxy-3,4-dihydroisoquinoline 319 (120 mg, 0.68 mmol, 1 equiv) in 
DMF (10 mL) was added tosyl-alcohol 239 (290 mg, 1.06 mmol, 1.56 equiv), Cs2CO3 (196 mg, 
1.02 mmol, 1.50 equiv) and KI (22.5 mg, 0.14 mmol, 0.2 equiv). The reaction was stirred at 70 °C 
for 2d. The solvents were evaporated in vacuo. The residue was diluted with water, extracted with 
DCM and the combined organic fractions washed with saturated aq. Na2CO3 and brine, before 
being dried with MgSO4 and the solvents were evaporated in vacuo. The residue was purified by 
flash chromatography (gradient from 3% to 8% of MeOH/DCM) to give 236 as a slightly yellow oil 
(123 mg, 65%). Rf = 0.33 (10% MeOH/DCM); 1H-NMR (400 MHz, CDCl3): δ = 2.65 (t, 2H, PhCH2), 
3.34 (s, 3H, OMe), 3.52-3.54 (m, 2H, CH2), 3.67-3.71 (m, 4H, CH2), 3.83-3.85 (m, 5H, OMe, CH2), 
4.16 (t, 2H, J = 5.1, CH2), 6.63 (s, 1H, CHar), 6.86 (s, 1H, CHar), 8.19 (s, 1H, CH-imine); 13C-NMR 
(101 MHz, CDCl3): δ = 24.7 (PhCH2), 46.9 (CH2N), 55.9 (OMe), 58.9 (OMe), 69.9 (CH2), 69.6 
(CH2), 70.7 (CH2), 71.9 (CH2), 110.7 (CHar), 113.5 (CHar), 121.2 (Cq), 130.5 (Cq), 147.0 (Cq), 152.2 
(Cq), 159.7 (CH-imine); HRMS (ESI): [M+H]+ calculated for C15H22O4N 280.15433, found 
280.15443. 
General procedure V: preparation of alkynylated tetrahydroisoquinolines via Sonogashira 
coupling 
To a solution of the corresponding alkyne (1 equiv) and aryliodide (1.2 equiv) in THF (50 mg alkyne 
in 3 mL), copper(I) iodide (0.1 equiv) and triethylamine (2 equiv) were added and the resulting 
mixture was degassed for 30 min. Tetrakis(triphenylphosphine)palladium(0) (0.05 equiv) was 
added and the reaction mixture was stirred overnight at RT. The solvents were removed in vacuo, 
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and the residue was purified by flash chromatography. The resulting material was subsequently 
dissolved in 5% HCl in methanol (1 mL) and stirred overnight. The solvents were removed in vacuo 
and the residue was washed several times with petroleum ether and diethyl ether to give the 
desired target compound. 
General procedure VI: preparation of alkynylated tetrahydroisoquinolines via imine 
alkynylation 
A solution of the corresponding 3,4-dihydroisoquinoline in THF (70 mg dihydroisoquinoline in 1 mL) 
was cooled to 0 °C, trimethylsilyl trifluoromethanesulfonate (1.05 equiv) was added dropwise and 
the reaction mixture was stirred for 2h. In a separate flask a solution of the acetylene (6 equiv) in 
THF (1 mL) was also cooled to 0 °C and isopropyl magnesium chloride (6 equiv) was added 
dropwise. After 10 min stirring this reaction mixture was transferred to the iminium salt/THF 
suspension. The resulting solution was stirred at 0 °C for 1h and then warmed to RT within 1h. The 
reaction was quenched by the addition of MeOH and the solvents were evaporated in vacuo. The 
residue was purified via flash chromatography. 
1-[(3-methoxyphenyl)ethynyl]-1,2,3,4-tetrahydroisoquinolinium chloride (73) 
 
According to general procedure V, 3,4-dihydroisoquinoline72 yielded 73 as a slightly yellow solid 
(25 mg, 16%). m.p. 155-157 °C; Rf = 0.32 (petroleum ether/ethyl acetate, 1:2); 1H-NMR (500 MHz, 
CD3OD): δ = 3.14-3.25 (m, 2H, PhCH2), 3.43 (br s, 1H, NH), 3.56-3.61 (m, 1H, CHN), 3.70-3.75 
(m, 1H, CHN), 3.78 (s, 3H, OMe), 5.80 (s, 1H, CH), 7.00 (dd, 1H, J1 = 8.4, J2 = 2.7, CHar) 7.04-7.05 
(m, 1H, CHar), 7.09 (d, 1H, J = 7.7, CHar), 7.27-7.30 (m, 2H, CHar), 7.34-7.38 (m, 2H, CHar), 7.54-
7.56 (m, 1H, CHar); 13C-NMR (126 MHz, CD3OD): δ = 25.9 (PhCH2), 41.3 (CH2N), 48.8 (CH), 55.9 
(OMe), 83.0 (Cq alkyne), 89.7 (Cq alkyne), 116.9 (CHar), 118.1 (CHar), 123.2 (Cq), 125.3 (CHar), 
128.4 (CHar), 128.6 (CHar), 130.2 (CHar), 130.3 (CHar), 130.5 (Cq), 130.9 (CHar), 132.3 (Cq), 161.1 
(Cq-OMe); HRMS (ESI): [M+H]+ calculated for C18H18ON 264.13829, found 264.13840. 
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1-Ethynyl-7-methoxy-1,2,3,4-tetrahydroisoquinolinium chloride (74) 
 
General procedure VI was modified as follows, dihydroisoquinoline 58 (70 mg, 0.43 mmol, 1 equiv) 
and ethynylmagnesium bromide (0.5 M in THF, 2.61 mL, 1.3 mmol, 3 equiv) yielded 74 as a 
slightly yellow wax (97 mg, 99%). Rf = 0.30 (ethylacetate); 1H-NMR (400 MHz, CD3OD): δ = 2.95-
3.07 (m, 2H, PhCH2), 3.26 (br s, 1H, NH), 3.41 (s, 1H, CH alkyne), 3.43-3.49 (m, 1H, CHN), 3.54-
3.63 (m, 1H, CHN), 3.74 (s, 3H, OMe), 5.48 (s, 1H, CH), 6.88 (d, 1H, J
 
= 8.0, CHar), 6.94 (s, 1H, 
CHar), 7.13 (d, 1H, J = 8.0, CHar); 13C-NMR (101 MHz, CD3OD): δ = 25.0 (PhCH2), 41.4 (CH2N), 
48.4 (CH), 55.9 (OMe), 78.0 (Cq alkyne), 79.7 (Cq alkyne), 112.8 (CHar), 116.5 (CHar), 123.8 (2Cq), 
130.9 (Cq), 131.4 (CHar), 160.1 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for C12H14ON 
188.10699, found 188.10690. 
7-Methoxy-1-(phenylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (75) 
 
According to general procedure V and VI, 75 was obtained as a slightly yellow solid. (4 mg, 24% 
over 2 steps, general procedure V and 53 mg, 41%, general procedure VI). Preparative chiral 
HPLC of the free amine with a Chiralpak® IC column and 30% DCM/EtOH (100:2) in hexanes as 
eluent, a flow rate of 3 mL/min and detection at 254 nm delivered the two enantiomers. m.p. 50 °C 
(decomposition); Rf = 0.46 (ethyl acetate); 1H-NMR (400 MHz, CD3OD): δ = 3.08-3.14 (m, 2H, 
PhCH2), 3.50-3.58 (m, 1H, CHN), 3.67-3.74 (m, 1H, CHN), 3.81 (s, 3H, OMe), 5.77 (s, 1H, CH), 
6.96 (dd, 1H, J1 = 8.5, J2 = 2.5, CHar), 7.07 (d, 1H, J = 2.5, CHar), 7.21 (d, 1H, J = 8.5, CHar), 7.36-
7.43 (m, 3H, CHar), 7.51-7.53 (m, 2H, CHar); 13C-NMR (101 MHz, CD3OD): δ = 25.2 (PhCH2), 41.4 
(CH2N), 49.23 (CH), 55.9 (OMe), 83.2 (Cq alkyne), 89.7 (Cq alkyne), 113.0 (CHar), 116.5 (CHar), 
122.2 (Cq), 124.0 (Cq), 129.8 (2C, CHar), 130.8 (CHar), 131.5 (Cq), 131.5 (CHar), 133.0 (2C, CHar), 
160.4 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for C18H18ON 264.13829, found 264.13842. 
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tert-Butyl 7-methoxy-1-(phenylethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (237) 
 
According to general procedure VI, 237 was obtained as a slightly brown oil (24 mg, 45% general 
procedure VI without Boc deprotection). Column purification (petroleum ether containing 2% ethyl 
acetate). Rf = 0.34 (petroleum ether/ethyl acetate, 9:1); 1H-NMR (400 MHz, CD3Cl3): δ = 1.52 (s, 
9H, Boc-(CH3)3), 2.71-2.92 (m, 2H, PhCH2), 3.32-3.50 (m, 1H, CHN), 3.80 (s, 3H, OMe), 4.05-4.26 
(m, 1H, CHN), 6.05 (br s, 1H, CH), 6.79 (dd, 1H, J1 = 8.5, J2 = 2.5, CHar), 6.89 (d, 1H, J = 2.5, 
CHar), 7.06 (d, 1H, J = 8.5, CHar), 7.25-7.27 (m, 3H, CHar), 7.37-7.38 (m, 2H, CHar); 13C-NMR (101 
MHz, CD3Cl3): δ = 27.7 (PhCH2), 28.5 (Boc-(CH3)3), 38.4 (CH2N), 46.9 (CH), 55.4 (OMe), 80.4 (Cq 
alkyne), 82.8 (Cq alkyne), 88.7 (Boc-Cq), 112.0 (CHar), 113.9 (CHar), 122.9 (Cq), 125.5 (Cq), 126.1 
(Cq), 128.1 (2C, CHar), 129.9 (CHar), 131.8 (2C, CHar), 154.3 (Boc-CO), 160.4 (Cq-OMe); HRMS 
(ESI): [M+H]+ calculated for C23H26O3N 364.19072, found 364.19092. 
7-Methoxy-1-[2-(4-methoxyphenyl)-2-oxoethyl]-1,2,3,4-tetrahydroisoquinolinium chloride 
(238) 
 
General procedure V was modified as follows, alkyne hydrolysis occurred upon Boc-deprotection 
using DCM/TFA (1:1), thus 238 was obtained as a brown solid (10 mg, 18% over two steps). m.p. 
165-167 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.03-3.10 (m, 2H, PhCH2), 3.37-3.43 (m, 1H, CHN), 
3.54-3.60 (m, 1H, CHN), 3.75 (s, 3H, OMe), 3.82-3.85 (m, 2H, CH2), 3.88 (s, 3H, OMe), 5.10-5.12 
(m, 1H, CH), 6.87-6.89 (m, 2H, CHar), 7.04 (d, 2H, J = 9.0, CHar), 7.17 (d, 1H, J = 9.0, CHar), 8.06 
(d, 2H, J
 
= 9.0, CHar); 13C-NMR (101 MHz, CD3OD): δ = 25.7 (PhCH2), 40.7 (CH2N), 42.6 (CH2), 
52.9 (CH), 55.9 (OMe), 56.2 (OMe), 112.1 (CHar), 115.1 (CHar), 115.8 (CHar), 124.8 (Cq), 130.1 
(Cq), 131.4 (CHar), 131.9 (CHar), 133.8 (Cq), 160.3 (Cq-OMe), 166.0 (Cq-OMe), 197.2 (CO); HRMS 
(ESI): [M+H]+ calculated for C19H22O3N 312.15942, found 312.15954. 
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7-Methoxy-1-[(2-methoxyphenyl)ethynyl]-1,2,3,4-tetrahydroisoquinolinium chloride (76) 
 
According to general procedure VI, 76 was obtained as a yellow solid (61 mg, 43%). m.p. 56-58 
°C; Rf = 0.34 (petroleum ether/ethyl acetate, 1:2); 1H-NMR (400 MHz, DMSO-d6): δ = 2.97-3.06 (m, 
2H, PhCH2), 3.45-3.53 (m, 2H, CH2N), 3.76 (s, 3H, OMe), 3.83 (s, 3H, OMe), 5.85 (s, 1H, CH), 
6.94-6.99 (m, 2H, CHar), 7.06 (d, 1H, J = 2.3, CHar), 7.11 (d, 1H, J = 8.5, CHar), 7.20 (d, 1H, J = 8.5, 
CHar), 7.41-7.45 (m, 2H, CHar), 9.91 (br s, 1H, NH), 10.17 (br s, 1H, NH); 13C-NMR (101 MHz, 
CD3OD): δ = 24.1 (PhCH2), 40.2 (CH2N), 48.3 (CH), 54.4 (OMe), 54.8 (OMe), 84.5 (Cq alkyne), 
86.5 (Cq alkyne), 110.1 (Cq), 110.7 (CHar), 111.7 (CHar), 114.7 (CHar), 118.7 (Cq), 120.1 (CHar), 
123.0 (Cq), 129.9 (CHar), 130.7 (CHar), 132.9 (CHar), 158.7 (Cq-OMe), 160.6 (Cq-OMe); HRMS 
(ESI): [M+H]+ calculated for C19H20O2N 294.14886, found 294.14881. 
7-Methoxy-1-[(3-methoxyphenyl)ethynyl]-1,2,3,4-tetrahydroisoquinolinium chloride (77) 
N
O
H
H
O
Cl
 
According to general procedure V and VI, 77 was obtained as a slightly yellow solid (47 mg, 95% 
over 2 steps, general procedure V and 49 mg, 35%, general procedure VI). Preparative chiral 
HPLC of the free amine with a Chiralpak® IC column and 30% DCM/EtOH (100:2) in hexanes as 
eluent, a flow rate of 3 mL/min and detection at 254 nm delivered the two enantiomers. m.p. 166-
168 °C; Rf = 0.30 (MeOH/DCM, 1:19); 1H-NMR (400 MHz, CD3OD): δ = 3.05-3.18 (m, 2H, PhCH2), 
3.52-3.58 (m, 1H, CHN), 3.67-3.74 (m, 1H, CHN), 3.78 (s, 3H, OMe), 3.80 (s, 3H, OMe), 5.77 (s, 
1H, CH), 6.94-7.01 (m, 2H, CHar), 7.05-7.10 (m, 1H, CHar), 7.21 (d, 1H, J = 8.5, CHar), 7.27-7.31 
(m, 1H, CHar); 13C-NMR (101 MHz, CD3OD): δ = 25.1 (PhCH2), 41.4 (CH2N), 49.1 (CH), 55.9 (2C, 
OMe), 83.0 (Cq alkyne), 89.6 (Cq alkyne), 113.0 (CHar), 116.5 (CHar), 116.9 (CHar), 118.0 (CHar), 
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123.2 (Cq), 124.0 (Cq), 125.3 (CHar), 130.9 (CHar), 131.4 (Cq), 131.5 (CHar), 160.4 (Cq-OMe), 161.1 
(Cq-OMe); HRMS (ESI): [M+H]+ calculated for C19H20O2N 294.14886, found 294.14897. 
7-Methoxy-1-{[4-(trifluoromethyl)phenyl]ethynyl}-1,2,3,4-tetrahydroisoquinolinium chloride 
(78) 
 
 
According to general procedure V, 78 was obtained as a slightly yellow solid (46 mg, 72% over 2 
steps). m.p. 217-218 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.07-3.20 (m, 2H, PhCH2), 3.55-3.61 (m, 
1H, CHN), 3.69-3.76 (m, 1H, CHN), 3.81 (s, 3H, OMe), 5.85 (s, 1H, CH), 6.96 (dd, J1 = 8.5, J2 = 
2.5, 1H, CHar), 7.07 (d, 1H, J = 2.5, CHar), 7.22 (d, 1H, J = 2.5, CHar), 7.69-7.74 (m, 4H, CHar); 
13C-NMR (101 MHz, CD3OD): δ = 25.1 (PhCH2), 41.4 (CH2N), 48.4 (CH), 55.9 (OMe), 85.8 (Cq 
alkyne), 88.0 (Cq alkyne), 113.0 (CHar), 116.6 (CHar), 124.0 (Cq), 125.1 (q, J = 248, CF3), 126.4 
(Cq), 126.7 (q, 2C, J = 4, CHar), 131.0 (Cq), 131.6 (CHar), 132.2 (q, J = 32.0, Cq-CF3), 133.6 (2C, 
CHar), 160.4 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for C19H17ONF3 332.12568, found 
332.12568. 
7-Methoxy-1-(thiophene-3-ylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (79) 
 
According to general procedure V and VI, 79 was obtained as a slightly yellow solid (25 mg, 46% 
over 2 steps, general procedure V and 44 mg, 33%, general procedure VI). m.p. 205-207 °C; Rf = 
0.29 (petroleum ether/ethyl acetate, 1:2); 1H-NMR (400 MHz, CD3OD): δ = 3.06-3.13 (m, 2H, 
PhCH2), 3.51-3.57 (m, 1H, CHN), 3.66-3.73 (m, 1H, CHN), 3.80 (s, 3H, OMe), 5.76 (s, 1H, CH), 
6.95 (dd, 1H, J1 = 8.3, J2 = 2.8, CHar), 7.04-7.05 (m, 1H, CHar), 7.18-7.21 (m, 2H, CHar), 7.47 (dd, 
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1H, J1 = 5.0, J2 = 3.0, CHar), 7.75 (dd, 1H, J1 = 3.0, J2 = 1.0, CHar); 13C-NMR (101 MHz, CD3OD): δ 
= 25.1 (PhCH2), 41.3 (CH2N), 49.2 (CH), 55.9 (OMe), 82.8 (Cq alkyne), 85.1 (Cq alkyne), 113.0 
(CHar), 116.5 (CHar), 121.2 (Cq), 124.0 (Cq), 127.5 (CHar), 130.7 (CHar), 131.4 (Cq), 131.5 (CHar), 
132.3 (CHar), 160.3 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for C16H16ONS 270.09471, found 
270.09479. 
7-Methoxy-1-(pyridine-3-ylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (80) 
 
According to general procedure V, 80 was obtained as a brown solid (12 mg, 46% over 2 steps). 
m.p. 139-140 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.12-3.16 (m, 2H, PhCH2), 3.59-3.65 (m, 1H, 
CHN), 3.73-3.79 (m, 1H, CHN), 3.81 (s, 3H, OMe), 5.95 (s, 1H, CH), 6.97 (dd, 1H, J1 = 8.5, 
J2 = 2.5, CHar), 7.08 (d, 1H, J = 2.5, CHar), 7.23 (d, 1H, J = 8.5, CHar), 8.1 (dd, 1H, J1 = 8.0, J2 = 
5.5, CHar), 8.73 (d, 1H, J = 8.0, CHar), 8.90 (d, 1H, J = 5.5, CHar), 9.14 (s, 1H, CHar); 13C-NMR (101 
MHz, CD3OD): δ = 25.1 (PhCH2), 41.4 (CH2N), 48.7 (CH), 56.0 (OMe), 82.7 (Cq alkyne), 90.8 (Cq 
alkyne), 113.2 (CHar), 116.7 (CHar), 123.2 (Cq), 124.1 (Cq), 128.5 (CHar), 130.2 (Cq), 131.7 (2C, 
CHar), 143.6 (CHar), 146.4 (CHar), 149.7 (CHar), 160.4 (Cq-OMe); HRMS (ESI): [M+H]+ calculated 
for C17H17ON2 265.13354, found 265.13364. 
1-Ethynyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinium chloride (81) 
 
General procedure VI was modified as follows, dihydroisoquinoline 59 (70 mg, 0.37 mmol, 1 equiv) 
and ethynylmagnesium bromide (0.5 M in THF, 2.2 mL, 1.1 mmol, 3 equiv) yielded 81 as a slightly 
yellow solid (44 mg, 47%). m.p. 190 °C (decomposition); Rf = 0.17 (ethyl acetate); 1H-NMR (400 
MHz, CD3OD): δ = 2.92-3.06 (m, 2H, PhCH2), 3.24 (br s, 1H, NH), 3.36 (s, 1H, H-alkyne), 3.39-
3.45 (m, 1H, CHN), 3.51-3.60 (m, 1H, CH2N), 3.68 (s, 6H, OMe), 5.32 (s, 1H, CH), 6.68 (s, 1H, 
CHar), 6.82 (s, 1H, CHar); 13C-NMR (101 MHz, CD3OD): δ = 24.1 (PhCH2), 39.9 (CH2N), 46.8 (CH), 
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55.3 (2C, OMe), 76.9 (Cq alkyne), 78.2 (Cq alkyne), 109.7 (CHar), 111.5 (CHar), 120.3 (Cq), 123.1 
(Cq), 148.4 (Cq-OMe), 149.7 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for C13H16O2N 218.11756, 
found 218.11753. 
6,7-Dimethoxy-1-(phenylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (82) 
 
According to general procedure V and VI, 82 was obtained as a slightly yellow solid (6 mg, 15% 
over 2 steps, general procedure V and 57 mg, 35%, general procedure VI). Preparative chiral 
HPLC of the free amine with a Chiralpak® IC column and 60% DCM/EtOH (100:2) in hexanes as 
eluent, a flow rate of 3 mL/min and detection at 254 nm delivered the two enantiomers. m.p. 240 
°C (decomposition); Rf = 0.25 (ethyl acetate); 1H-NMR (400 MHz, CD3OD): δ = 3.06-3.17 (m, 2H, 
PhCH2), 3.51-3.58 (m, 1H, CHN), 3.68-3.74 (m, 1H, CHN), 3.83 (s, 3H, OMe), 3.84 (s, 3H, OMe), 
5.71 (s, 1H, CH), 6.85 (s, 1H, CHar), 7.05 (s, 1H, CHar), 7.36-7.42 (m, 3H, CHar), 7.50-7.52 (m, 2H, 
CHar); 13C-NMR (101 MHz, CD3OD): δ = 25.5 (PhCH2), 41.2 (CH2N), 48.2 (CH), 56.5 (OMe), 56.6 
(OMe), 83.5 (Cq alkyne), 89.5 (Cq alkyne), 111.2 (CHar), 112.9 (CHar), 122.2 (Cq), 122.3 (Cq), 124.6 
(Cq), 129.8 (CHar), 130.8 (CHar), 133.0 (CHar), 150.0 (Cq-OMe), 151.2 (Cq-OMe); HRMS (ESI): 
[M+H]+ calculated for C19H20O2N 294.14886, found 294.14891. 
6,7-Dimethoxy-1-[(2-methoxyphenyl)ethynyl]-1,2,3,4-tetrahydroisoquinolinium chloride (83)  
 
According to general procedure VI, 83 was obtained as a yellow wax (13 mg, 10%). Rf = 0.31 (8% 
MeOH/DCM); 1H-NMR (600 MHz, CD3OD): δ = 3.05-3.17 (m, 2H, PhCH2), 3.43 (br s, 1H, NH), 
3.49-3.55 (m, 1H, CHN), 3.67-3.74 (m, 1H, CHN), 3.83 (s, 3H, OMe), 3.84 (s, 3H, OMe), 3.85 (s, 
3H, OMe), 5.68 (s, 1H, CH), 6.83 (s, 1H, CHar), 6.92-6.95 (m, 1H, CHar), 7.03 (d, 1H, J = 8.2, CHar), 
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7.11 (m, 1H, CHar), 7.37-7.42 (m, 2H, CHar); 13C-NMR (151 MHz, CD3OD): δ = 25.5 (PhCH2), 41.4 
(CH2N), 48.2 (CH), 56.3 (OMe), 56.3 (OMe), 56.7 (OMe), 62.6 (Cq alkyne), 87.1 (Cq alkyne), 111.3 
(Cq), 111.5 (CHar), 112.2 (CHar), 112.9 (CHar), 121.6 (CHar), 122.5 (Cq), 124.7 (Cq), 132.4 (CHar), 
134.5 (CHar), 150.0 (Cq-OMe), 151.2 (Cq-OMe), 162.1 (Cq-OMe); HRMS (ESI): [M+H]+ calculated 
for C20H22O3N 324.15942, found 324.15959. 
6,7-Dimethoxy-1-[(3-methoxyphenyl)ethynyl]-1,2,3,4-tetrahydroisoquinolinium chloride (84) 
 
According to general procedure V and VI, 84 was obtained as a slightly yellow solid (6 mg, 31% 
over 2 steps, general procedure V and 119 mg, 90% general procedure VI). Preparative chiral 
HPLC of the free amine with a Chiralpak® IC column and 50% DCM/EtOH (100:2) in hexanes as 
eluent, a flow rate of 3 mL/min and detection at 254 nm delivered the two enantiomers. m.p. 180-
182 °C; Rf = 0.36 (8% MeOH/DCM); 1H-NMR (400 MHz, CD3OD): δ = 3.05-3.17 (m, 2H, PhCH2), 
3.51-3.57 (m, 1H, CHN), 3.68-3.74 (m, 1H, CHN), 3.78 (s, 3H, OMe), 3.84 (s, 6H, 2OMe), 5.70 (s, 
1H, CH), 6.84 (s, 1H, CHar), 6.98-7.09 (m, 4H, CHar), 7.27-7.31 (m, 1H, CHar); 13C-NMR (101 MHz, 
CD3OD): δ = 25.5 (PhCH2), 41.2 (CH2N), 51.0 (CH), 55.9 (OMe), 56.6 (OMe), 83.2 (Cq alkyne), 
89.5 (Cq alkyne), 111.2 (CHar), 112.9 (CHar), 116.8 (CHar), 118.1 (CHar), 122.2 (Cq), 123.3 (Cq), 
124.6 (Cq), 125.3 (CHar), 131.0 (CHar), 150.1 (Cq-OMe), 151.3 (Cq-OMe), 161.1 (Cq-OMe); HRMS 
(ESI): [M+H]+ calculated for C20H22O3N 324.15942, found 324.15950. 
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6,7-Dimethoxy-1-{[4-(trifluoromethyl)phenyl]ethynyl}-1,2,3,4-tetrahydroisoquinolinium 
chloride (85) 
 
According to general procedure V, 85 was obtained as a slightly yellow solid (29 mg, 71% over 2 
steps). m.p. 207-208 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.11-3.18 (m, 2H, PhCH2), 3.55-3.61 (m, 
1H, CHN), 3.69-3.76 (m, 1H, CHN), 3.84 (s, 6H, OMe), 5.78 (s, 1H, CH), 6.86 (s, 1H, CHar), 7.05 
(s, 1H, CHar), 7.68-7.73 (m, 4H, CHar); 13C-NMR (101 MHz, CD3OD): δ = 25.5 (PhCH2), 41.1 
(CH2N), 48.4 (CH), 56.5 (OMe), 56.7 (OMe), 86.1 (Cq alkyne), 87.9 (Cq alkyne), 111.2 (CHar), 112.9 
(CHar), 121.8 (Cq), 124.8 (Cq), 125.2 (q, J = 296, CF3), 126.6 (2C, CHar), 132.2 (q, J = 32.0, 
Cq-CF3), 133.6 (2C, CHar), 132.4 (Cq), 150.0 (Cq-OMe), 151.3 (Cq-OMe); HRMS (ESI): [M+H]+ 
calculated for C20H19O2NF3 362.13624, found 362.13629. 
6,7-Dimethoxy-1-(thiophen-3-ylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (86) 
 
According to general procedure VI, 86 was obtained as a slightly yellow solid (83 mg, 68%). m.p. 
190 °C (decomposition); Rf = 0.38 (8% MeOH/DCM); 1H-NMR (400 MHz, DMSO-d6): δ = 2.96-3.01 
(m, 2H, PhCH2), 3.43-3.49 (m, 2H, CH2N), 3.74 (s, 3H, OMe), 3.75 (s, 3H, OMe), 5.72 (s, 1H, CH), 
6.83 (s, 1H, CHar), 6.95 (s, 1H, CHar), 7.21 (dd, 1H, J1 = 5.0, J2 = 1.1, CHar), 7.65 (dd, 1H, J1 = 5.0, 
J2 = 2.8, CHar), 7.92 (dd, 1H, J1 = 2.8, J2 = 1.1, CHar), 9.94 (br s, 1H, NH), 10.20 (br s, 1H, NH); 
13C-NMR (101 MHz, CD3OD): δ = 25.5 (PhCH2), 41.1 (CH2N), 48.9 (CH), 55.6 (OMe), 56.7 (OMe), 
82.9 (Cq alkyne), 84.9 (Cq alkyne), 111.1 (CHar), 112.8 (CHar), 121.1 (Cq), 122.1 (Cq), 124.5 (Cq), 
127.4 (CHar), 130.6 (CHar), 132.2 (CHar), 149.8 (Cq-OMe), 151.0 (Cq-OMe); HRMS (ESI): [M+H]+ 
calculated for C17H18O2NS 300.10528, found 300.10528. 
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2-(2-Methoxyethoxy)ethyl tosylate (239) 
 
To a solution of 2-(2-methoxyethoxy)ethanol (0.75 mL, 6.3 mmol, 1.2 equiv) in pyridine (5 mL), 
tosyl chloride (1 g, 5.3 mmol, 1 equiv) was added under ice cooling. The mixture was stirred at RT 
for 2h. The mixture was diluted with water and extracted with ethyl acetate (3 × 30 mL). The 
combined organic fractions were washed with saturated aq. Na2CO3 solution and brine, dried with 
MgSO4, filtered and the solvents were evaporated in vacuo to yield 239 as a colourless oil (1.1 g, 
79%). Rf = 0.46 (petroleum ether/ethyl acetate, 1:1); 1H-NMR (500 MHz, CDCl3): δ = 2.39 (s, 
3H,Tos-CH3), 3.28-3.29 (m, 3H, OMe), 3.41-3.43 (m, 2H, CH2), 3.51-3.52 (m, 2H, CH2), 3.62-3.64 
(m, 2H, CH2), 4.10-4.12 (m, 2H, CH2), 7.29 (d, 2H, J = 7.9, Tos-CHar), 7.73-7.75 (m, 2H, Tos-CHar); 
13C-NMR (126 MHz, CDCl3): δ = 21.4 (Tos-CH3), 58.8 (OMe), 68.5 (CH2), 69.1 (CH2), 70.5 (CH2), 
71.6 (CH2), 127.8 (2 Tos-CHar), 129.7 (2 Tos-CHar), 132.9 (Tos-Cq), 144.7 (Tos-Cq); HRMS (ESI): 
calculated for [M+H]+ C12H19O5S 275.09477, found 275.09501. 
1-Ethynyl-3-[2-(2-methoxyethoxy)ethoxy]benzene (240) 
 
To a solution of 3-hydroxyphenylacetylene (0.3 mL, 2.75 mmol, 1 equiv) in DMF (10 mL) tosylate 
239 (1.10 g, 4.13 mmol, 1.5 equiv), Cs2CO3 (0.8 g, 4.13 mmol, 1.5 equiv) and KI (91 mg, 0.55 
mmol, 0.2 equiv) were added. The reaction mixture was stirred at 70 °C overnight. The solvents 
were evaporated in vacuo, the residue was dissolved in water and extracted with ethyl acetate (3 × 
30 mL). The combined organic fractions were washed with brine, dried with MgSO4 and the 
solvents were evaporated in vacuo. The residue was purified via flash chromatography (petroleum 
ether/ethyl acetate, 12:1) to give 241 as a colourless oil (441 mg, 73%). Rf = 0.46 (petroleum 
ether/ethyl acetate, 3:1); 1H-NMR (500 MHz, CDCl3): δ = 3.04 (s, 1H, CH alkyne), 3.36 (m, 3H, 
OMe), 3.54-3.56 (m, 2H, CH2), 3.68-3.70 (m, 2H, CH2), 3.81-3.83 (m, 2H, CH2), 4.09-4.11 (m, 2H, 
CH2), 6.90 (dd, J1 = 8.2, J2 = 2.5, CHar), 7.01 (br s, 1H, CHar), 7.06 (d, 1H, J = 7.3, CHar), 7.17-7.20 
(m, 1H, CHar); 13C-NMR (126 MHz, CDCl3): δ = 59.0 (OMe), 67.4 (CH2), 69.6 (CH2), 70.7 (CH2), 
71.9 (CH2), 76.9 (CH alkyne), 83.4 (Cq alkyne), 115.9 (CHar), 117.7 (CHar), 123.0 (Cq), 124.7 
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(CHar), 129.3 (CHar), 158.4 (Cq-O); HRMS (ESI): calculated for [M+H]+ C13H17O3S 221.11722, found 
221.11731. 
6,7-dimethoxy-1-({3-[2-(2-methoxyethoxy)ethoxy]phenyl}ethynyl)-1,2,3,4-
tetrahydroisoquinolinium chloride (87) 
 
General procedure VI was modified as follows, dihydroisoquinoline 59 and alkyne 240 (3 equiv) 
yielded 87 as a slightly yellow solid (27 mg, 16%). m.p. 99-100 °C; Rf = 0.33 (MeOH/DCM, 1:10); 
1H-NMR (600 MHz, CD3OD): δ = 3.07-3.15 (m, 2H, PhCH2), 3.34 (s, 3H, OMe), 3.52-3.57 (m, 3H, 
CHN, CH2), 3.66-3.67 (m, 2H, CH2), 3.69-3.73 (m, 1H, CHN), 3.79-3.82 (m, 2H, CH2), 3.83 (s, 3H, 
OMe), 3.83 (s, 3H, OMe), 4.10-4.12 (m, 2H, CH2), 5.71 (s, 1H, CH), 6.84 (s, 1H, CHar), 7.02 (dd, J1 
= 8.4, J2 = 2.5, CHar), 7.03 (s, 1H, CHar), 7.07 (m, 1H, CHar), 7.09 (dd, J1 = 7.6, J2 = 0.9, CHar), 
7.27-7.30 (m, 1H, CHar); 13C-NMR (151 MHz, CD3OD): δ = 25.5 (PhCH2), 41.1 (CH2N), 48.8 (CH), 
56.5 (OMe), 56.7 (OMe), 68.8 (CH2), 70.7 (CH2), 71.5 (CH2), 72.9 (CH2), 83.3 (Cq alkyne), 89.4 (Cq 
alkyne), 111.3 (CHar), 112.9 (CHar), 117.5 (CHar), 118.8 (CHar), 122.2 (Cq), 123.3 (Cq), 124.7 (Cq), 
125.5 (CHar), 131.0 (CHar), 150.1 (Cq-OMe), 151.3 (Cq-OMe), 160.3 (Cq-OMe); HRMS (ESI): 
[M+H]+ calculated for C24H30O5N 412.21185, found 412.21136. 
7-Bromo-1-(phenylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (88) 
 
According to general procedure V, 88 was obtained as a slightly yellow solid (13 mg, 45% over 2 
steps). m.p. 223-224 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.09-3.21 (m, 2H, PhCH2), 3.55-3.61 (m, 
1H, CHN), 3.69-3.76 (m, 1H, CHN), 5.83 (s, 1H, CH), 7.24 (d, 1H, J = 8.2, CHar), 7.37-7.46 (m, 3H, 
CHar), 7.52-7.55 (m, 3H, CHar), 7.72 (s, 1H, CHar); 13C-NMR (101 MHz, CD3OD): δ = 25.5 (PhCH2), 
41.1 (CH2N), 48.7 (CH), 82.6 (Cq alkyne), 90.3 (Cq alkyne), 121.9 (Cq), 122.0 (Cq), 129.8 (2C, 
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CHar), 131.2 (CHar), 131.7 (Cq), 132.3 (CHar), 132.8 (Cq), 133.0 (2C, CHar), 133.3 (CHar); HRMS 
(ESI): [M+H]+ calculated for C17H15NBr 312.03824, found 312.03865. 
7-Bromo-1-[(3-methoxyphenyl)ethynyl]-1,2,3,4-tetrahydroisoquinolinium chloride (89) 
N
Br
H
H
O
Cl
 
According to general procedure V, 89 was obtained as a slightly yellow solid (15.3 mg, 32% over 2 
steps). m.p. 195-196 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.09-3.21 (m, 2H, PhCH2), 3.55-3.61 (m, 
1H, CHN), 3.69-3.76 (m, 1H, CHN), 3.79 (s, 3H, OMe), 5.82 (s, 1H, CH), 7.00-7.11 (m, 3H, CHar), 
7.23-7.32 (m, 2H, CHar), 7.53 (dd, 1H, J1 = 8.2, J2 = 1.6, CHar), 7.71 (d, 1H, J = 1.6, CHar); 13C-NMR 
(101 MHz, CD3OD): δ = 25.5 (PhCH2), 41.0 (CH2N), 48.7 (CH), 55.9 (OMe), 82.4 (Cq alkyne), 90.2 
(Cq alkyne), 117.1 (CHar), 118.1 (CHar), 121.8 (Cq), 123.0 (Cq), 125.4 (CHar), 130.9 (CHar), 131.2 
(CHar), 131.7 (Cq), 132.3 (CHar), 132.8 (Cq), 133.3 (CHar), 161.1 (Cq-OMe); HRMS (ESI): [M+H]+ 
calculated for C18H17ONBr 342.04880, found 342.04920. 
7-Bromo-1-{[4-(trifluoromethyl)phenyl]ethynyl}-1,2,3,4-tetrahydroisoquinolinium chloride 
(90) 
 
According to general procedure V, 90 was obtained as a slightly yellow solid (30 mg, 59% over 2 
steps). m.p. 192-193 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.10-3.24 (m, 2H, PhCH2), 3.58-3.66 (m, 
1H, CHN), 3.71-3.78 (m, 1H, CHN), 5.91 (s, 1H, CH), 7.25 (d, J
 
= 8.5, 1H, CHar), 7.53 (dd, 1H, J1 = 
8.5, J2 = 1.8, CHar), 7.70-7.75 (m, 5H, CHar); 13C-NMR (101 MHz, CD3OD): δ = 24.00 (PhCH2), 39.5 
(CH2N), 46.9 (CH), 83.7 (Cq alkyne), 87.0 (Cq alkyne), 120.3 (Cq), 123.5 (q, J = 228, CF3), 125.2 (q, 
2C, J = 4, CHar), 129.7 (CHar), 130.3 (Cq), 130.5 (q, J = 35.0, Cq-CF3), 130.9 (CHar), 131.0 (Cq), 
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131.9 (CHar), 132.1 (Cq), 132.2 (CHar); HRMS (ESI): [M+H]+ calculated for C18H14NBrF3 380.02562, 
found 380.02656. 
General procedure VII: preparation of methyl-3,4-dihydroisoquinolinium Iodides 
To a solution of the corresponding 3,4-dihydroisoquinoline (1 equiv) in diethyl ether (1 g starting 
material in 30 mL) methyl iodide (2 equiv) was added. The reaction mixture was refluxed overnight. 
The resulting yellow precipitate was filtered and washed with diethyl ether to give the desired target 
compound as air-stable salt. 
2-Methyl-3,4-dihydroisoquinolinium Iodide (61) 
 
According to general procedure VII, 3,4-dihydroisoquinoline72 yielded iminium salt 61 as a yellow 
solid (1.10 g, 54%). m.p. 124-125 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.11 (t, 2H, J = 8.2, 
PhCH2), 3.82 (s, 3H, NCH3), 4.10 (t, 2H, J = 8.2, CH2N), 7.49-7.56 (m, 2H, CHar), 7.78-7.85 (m, 2H, 
CHar), 9.17 (s, 1H, CH imine); 13C-NMR (101 MHz, CD3OD): δ = 26.0 (PhCH2), 48.4 (NCH3), 51.4 
(CH2N), 126.1 (Cq), 129.5 (CHar), 129.5 (CHar), 134.7 (CHar), 137.6 (Cq), 139.1 (CHar), 168.5 (CH 
imine), HRMS (ESI): [M]+ calculated for C10H12N 146.09643, found 146.09622. 
7-methoxy-2-methyl-3,4-dihydroisoquinolinium Iodide (62) 
 
According to general procedure VII, 7-methoxy-3,4-dihydroisoquinoline 58 yielded iminium salt 62 
as a yellow solid (1.40 g, 69%). m.p. 161-163 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.22 (t, 2H, J = 
8.2, PhCH2), 3.81 (br s, 3H, NCH3), 3.81 (s, 3H, OMe), 4.05 (t, 2H, J = 8.2, CH2N), 7.30 (dd, 1H, J1 
= 8.4, J2 = 2.6, 6-H), 7.36-7.38 (m, 1H, 5-H), 7.41 (d, 1H, J = 2.6, 8-H), 9.20 (s, 1H, CH imine); 13C-
NMR (101 MHz, CD3OD): δ = 25.2 (PhCH2), 48.7 (NCH3), 52.0 (CH2N), 56.7 (OMe), 118.5 (CHar), 
125.1 (CHar), 126.6 (Cq), 129.3 (Cq), 130.6 (CHar), 160.4 (CH imine), 168.0 (Cq-OMe); HRMS (ESI): 
[M]+ calculated for C11H14ON 176.10699, found 176.10660. 
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6,7-Dimethoxy-2-methyl-3,4-dihydroisoquinolinium iodide (63) 
 
According to general procedure VII, 6,7-dimethoxy-3,4-dihydroisoquinoline 5973 yielded iminium 
salt 63 as a yellow solid (1.56 g, 78%). m.p. 200-201 °C; 1H-NMR (400 MHz, CDCl3): δ = 3.33 (t, 
2H, J = 8.0, PhCH2), 3.89 (s, 3H, NCH3), 3.91 (s, 3H, OMe), 3.98 (s, 3H, OMe), 4.05 (t, 2H, J = 8.0, 
CH2N), 6.86 (s, 1H, CHar), 7.59 (s, 1H, CHar), 9.74 (s, 1H, CH imine); 13C-NMR (101 MHz, CDCl3): 
δ = 25.4 (PhCH2), 47.8 (CH2N), 50.2 (CH2N), 56.7 (OMe), 56.8 (OMe), 110.8 (CHar), 115.4 (CHar), 
117.0 (Cq), 131.8 (Cq), 148.7 (Cq-OMe), 157.3 (Cq-OMe), 164.6 (CH imine); HRMS (ESI): [M]+ 
calculated for C12H16O2N 206.1190, found 206.11748. Analytical data according with literature.76 
2-Allyl-6,7-dimethoxy-3,4-dihydroisoquinolinium bromide (242)  
 
To a solution of 6,7-dimethoxy-3,4-dihydroisoquinoline 5973 (0.50 g, 2.61 mmol, 1 equiv) in diethyl 
ether (30 mL) allylbromide (0.53 mL, 5.23 mmol, 2 equiv) was added. The reaction mixture was 
refluxed overnight. The resulting yellow precipitate was filtered and washed with diethyl ether to 
give 243 as a yellow solid (0.52 g, 64%). m.p. 70-71 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.23 (t, 
2H, J = 8.3, PhCH2), 3.78-3.83 (m, 1H, CHN), 3.89 (s, 3H, OMe), 3.95-3.96 (m, 1H, CHN), 3.99 (s, 
3H, OMe), 4.58 (d, 2H, J = 6.5, CH2N), 5.56-5.65 (m, 2H, CH2 allyl), 6.02-6,11 (m, 1H, CH allyl), 
7.12 (s, 1H, CHar), 7.40 (s, 1H, CHar), 8.92 (s, 1H, CH imine); 13C-NMR (101 MHz, CD3OD): δ = 
26.2 (PhCH2), 48.8 (CH2N), 56.8 (OMe), 57.3 (OMe), 63.1 (CH2N), 112.3 (CHar), 116.4 (CHar), 
118.4 (Cq), 124.3 (CH2 allyl), 130.4 (CH allyl), 134.5 (Cq), 150.3 (Cq-OMe), 159.5 (Cq-OMe), 166.1 
(CH imine); HRMS (ESI): [M]+ calculated for C14H18O2N 232.13321, found 232.13319. 
General procedure VIII: preparation of N-methylated alkynylated tetrahydroisoquinolines 
A solution of the corresponding iminium salt (1 equiv) in THF (50 mg starting material in 1 mL) was 
cooled to 0 °C. In a separate flask the corresponding alkyne (6 equiv) in THF (0.5 mL) was also 
cooled to 0 °C and isopropyl magnesium chloride lithium chloride complex solution (1.3 M in THF, 
6 equiv) was added dropwise. After 10 min stirring this reaction mixture was transferred to the 
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iminium salt suspension. The resulting solution was stirred at 0 °C for 1h and then warmed to RT 
within 1h. The reaction was quenched by the addition of methanol (0.5 mL) and the crude reaction 
mixture was purified by flash chromatography (cyclohexane/ethyl acetate, gradient from 0 to 100% 
ethyl acetate). Most of the amines were then converted to the corresponding HCl-salt by addition of 
HCl in diethyl ether (1 M). 
2-Methyl-1-(phenylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (91) 
 
According to general procedure VIII, 91 was obtained as a yellow wax (43 mg, 83%). Rf = 0.50 
(petroleum ether/ethyl acetate, 2:1); 1H-NMR (400 MHz, CD3OD): δ = 3.12-3.20 (m, 5H, NCH3, 
PhCH2), 3.65-3.84 (m, 2H, CH2N), 5.85 (s, 1H, CH), 7.32-7.52 (m, 9H, CHar); 13C-NMR (101 MHz, 
CD3OD): δ = 26.3 (PhCH2), 42.0 (NCH3), 48.7 (CH2N), 58.4 (CH), 69.2 (Cq alkyne), 79.2 (Cq 
alkyne), 122.0 (Cq), 128.9 (CHar), 129.9 (3CHar), 130.4 (CHar), 130.5 (CHar), 131.1 (CHar), 131.4 
(2Cq), 133.2 (CHar); HRMS (ESI): [M+H]+ calculated for C18H18N 248.14338, found 248.14341. 
1-[(2-Methoxyphenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydroisoquinolinium chloride (92) 
 
According to general procedure VIII, 92 was obtained as a slightly yellow wax (42 mg, 73%). Rf = 
0.49 (petroleum ether/ethyl acetate, 1:1); 1H-NMR (600 MHz, CD3OD): δ = 3.11 (s, 3H, NCH3), 
3.14-3.20 (m, 2H, PhCH2), 3.49-3.53 (m, 1H, CHN), 3.72-3.77 (m, 1H, CHN), 3.80 (s, 3H, OMe), 
5.68 (s, 1H, CH), 6.85-6.98 (m, 1H, CHar), 6.97 (d, 1H, J = 8.5, CHar), 7.24 (m, 1H, J = 7.0, CHar), 
7.29-7.36 (m, 3H, CHar), 7.49-7.55 (m, 1H, CHar); 13C-NMR (151 MHz, CD3OD): δ = 26.1 (PhCH2), 
41.8 (NCH3), 49.3 (CH2N), 56.4 (OMe), 59.0 (CH), 83.9 (Cq alkyne), 90.8 (Cq alkyne), 111.0 (Cq), 
112.1 (CHar), 121.6 (CHar), 128.6 (CHar), 128.8 (CHar), 130.3 (4CHar), 132.6 (Cq), 134.3 (Cq); HRMS 
(ESI): [M+H]+ calculated for C19H20ON 278.15394, found 278.15392. 
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1-[(3-Methoxyphenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydroisoquinolinium chloride (93) 
 
According to general procedure VIII, 93 was obtained as a slightly yellow wax (49 mg, 85%). 
General procedure XIII using (S)-QUINAP yielded (S)-(+)-93 (31 mg, 99%). [α]D20 = +39° (c = 1.0, 
CH2Cl2); Rf = 0.44 (petroleum ether/ethyl acetate, 1:1); 1H-NMR (600 MHz, CD3OD): δ = 3.19-3.29 
(m, 5H, NCH3, PhCH2), 3.60-3.70 (m, 1H, CHN), 3.78-3.90 (m, 3H, OMe, CHN), 5.85 (s, 1H, CH), 
7.00 (d, 1H, J = 7.9, CHar), 7.06-7.10 (m, 2H, CHar), 7.27-7.33 (m, 2H, CHar), 7.36-7.38 (m, 2H, 
CHar), 7.51 (br s, 1H, CHar); 13C-NMR (151 MHz, CDCl3): δ = 26.9 (PhCH2), 48.9 (CH2N), 55.8 
(NCH3), 55.9 (OMe), 55.9 (CH), 79.7 (Cq alkyne), 91.8 (Cq alkyne), 116.4 (CHar), 117.3 (CHar), 
121.5 (Cq), 124.7 (CHar), 127.7 (CHar), 127.9 (CHar), 129.2 (CHar), 129.3 (CHar), 129.3 (CHar), 129.8 
(2Cq); HRMS (ESI): [M+H]+ calculated for C19H20ON 278.15394, found 278.15426. 
2-Methyl-1-(thien-3-ylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (94) 
 
According to general procedure VIII, 94 (TZ329) was obtained as a slightly brown solid (53 mg, 
99%). m.p. 165-167 °C; Rf = 0.44 (petroleum ether/ethyl acetate, 2:1); 1H-NMR (600 MHz, 
CD3OD): δ = 3.17-3.19 (m, 5H, NCH3, PhCH2), 3.64-3.81 (m, 1H, CH2N), 5.8 (s, 1H, CH), 7.19 (s, 
1H, CHar), 7.30-7.31 (m, 1H, CHar), 7.34-7.39 (m, 2H, CHar), 7.45-7.65 (m, 2H, CHar), 7.78 (m, 1H, 
CHar); 13C-NMR (151 MHz, CD3OD): δ = 24.9 (PhCH2), 40.7 (NCH3), 50.6 (CH2N), 56.3 (CH), 81.3 
(Cq alkyne), 85.5 (Cq alkyne), 119.7 (Cq) 126.4 (2CHar), 127.5 (CHar), 129.1 (Cq), 129.2 (Cq), 129.5 
(2CHar), 130.2 (CHar), 131.6 (CHar); HRMS (ESI): [M+H]+ calculated for C16H16NS 254.09980, found 
254.09998. 
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1-Ethynyl-7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline (95) 
 
General procedure VII was modified as follows, iminium salt 62 and ethynylmagnesium bromide 
(0.5 M in THF, 1.98 mL, 1.0 mmol, 6 equiv) yielded 95 as a slightly yellow oil (27 mg, 81%). Rf = 
0.35 (petroleum ether/ethyl acetate, 1:1); 1H-NMR (400 MHz, CDCl3): δ = 2.41 (d, 1H, J = 2.3, CH 
alkyne), 2.54 (s, 3H, NCH3), 2.62-2.67 (m, 1H, PhCH), 2.73-2.78 (m, 1H, PhCH), 2.84-2.96 (m, 2H, 
CH2N), 3.76 (s, 3H, OMe), 4.45 (s, 1H, CH), 6.75 (dd, 1H, J1 = 8.5, J2 = 2.7, CHar), 6.81 (d, 1H, J = 
2.7, CHar), 7.00 (d, 1H, J = 8.4, CHar); 13C-NMR (101 MHz, CDCl3): δ = 27.8 (PhCH2), 43.3 (NCH3), 
48.4 (CH2N), 55.2 (OMe), 56.2 (CH), 74.1 (CH alkyne), 81.5 (Cq alkyne), 112.0 (CHar), 113.6 
(CHar), 125.4 (Cq), 129.7 (CHar), 135.6 (Cq), 157.6 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for 
C13H16ON 202.1226, found 202.1225. 
7-Methoxy-2-methyl-1-(phenylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (96) 
 
According to general procedure VIII, 96 was obtained as a colourless solid (52 mg, 99%). m.p. 
164-166 °C; Rf = 0.49 (petroleum ether/ethyl acetate, 1:1); 1H-NMR (600 MHz, CD3OD): δ = 3.18-
3.22 (m, 5H, NCH3, PhCH2), 3.59-3.63 (m, 1H, CHN), 3.80-3.83 (m, 4H, OMe, CHN), 5.80 (s, 1H, 
CH), 6.97 (dd, 1H, J1 = 8.5, J2 = 2.1, CHar), 7.04 (br s, 1H, CHar), 7.20 (d, 1H, J = 8.5, CHar), 7.37-
7.40 (m, 2H, CHar), 7.42-7.44 (m, 1H, CHar), 7.53 (d, 2H, J = 7.6, CHar); 13C-NMR (151 MHz, 
CD3OD): δ = 24.1 (PhCH2), 40.4 (NCH3), 49.5 (CH2N), 54.9 (OMe), 56.9 (CH), 80.3 (Cq alkyne), 
89.8 (Cq alkyne), 112.2 (CHar), 115.7 (CHar), 121.9 (Cq), 128.7 (2C, CHar), 129.6 (CHar), 130.3 (Cq), 
130.4 (CHar), 131.9 (2CHar), 131.9 (Cq), 160.0 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for 
C19H20ON 278.15394, found 278.15400. 
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7-Methoxy-1-[(2-methoxyphenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydroisoquinolinium chloride 
(97) 
 
According to general procedure VIII, 97 was obtained as a yellow solid (50 mg, 88%). m.p. 164-
166 °C; Rf = 0.40 (petroleum ether/ethyl acetate, 1:1); 1H-NMR (600 MHz, CD3OD): δ = 3.10-3.21 
(m, 5H, NCH3, PhCH2), 3.62-3.63 (m, 1H, CHN), 3.82-3.85 (m, 4H, OMe, CHN), 3.87 (s, 3H, OMe), 
5.79 (s, 1H, CH), 6.91-6.96 (m, 2H, CHar), 7.04 (d, 1H, J = 8.2, CHar), 7.08-7.16 (m, 1H, CHar), 7.22 
(d, 1H, J = 8.2, CHar), 7.39-7.44 (m, 2H, CHar); 13C-NMR (151 MHz, CD3OD): δ = 25.4 (PhCH2), 
41.5 (NCH3), 49.1 (CH2N), 56.0 (OMe, CH), 56.0 (OMe), 69.1 (Cq alkyne), 87.7 (Cq alkyne), 111.0 
(Cq), 112.1 (CHar), 113.4 (Cq), 116.8 (CHar), 121.7 (2C, CHar), 123.0 (Cq), 131.3 (CHar), 132.6 
(CHar), 134.2 (CHar), 160.4 (Cq-OMe), 162.3 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for 
C20H22O2N 308.16451, found 308.16459. 
7-Methoxy-1-[(3-methoxyphenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline (98) 
 
According to general procedure VIII, 98 was obtained as a yellow oil (72 mg, 71%). General 
procedure XIII using (S)-QUINAP yielded (S)-(–)-98 (30 mg, 99%). [α]D20 = –45° (c = 1.0, CH2Cl2); 
Rf = 0.42 (petroleum ether/ethyl acetate, 1:1); 1H-NMR (400 MHz, CDCl3): δ = 2.62 (s, 3H, NCH3), 
2.67-3.07 (m, 4H, PhCH2, CH2N), 3.77 (s, 3H, OMe), 3.78 (s, 3H, OMe), 4.67 (s, 1H, CH), 6.77 (dd, 
1H, J1 = 8.4, J2 = 2.6, CHar), 6.83 (ddd, 1H, J1 = 8.4, J2 = 2.6, J3 = 0.9, CHar), 6.89 (d, 1H, J = 2.6, 
CHar), 6.94-6.95 (m, 1H, CHar), 7.01-7.04 (m, 2H, CHar), 7.16-7.20 (m, 1H, CHar); 13C-NMR (101 
MHz, CDCl3): δ = 27.8 (PhCH2), 43.5 (NCH3), 48.8 (CH2N), 55.2 (OMe), 55.3 (OMe), 57.0 (CH), 
86.2 (Cq alkyne), 87.0 (Cq alkyne), 112.3 (CHar), 113.4 (CHar), 114.6 (CHar), 116.5 (CHar), 123.0 
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(Cq), 124.3 (CHar), 125.4 (Cq), 129.2 (CHar), 129.7 (CHar), 135.8 (Cq), 157.6 (Cq-OMe), 159.2 (Cq-
OMe); HRMS (ESI): [M+H]+ calculated for C20H22O2N 308.16451, found 308.16515. 
7-Methoxy-2-methyl-1-(thien-3-ylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (99) 
 
According to general procedure VIII, 99 was obtained as a colourless solid (47 mg, 89%). m.p. 
166-168 °C; Rf = 0.46 (petroleum ether/ethyl acetate, 1:1); 1H-NMR (600 MHz, CD3OD): δ = 3.14-
3.17 (m, 5H, NCH3, PhCH2), 3.57-3.59 (m, 1H, CHN), 3.76-3.79 (m, 4H, OMe, CHN), 5.76 (s, 1H, 
CH), 6.95 (d, 1H, J = 6.8, CHar), 7.01 (s, 1H, CHar), 7.19-7.21 (m, 2H, CHar), 7.45-7.46 (m, 1H, 
CHar), 7.77-7.78 (m, 1H, CHar); 13C-NMR (151 MHz, CD3OD): δ = 25.4 (PhCH2), 41.6 (NCH3), 50.6 
(CH2N), 56.0 (OMe), 58.2 (CH), 81.1 (Cq alkyne), 87.5 (Cq alkyne), 113.1 (CHar), 116.8 (CHar), 
120.9 (Cq), 123.0 (Cq), 127.5 (CHar), 130.7 (CHar), 131.4 (Cq), 131.4 (CHar), 132.6 (CHar), 160.3 (Cq-
OMe); HRMS (ESI): [M+H]+ calculated for C17H18ONS 284.11036, found 284.11040. 
7-Methoxy-2-methyl-1-(pyridin-3-ylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (100) 
 
According to general procedure VIII, 100 was obtained as a brown solid (35 mg, 67%). m.p. 121-
123 °C; Rf = 0.49 (ethyl acetate); 1H-NMR (400 MHz, CDCl3): δ = 2.92-3.01 (m, 4H, NCH3, PhCH), 
3.27-3.42 (m, 3H, PhCH, CH2N), 3.79-3.85 (m, 3H, OMe), 5.23 (s, 1H, CH), 6.86 (s, 2H, CHar), 
7.11 (s, 1H, CHar), 7.30 (s, 1H, CHar), 7.76 (s, 1H, CHar), 8.67-8.78 (m, 2H, CHar); 13C-NMR (101 
MHz, CDCl3): δ = 25.6 (PhCH2), 42.2 (NCH3), 48.9 (CH2N), 55.6 (OMe), 56.2 (CH), 85.7 (Cq 
alkyne), 86.6 (Cq alkyne), 112.3 (CHar), 115.1 (CHar), 122.7 (2Cq), 123.4 (CHar), 130.2 (CHar), 131.1 
(Cq), 139.2 (CHar), 149.5 (CHar), 152.5 (CHar), 158.4 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for 
C18H19ON2 279.14919, found 279.14932. 
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1-Ethynyl-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline (101) 
 
General procedure VII was modified as follows, iminium salt 63 and ethynylmagnesium bromide 
(0.5 M in THF, 1.80 mL, 0.90 mmol, 6 equiv) yielded 101 as a slightly yellow solid (21 mg, 61%). 
m.p. 95-97 °C; Rf = 0.26 (petroleum ether/ethyl acetate, 1:1); 1H-NMR (400 MHz, CDCl3): δ = 2.41 
(d, 1H, J = 2.3, CH alkyne), 2.54 (s, 3H, NCH3), 2.64-2.78 (m, 2H, PhCH2), 2.85-2.95 (m, 2H, 
CH2N), 3.83 (s, 3H, OMe), 3.85 (s, 3H, OMe), 4.41 (s, 1H, CH), 6.57 (s, 1H, CHar), 6.74 (s, 1H, 
CHar); 13C-NMR (101 MHz, CDCl3): δ = 28.3 (PhCH2), 43.4 (NCH3), 48.2 (CH2N), 55.7 (CH), 56.2 
(OMe), 55.9 (OMe), 74.0 (CH alkyne), 109.9 (CHar), 111.2 (CHar), 125.4 (Cq), 126.5 (Cq), 147.4 
(Cq-OMe), 148.2 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for C14H18O2N 232.13321, found 
232.13334. 
6,7-Dimethoxy-2-methyl-1-(phenylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (102) 
 
According to general procedure VIII, 102 was obtained as a yellow solid (21 mg, 41%). m.p. 
153-155 °C; Rf = 0.41 (petroleum ether/ethyl acetate, 1:2); 1H-NMR (600 MHz, CD3OD): δ = 3.16-
3.18 (m, 5H, NCH3, PhCH2), 3.58-3.60 (m, 1H, CHN), 3.79-3.81 (m, 1H, CHN), 3.82-3.83 (m, 6H, 
2OMe), 5.71 (s, 1H, CH), 6.85 (s, 1H, CHar), 7.01 (s, 1H, CHar), 7.36-7.42 (m, 3H, CHar), 7.51-7.53 
(m, 2H, CHar); 13C-NMR (151 MHz, CD3OD): δ = 25.7 (PhCH2), 41.5 (NCH3), 50.9 (CH2N), 56.5 
(OMe), 56.7 (OMe), 57.8 (CH), 81.6 (Cq alkyne), 90.8 (Cq alkyne), 111.4 (CHar), 112.7 (CHar), 122.0 
(Cq), 123.8 (Cq), 129.8 (CHar), 130.9 (CHar), 132.3 (Cq), 133.0 (CHar), 150.2 (Cq-OMe), 151.5 (Cq-
OMe); HRMS (ESI): [M+H]+ calculated for C20H22O2N 308.16451, found 308.16455. 
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6,7-Dimethoxy-1-[(2-methoxyphenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydroisoquinolinium 
chloride (103) 
 
According to general procedure VIII, 103 was obtained as a yellow wax (50 mg, 89%). Rf = 0.32 
(petroleum ether/ethyl acetate, 1:2); 1H-NMR (400 MHz, CD3OD): δ = 3.13-3.24 (m, 5H, NCH3, 
PhCH2), 3.39-3.65 (m, 2H, CH2N), 3.81-3.83 (m, 9H, 3OMe), 5.71 (br s, 1H, CH), 6.82-7.14 (m, 4H, 
CHar), 7.37-7.55 (m, 2H, CHar); 13C-NMR (126 MHz, CD3OD): δ = 25.9 (PhCH2), 40.0 (NCH3), 49.1 
(CH2N), 56.6, 56.7, 56.8 (3OMe, CH), 59.4 (Cq alkyne), 84.6 (Cq alkyne), 110.9 (CHar), 112.1 
(CHar), 112.8 (CHar), 121.6 (CHar), 129.8 (CHar), 132.2 (Cq), 132.5 (Cq), 133.4 (CHar), 134.3 (Cq), 
150.0 (Cq-OMe), 151.3 (Cq-OMe), 162.1 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for C21H23O3N 
338.17502, found 338.17520. 
2-Allyl-6,7-dimethoxy-1-[(3-methoxyphenyl)ethynyl]-1,2,3,4-tetrahydroisoquinolinium 
chloride (104) 
 
According to general procedure VIII, 104 was obtained as a yellow solid (46 mg, 72%). General 
procedure XIII using (R)-QUINAP yielded (R)-(–)-104 (25 mg, 78%). [α]D20 = –18° (c = 0.3, CH2Cl2); 
m.p. 133-135 °C; Rf = 0.38 (petroleum ether/ethyl acetate, 1:1); 1H-NMR (500 MHz, CDCl3): δ = 
2.81-2.96 (m, 1H, PhCH), 3.41-3.69 (m, 5H, PhCH, 2CH2N), 3.76 (s, 3H, OMe), 3.83 (s, 3H, OMe), 
3.89 (s, 3H, OMe), 5.39 (s, 1H, CH), 5.61-5.66 (m, 2H, CH2 allyl), 6.44 (s, 1H, CH allyl), 6.62-6.70 
(m, 2H, CHar), 6.91-6.92 (m, 2H, CHar), 6.99-7.00 (m, 1H, CHar), 7.21-7.24 (m, 1H, CHar), 13.4 (s, 
1H, NH); 13C-NMR (126 MHz, CDCl3): δ = 26.8 (PhCH2), 46.2 (CH2N), 53.1 (CH2N), 55.4 (OMe), 
55.9 (OMe), 56.1 (OMe), 57.7 (CH), 79.7 (Cq alkyne), 91.4 (Cq alkyne), 109.8 (CHar), 111.1 (CHar), 
115.9 (CHar), 117.1 (CHar), 120.8 (Cq), 121.4 (Cq), 122.5 (Cq), 124.4 (CHar), 125.9 (CH2 allyl), 126.9 
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(CHar), 129.6 (CH allyl), 148.4 (Cq-OMe), 149.6 (Cq-OMe), 159.3 (Cq-OMe); HRMS (ESI): [M+H]+ 
calculated for C23H26O3N 364.19072, found 364.19095. 
6,7-Dimethoxy-2-methyl-1-(thien-3-ylethynyl)-1,2,3,4-tetrahydroisoquinolinium chloride (105) 
 
According to general procedure VIII, 105 was obtained as a slightly yellow solid (21 mg, 40%, 
general procedure VI). m.p. 155-157 °C; Rf = 0.38 (petroleum ether/ethyl acetate, 1:2); 1H-NMR 
(600 MHz, CD3OD): δ = 3.15-3.20 (m, 5H, NCH3, PhCH2), 3.55-3.60 (m, 1H, CHN), 3.78-3.80 (m, 
1H, CHN), 3.81 (s, 3H, OMe), 3.83 (s, 3H, OMe), 5.70 (s, 1H, CH), 6.84 (s, 1H, CHar), 6.98 (s, 1H, 
CHar), 7.19 (d, 1H, J = 4.7, CHar), 7.45-7.47 (m, 1H, CHar), 7.77-7.78 (m, 1H, CHar); 13C-NMR (151 
MHz, CD3OD): δ = 25.7 (PhCH2), 41.5 (NCH3), 49.5 (CH2N), 56.6 (OMe), 56.7 (OMe), 57.9 (CH), 
79.3 (Cq alkyne), 87.6 (Cq alkyne), 111.4 (CHar), 112.7 (CHar), 120.9 (Cq), 122.0 (Cq), 123.7 (Cq), 
127.5 (CHar), 130.7 (CHar), 132.7 (CHar), 150.1 (Cq-OMe), 151.5 (Cq-OMe); HRMS (ESI): [M+H]+ 
calculated for C18H20O2NS 314.12093, found 314.12103. 
General procedure IX: preparation of alkynylated cotarnine derivatives 
A suspension of cotarnine iodide 23 (50 mg, 0.14 mmol, 1 equiv) in THF (1 mL) was cooled to 
0 °C. In a separate flask the corresponding alkyne (0.43 mmol, 3 equiv) in THF (1.5 mL) was also 
cooled to 0 °C and isopropyl magnesium chloride lithium chloride complex solution (1.3 M in THF, 
332 µL, 0.43 mmol, 3 equiv) added dropwise. After 10 min stirring this reaction mixture was 
transferred to the cotarnine iodide suspension. The resulting solution was stirred at 0 °C for one 
hour and then warmed to RT within one hour. The reaction was quenched by the addition of 
saturated aq. NaHCO3 solution and extracted with diethyl ether (3 × 20 mL). The combined organic 
fractions were dried with MgSO4, filtered and the solvent evaporated in vacuo. The residue was 
purified via flash chromatography. Most of the amines were then converted to the corresponding 
HCl-salt by addition of HCl in diethyl ether (1 M). 
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5-Ethynyl-4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline (106) 
 
General procedure IX was modified as follows, cotarnine iodide 23 and ethynylmagnesium bromide 
(0.5 M in THF, 0.86 mL, 0.43 mmol, 3 equiv) yielded 106 as a slightly yellow oil (27 mg, 76%). 
Flash chromatography (petroleum ether/ethyl acetate, 2:1). Rf = 0.43 (petroleum ether/ethyl 
acetate, 1:1); 1H-NMR (400 MHz, CDCl3): δ = 2.34 (d, 1H, J = 2.3, CH alkyne), 2.51 (s, 3H, NCH3), 
2.58-2.70 (m, 2H, PhCH2), 2.82-2.98 (m, 2H, CH2N), 4.02 (s, 3H, OMe), 4.71 (s, 1H, CH), 5.86 (dd, 
2H, J1 = 6.8, J2 = 1.3, O2CH2), 6.31 (s, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 28.7 (PhCH2), 
42.9 (NCH3), 46.4 (CH2N), 50.5 (CH), 59.5 (OMe), 73.1 (CH alkyne), 80.8 (Cq alkyne), 100.7 
(O2CH2), 102.9 (CHar), 120.6 (Cq), 127.4 (Cq), 134.3 (Cq), 139.7 (Cq), 148.4 (Cq); HRMS (ESI): 
[M+H]+ calculated for C14H15O3N 246.11247, found 246.11244. 
4-Methoxy-6-methyl-5-(phenylethynyl)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline (107) 
 
According to general procedure IX, 107 was obtained as a slightly yellow oil (44 mg, 95%). Flash 
chromatography (petroleum ether/ethyl acetate, 2:1). Preparative chiral HPLC with a Chiralpak® IC 
column and 30% DCM/EtOH (100:2) in hexanes as eluent, a flow rate of 4 mL/min and detection at 
254 nm delivered, S-(–)-107, [α]D20 = –110.5 (c = 1.0, CH2Cl2) and R-(+)-107, [α]D20 = +114.0° (c = 
1.0, CH2Cl2); Rf = 0.40 (petroleum ether/ethyl acetate, 1:1); 1H-NMR (400 MHz, CDCl3): δ = 2.86 
(s, 3H, NCH3), 2.90-3.01 (m, 2H, PhCH2), 3.20-3.30 (m, 2H, CH2N), 4.32 (s, 3H, OMe), 5.21 (s, 1H, 
CH), 6.15 (d, 2H, J = 2.0, O2CH2), 6.61 (s, 1H, CHar), 7.52-7.54 (m, 3H, CHar), 7.66-7.69 (m, 2H, 
CHar); 13C-NMR (101 MHz, CDCl3): δ = 28.8 (PhCH2), 43.1 (NCH3), 46.7 (CH2N), 51.1 (CH), 59.6 
(OMe), 85.6 (Cq alkyne), 86.8 (Cq alkyne), 100.7 (O2CH2), 103.0 (CHar), 121.2 (Cq), 123.4 (Cq), 
127.4 (Cq), 127.8 (CHar), 128.1 (2C, CHar), 131.7 (2C, CHar), 134.5 (Cq), 139.9 (Cq), 148.4 (Cq); 
HRMS (ESI): [M+H]+ calculated for C20H20O3N 322.14377, found 322.14380. 
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4-Methoxy-5-[(2-methoxyphenyl)ethynyl]-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g] 
isoquinolin-6-ium chloride (108)  
 
According to general procedure IX, 108 was obtained as a slightly yellow wax (22 mg, 39%). Flash 
chromatography (gradient from 0 to 100% ethyl acetate in cyclohexane). Rf = 0.28 (petroleum 
ether/ethyl acetate, 2:1); 1H-NMR (400 MHz, CD3OD): δ = 3.04-3.10 (m, 1H, PhCH), 3.15 (s, 3H, 
NCH3), 3.18-3.26 (m, 1H, PhCH), 3.55-3.60 (m, 1H, CHN), 3.68-3.81 (m, 1H, CHN), 3.85 (s, 3H, 
OMe), 4.10 (s, 3H, OMe), 5.72 (s, 1H, CH), 5.97 (s, 2H, O2CH2), 6.50 (s, 1H, CHar), 6.90-6.93 (m, 
1H, CHar), 7.01-7.03 (m, 1H, CHar), 7.36-7.40 (m, 2H, CHar); 13C-NMR (151 MHz, CD3OD): δ = 26.9 
(PhCH2), 42.0 (NCH3), 48.9 (CH2N), 54.0 (CH), 56.5 (OMe), 60.7 (OMe), 88.3 (Cq alkyne), 88.5 (Cq 
alkyne), 103.2 (O2CH2), 103.8 (CHar), 111.4 (Cq), 112.2 (CHar), 117.3 (Cq), 121.8 (CHar), 125.6 (Cq), 
132.5 (CHar), 134.3 (CHar), 136.6 (Cq), 141.4 (Cq), 152.1 (Cq), 162.3 (Cq); HRMS (ESI): [M+H]+ 
calculated for C21H22O4N 352.15433, found 352.15457. 
4-Methoxy-5-[(3-methoxyphenyl)ethynyl]-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g] 
isoquinoline (109) 
 
According to general procedure IX, 109 was obtained as a slightly yellow oil (48 mg, 99%). General 
procedure XIII using (R)-QUINAP yielded (R)-(+)-109 (25 mg, 99%), [α]D20 = +70° (c = 1.0, 
CH2Cl2).Flash chromatography (petroleum ether/ethyl acetate, 2:1). Rf = 0.34 (petroleum 
ether/ethyl acetate, 1:1); 1H-NMR (400 MHz, CDCl3): δ = 2.58 (s, 3H, NCH3), 2.62-2.76 (m, 2H, 
PhCH2), 2.92-3.02 (m, 2H, CH2N), 3.76 (s, 3H, OMe), 4.04 (s, 3H, OMe), 4.92 (s, 1H, CH), 5.87-
5.88 (m, 2H, O2CH2), 6.33 (s, 1H, CHar), 6.80-6.83 (m, 1H, CHar), 6.92-6.93 (m, 1H, CHar), 6.98-
7.01 (m, 1H, CHar), 7.14-7.18 (m, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 28.8 (PhCH2), 43.1 
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(NCH3), 46.7 (CH2N), 51.2 (CH), 55.2 (OMe), 59.6 (OMe), 85.5 (Cq alkyne), 86.8 (Cq alkyne), 100.7 
(O2CH2), 103.0 (CHar), 114.2 (CHar), 116.7 (CHar), 121.2 (Cq), 124.3 (CHar), 124.4 (Cq), 127.5 (Cq), 
129.1 (CHar), 134.5 (Cq), 139.9 (Cq), 148.3 (Cq), 159.2 (Cq); HRMS (ESI): [M+H]+ calculated for 
C21H22O4N 352.15433, found 352.15433. 
4-Methoxy-5-[(4-methoxyphenyl)ethynyl]-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g] 
isoquinoline (110) 
 
According to general procedure IX, 110 was obtained as a slightly yellow oil (46 mg, 91%). Flash 
chromatography (petroleum ether/ethyl acetate, 2:1). Rf = 0.29 (petroleum ether/ethyl acetate, 1:1); 
1H-NMR (400 MHz, CDCl3): δ = 2.57 (s, 3H, NCH3), 2.61-2.73 (m, 2H, PhCH2), 2.92-3.00 (m, 2H, 
CH2N), 3.77 (s, 3H, OMe), 4.03 (s, 3H, OMe), 4.91 (s, 1H, CH), 5.86-5.87 (m, 2H, O2CH2), 6.32 (s, 
1H, CHar), 6.76-6.80 (m, 2H, CHar), 7.31-7.34 (m, 2H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 28.7 
(PhCH2), 43.0 (NCH3), 46.7 (CH2N), 51.2 (CH), 55.2 (OMe), 59.6 (OMe), 85.2 (Cq alkyne), 85.4 (Cq 
alkyne), 100.7 (O2CH2), 103.0 (CHar), 113.7 (2C, CHar), 115.6 (Cq), 121.4 (Cq), 127.4 (Cq), 133.0 
(2C, CHar), 134.6 (Cq), 139.9 (Cq), 148.3 (Cq), 159.2 (Cq); HRMS (ESI): [M+H]+ calculated for 
C21H22O4N 352.15433, found 352.15433. 
4-Methoxy-6-methyl-5-{[4-(trifluoromethyl)phenyl]ethynyl}-5,6,7,8-tetrahydro[1,3]dioxolo 
[4,5-g]isoquinoline (111) 
 
According to general procedure IX, 111 was obtained as a slightly yellow solid (56 mg, 99%). Flash 
chromatography (petroleum ether/ethyl acetate, 3:1). Rf = 0.43 (petroleum ether/ethyl acetate, 1:1); 
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m.p. 97-98 °C; 1H-NMR (400 MHz, CDCl3): δ = 2.58 (s, 3H, NCH3), 2.63-2.76 (m, 2H, PhCH2), 
2.90-3.03 (m, 2H, CH2N), 4.04 (s, 3H, OMe), 4.93 (s, 1H, CH), 5.87-5.88 (m, 2H, O2CH2), 6.34 (s, 
1H, CHar), 7.47-7.52 (m, 4H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 28.7 (PhCH2), 43.1 (NCH3), 
46.8 (CH2N), 51.2 (CH), 59.5 (OMe), 84.3 (Cq alkyne), 89.7 (Cq alkyne), 100.8 (O2CH2), 102.9 
(CHar), 120.5 (Cq), 123.9 (q, J = 271, CF3), 125.0 (q, 2C, J = 4.0, CHar), 127.2 (Cq), 127.5 (Cq), 
129.5 (q, J = 32.0, Cq-CF3), 131.9 (CHar), 134.4 (Cq), 139.8 (Cq), 148.4 (Cq); HRMS (ESI): [M+H]+ 
calculated for C21H19O3NF3 390.13201, found 390.13115. 
4-Methoxy-6-methyl-5-(thien-3-ylethynyl)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline 
(112) 
 
According to general procedure IX, 112 was obtained as a slightly yellow solid (35 mg, 74%). Flash 
chromatography (petroleum ether/ethyl acetate, 3:1). Rf = 0.37 (petroleum ether/ethyl acetate, 1:1); 
m.p. 123-124 °C; 1H-NMR (400 MHz, CDCl3): δ = 2.56 (s, 3H, NCH3), 2.61-2.75 (m, 2H, PhCH2), 
2.92-3.01 (m, 2H, CH2N), 4.02 (s, 3H, OMe), 4.90 (s, 1H, CH), 5.87-5.88 (m, 2H, O2CH2), 6.33 (s, 
1H, CHar), 7.06 (dd, 1H, J1 = 5.0, J2 = 1.3, CHar), 7.20 (dd, 1H, J1 = 5.0, J2 = 2.8, CHar), 7.36 (dd, 
1H, J1 = 2.8, J2 = 1.3, CHar); 13C-NMR (101 MHz, CDCl3): δ = 28.7 (PhCH2), 43.1 (NCH3), 46.7 
(CH2N), 51.1 (CH), 59.6 (OMe), 80.5 (Cq alkyne), 86.3 (Cq alkyne), 100.7 (O2CH2), 102.9 (CHar), 
121.1 (Cq), 122.3 (Cq), 124.9 (CHar), 127.4 (Cq), 128.1 (CHar), 130.1 (CHar), 134.5 (Cq), 139.9 (Cq), 
148.3 (Cq); HRMS (ESI): [M+H]+ calculated for C18H18O3NS 328.10029, found 328.10019. 
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4-Methoxy-6-methyl-5-(pyridin-3-ylethynyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-
6-ium chloride (113)  
 
According to general procedure IX, 113 was obtained as a slightly yellow wax (12 mg, 23%). Flash 
chromatography (gradient from 0 to 100% ethyl acetate in cyclohexane). Rf = 0.30 (petroleum 
ether/ethyl acetate, 1:1); 1H-NMR (400 MHz, CD3OD): δ = 3.03-3.09 (m, 1H, PhCH), 3.12 (s, 3H, 
NCH3), 3.16-3.22 (m, 1H, PhCH), 3.52-3.57 (m, 1H, CHN), 3.68-3.76 (m, 1H, CHN), 4.11 (s, 3H, 
OMe), 5.74 (s, 1H, CH), 5.98 (s, 2H, O2CH2), 6.51 (s, 1H, CHar), 7.44-7.47 (m, 1H, CHar), 7.94-7.96 
(m, 1H, CHar), 8.55-8.67 (m, 2H, CHar); 13C-NMR (126 MHz, CD3OD): δ = 24.6 (PhCH2), 41.3 
(NCH3), 47.8 (CH2N), 51.3 (CH), 59.4 (OMe), 85.8 (Cq alkyne), 91.3 (Cq alkyne), 101.8 (O2CH2), 
102.6 (CHar), 113.1 (Cq), 118.9 (Cq), 124.2 (CHar), 124.5 (Cq), 135.3 (Cq), 136.7 (Cq), 139.3 (CHar), 
151.0 (CHar), 151.1 (Cq), 151.6 (CHar); HRMS (ESI): [M+H]+ calculated for C19H19O3N2 323.13902, 
found 323.13916. 
4-Methoxy-6-methyl-5-(naphthalen-1-ylethynyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g] 
isoquinolin-6-ium chloride (114)  
 
According to general procedure IX, 114 was obtained as a slightly yellow wax (38 mg, 69%). Flash 
chromatography (gradient from 0 to 100% ethyl acetate in cyclohexane). Rf = 0.32 (petroleum 
ether/ethyl acetate, 4:1); 1H-NMR (600 MHz, CD3OD): δ = 3.12-3.28 (m, 5H, NCH3, PhCH2), 3.61-
3.66 (m, 1H, CHN), 3.81-3.86 (m, 1H, CHN), 4.15 (s, 3H, OMe), 5.90 (s, 1H, CH), 5.99 (s, 2H, 
O2CH2), 6.54 (s, 1H, CHar), 7.46-7.49 (m, 1H, CHar), 7.54-7.60 (m, 2H, CHar), 7.73-7.75 (m, 1H, 
CHar), 7.91-7.96 (m, 2H, CHar), 8.14-8.15 (m, 1H, CHar); 13C-NMR (151 MHz, CD3OD): δ = 25.6 
(PhCH2), 40.4 (NCH3), 48.7 (CH2N), 52.2 (CH), 59.2 (OMe), 88.1 (Cq alkyne), 90.4 (Cq alkyne), 
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103.3 (O2CH2), 103.8 (CHar), 118.6 (Cq), 124.3 (Cq), 126.4 (CHar), 126.5 (CHar), 128.0 (CHar), 128.6 
(CHar), 129.9 (CHar), 131.2 (Cq), 131.5 (CHar), 132.5 (CHar), 134.6 (Cq), 134.8 (Cq), 134.9 (Cq), 
139.9 (Cq), 150.8 (Cq); HRMS (ESI): [M+H]+ calculated for C24H22O3N 372.15942, found 
372.15952. 
5-[(2-Chlorophenyl)ethynyl]-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g] 
isoquinolin-6-ium chloride (115)  
 
According to general procedure IX, 115 was obtained as a slightly yellow wax (27 mg, 48%). Flash 
chromatography (gradient from 0 to 100% ethyl acetate in cyclohexane). Rf = 0.44 (petroleum 
ether/ethyl acetate, 4:1); 1H-NMR (400 MHz, CD3OD): δ = 3.03-3.09 (m, 1H, PhCH), 3.15 (s, 3H, 
NCH3), 3.18-3.26 (m, 1H, PhCH), 3.56-3.60 (m, 1H, CHN), 3.70-3.78 (m, 1H, CHN), 4.11 (s, 3H, 
OMe), 5.77 (s, 1H, CH), 5.97 (s, 2H, O2CH2), 6.49 (s, 1H, CHar), 7.29-7.33 (m, 1H, CHar), 7.37-7.41 
(m, 1H, CHar), 7.46-7.48 (m, 1H, CHar) 7.55 (dd, 1H, J1 = 7.8, J2 = 1.5, CHar); 13C-NMR (101 MHz, 
CD3OD): δ = 26.3 (PhCH2), 41.8 (NCH3), 48.6 (CH2N), 53.2 (CH), 60.4 (OMe), 86.3 (Cq alkyne), 
87.7 (Cq alkyne), 103.0 (O2CH2), 103.6 (CHar), 115.6 (CHar), 122.1 (CHar), 125.8 (CHar), 128.2 
(CHar), 130.5 (Cq), 132.1 (Cq), 134.7 (Cq), 136.2 (Cq), 137.1 (Cq), 141.0 (Cq), 152.0 (Cq); HRMS 
(ESI): [M+H]+ calculated for C20H19O3NCl 356.10480, found 356.10511. 
5-[(3-Chlorophenyl)ethynyl]-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g] 
isoquinolin-6-ium chloride (116)  
 
According to general procedure IX, 116 was obtained as a slightly yellow wax (21 mg, 37%). Flash 
chromatography (gradient from 0 to 100% ethyl acetate in cyclohexane). Rf = 0.38 (petroleum 
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ether/ethyl acetate, 4:1); 1H-NMR (600 MHz, CD3OD): δ = 3.04-3.08 (m, 1H, PhCH), 3.10 (s, 3H, 
NCH3), 3.16-3.22 (m, 1H, PhCH), 3.51-3.54 (m, 1H, CHN), 3.68-3.72 (m, 1H, CHN), 4.10 (s, 3H, 
OMe), 5.69 (s, 1H, CH), 5.97 (s, 2H, O2CH2), 6.50 (s, 1H, CHar), 7.34-7.37 (m, 1H, CHar), 7.41-7.44 
(m, 2H, CHar), 7.51-7.52 (m, 1H, CHar); 13C-NMR (151 MHz, CD3OD): δ = 24.6 (PhCH2), 40.4 
(NCH3), 47.5 (CH2N), 53.1 (CH), 60.4 (OMe), 81.2 (Cq alkyne), 89.0 (Cq alkyne), 103.1 (O2CH2), 
103.7 (CHar), 124.1 (Cq), 125.8 (Cq), 130.9 (CHar), 131.0 (Cq),131.6 (CHar), 131.6 (CHar), 132.1 
(CHar), 135.5 (Cq), 136.4 (Cq), 141.3 (Cq), 152.1 (Cq); HRMS (ESI): [M+H]+ calculated for 
C20H19O3NCl 356.10480, found 356.10503. 
5-[(3,5-dimethoxyphenyl)ethynyl]-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g] 
isoquinolin-6-ium chloride (117)  
 
According to general procedure IX, 117 was obtained as a slightly yellow wax (8 mg, 13%). 
General procedure XIII using (R)-QUINAP yielded (R)-(+)-117 (27 mg, 98%), [α]D20 = +73° (c = 1.0, 
CH2Cl2). Flash chromatography (gradient from 0 to 100% ethyl acetate in cyclohexane). Rf = 0.31 
(petroleum ether/ethyl acetate, 2:1); 1H-NMR (600 MHz, CD3OD): δ = 3.04-3.07 (m, 1H, PhCH), 
3.09 (s, 3H, NCH3), 3.15-3.21 (m, 1H, PhCH), 3.49-3.53 (m, 1H, CHN), 3.68-3.73 (m, 1H, CHN), 
3.75 (s, 6H, OMe), 4.10 (s, 3H, OMe), 5.65 (s, 1H, CH), 5.97 (s, 2H, O2CH2), 6.50 (s, 1H, CHar), 
6.54 (t, 1H, J = 2.6 Hz, CHar), 6.61 (d, 2H, J = 2.6 Hz, CHar); 13C-NMR (151 MHz, CD3OD): δ = 26.6 
(PhCH2), 40.3 (NCH3), 48.3 (CH2N), 53.4 (CH), 56.1 (OMe), 60.6 (OMe), 80.6 (Cq alkyne), 90.8 (Cq 
alkyne), 103.2 (O2CH2), 103.6 (CHar), 103.8 (CHar), 110.9 (2CHar), 123.7 (Cq), 125.9 (Cq), 130.0 
(Cq), 132.0 (Cq), 136.6 (Cq), 152.1 (Cq), 162.5 (2Cq); HRMS (ESI): [M+H]+ calculated for C22H24O5N 
382.16490, found 382.16548. 
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4-methoxy-5-({3-[2-(2-methoxyethoxy)ethoxy]phenyl}ethynyl)-6-methyl-5,6,7,8-tetrahydro- 
[1,3]dioxolo[4,5-g]isoquinolin-6-ium chloride (118)  
 
According to general procedure IX, 118 was obtained as a slightly yellow wax (27 mg, 39%). Flash 
chromatography (gradient from 0 to 100% ethyl acetate in cyclohexane). Rf = 0.33 (petroleum 
ether/ethyl acetate, 1:1); 1H-NMR (600 MHz, CD3OD): δ = 3.06-3.09 (m, 1H, PhCH), 3.14 (s, 3H, 
NCH3), 3.18-3.27 (m, 1H, PhCH), 3.34 (OMe), 3.35-3.54 (m, 2H, CH2), 3.56-3.60 (m, 1H, CHN), 
3.65-3.67 (m, 2H, CH2), 3.70-3.72 (m, 1H, CHN), 3.79-3.81 (m, 2H, CH2), 4.10 (br s, 5H, OMe, 
CH2), 5.72 (br s, 1H, CH), 5.97 (s, 2H, O2CH2), 6.50 (s, 1H, CHar), 7.00-7.07 (m, 3H, CHar), 7.25-
7.28 (m, 1H, CHar); 13C-NMR (151 MHz, CD3OD): δ = 26.5 (PhCH2), 40.2 (NCH3), 49.6 (CH2N), 
53.3 (CH), 59.1 (OMe), 60.5 (OMe), 68.8 (CH2), 70.7 (CH2), 71.5 (CH2), 72.9 (CH2), 89.9 (Cq 
alkyne), 91.0 (Cq alkyne), 103.1 (O2CH2), 103.7 (CHar), 117.7 (CHar), 118.8 (CHar), 123.1 (Cq), 
125.6 (CHar), 130.8 (Cq), 130.9 (CHar), 136.7 (Cq), 139.9 (Cq), 141.0 (Cq), 152.0 (Cq) 160.2 (Cq); 
HRMS (ESI): [M+H]+ calculated for C25H30O6N 440.20676, found 440.20642. 
5-(Cyclopropylethynyl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g] 
isoquinoline (119) 
 
According to general procedure IX, 119 was obtained as a colourless solid (6 mg, 16%). The 
product was purified via flash chromatography (petroleum ether/ethyl acetate, 2:1). Rf = 0.33 
(petroleum ether/ethyl acetate, 1:1); m.p. 102-104 °C; 1H-NMR (400 MHz, CDCl3): δ = 0.60-0.63 
(m, 2H, CH2), 0.68-0.72 (m, 2H, CH2), 1.21-1.24 (m, 1H, CH), 2.46 (s, 3H, NCH3), 2.56-2.65 (m, 
2H, PhCH2), 2.81-2.93 (m, 2H, CH2N), 3.99 (s, 3H, OMe), 4.64 (s, 1H, CH), 5.86 (s, 2H, O2CH2), 
6.29 (s, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ = -0.4 (CH), 18.4 (2C, CH2), 28.7 (PhCH2), 42.9 
(NCH3), 46.4 (CH2N), 50.6 (CH), 59.6 (OMe), 72.0 (Cq alkyne), 89.0 (Cq alkyne), 100.7 (O2CH2), 
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103.0 (CHar), 121.9 (Cq), 127.2 (Cq), 134.5 (Cq), 139.8 (Cq), 148.1 (Cq); HRMS (ESI): calculated for 
[M+H]+ C17H20O3N 286.14377, found 286.14362.  
5-[3-(4-Fluorophenoxy)prop-1-ynyl]-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo 
[4,5-g]isoquinoline (120) 
 
A suspension of cotarnine iodide 23 (100 mg, 0.29 mmol, 1 equiv) in THF (1 mL) was cooled to 
0 °C. In a separate flask 1-fluoro-4-(prop-2-ynyloxy)benzene154 (230 µL, 1.73 mmol, 6 equiv) in 
THF (1.5 mL) was cooled to 0 °C and isopropyl magnesium chloride lithium chloride complex 
solution (1.3 M in THF, 1.33 mL, 1.73 mmol, 6 equiv) added dropwise. After 10 min stirring the 
reaction mixture was transferred to the cotarnine iodide/THF suspension. The resulting solution 
was stirred at 0 °C for 1h and then warmed to RT within 1h. The reaction was quenched by the 
addition of saturated aq. NaHCO3 solution and extracted with diethyl ether (3 × 20 mL). The 
combined organic fractions were dried with MgSO4, filtered and the solvent was evaporated in 
vacuo. The residue was purified via flash chromatography (petroleum ether/ethyl acetate, 2:1) to 
give 120 as a slightly yellow solid (106 mg, 99%). Rf = 0.41 (petroleum ether/ethyl acetate, 1:1); 
m.p. 166-167 °C; 1H-NMR (400 MHz, CDCl3): δ = 2.42 (s, 3H, NCH3), 2.54-2.58 (m, 1H, PhCH), 
2.61-2.65 (m, 1H, PhCH), 2.73-2.78 (m, 1H, CHN), 2.88-2.95 (m, 1H, CHN), 3.94 (s, 3H, OMe), 
4.67 (d, 2H, J = 1.9, OCH2), 4.71 (s, 1H, CH), 5.86 (s, 2H, O2CH2), 6.29 (s, 1H, CHar), 6.87-6.95 
(m, 4H, CHar); 13C-NMR (126 MHz, CDCl3): δ = 28.6 (PhCH2), 42.9 (NCH3), 46.6 (CH), 50.7 
(CH2N), 57.1 (OCH2), 59.4 (OMe), 80.2 (Cq alkyne), 85.0 (Cq alkyne), 100.7 (O2CH2), 102.8 (CHar), 
115.6 (d, J = 22.5, CHar-CF), 116.5 (d, J = 7.5, CHar), 120.5 (Cq), 127.5 (Cq), 134.2 (Cq), 139.8 (Cq), 
148.4 (Cq), 153.7 (Cq), 157.6 (d, J = 237.5, Cq-F); HRMS (ESI): [M+H]+ calculated for C21H21O4NF 
370.14491, found 370.14494. 
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General procedure X: quaternisation of tertiary tetrahydroisoquinolines 
The corresponding tertiary amine was dissolved in dry acetonitrile (1 mL) and methyl iodide 
(40 equiv) was added dropwise. The reaction mixture was stirred overnight and the solvents were 
evaporated under reduced pressure to give the desired target compound.  
5-Ethynyl-4-methoxy-6,6-dimethyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-6-ium 
iodide (121) 
 
According to general procedure X, tertiary amine 106 (14.7 mg, 0.06 mmol, 1 equiv) yielded 121 as 
a colourless solid (159 mg, 88%). m.p. 232-233 °C; 1H-NMR (400 MHz, DMSO-d6): δ = 3.03 (s, 3H, 
NCH3), 3.06-3.09 (m, 3H, NCH3), 3.29 (s, 3H, NCH3), 3.64-3.67 (m, 2H, CH2N), 3.99 (s, 3H, OMe), 
4.20 (d, 1H, J = 1.9, CH alkyne), 5.67 (s, 1H, CH), 6.04 (d, 2H, J = 0.8, O2CH2), 6.62 (s, 1H, CHar); 
13C-NMR (126 MHz, DMSO-d6): δ = 23.1 (PhCH2), 46.8 (NCH3), 52.6 (NCH3), 54.4 (CH2N), 58.0 
(CH), 59.6 (OMe), 75.7 (CH alkyne), 83.1 (Cq alkyne), 101.6 (O2CH2), 102.8 (CHar), 113.5 (Cq), 
123.1 (Cq), 134.8 (Cq), 139.2 (Cq), 149.8 (Cq); HRMS (ESI): [M]+ calculated for C15H18O3N 
260.12812, found 260.12816. 
4-Methoxy-6,6-dimethyl-5-(phenylethynyl)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-6-
ium iodide (122) 
 
According to general procedure X, tertiary amine 107 (13 mg, 0.04 mmol, 1 equiv) yielded 122 as a 
colourless solid (22.7 mg, 99%). m.p. 113-114 °C; 1H NMR (400 MHz, CD3OD): δ = 3.18 (s, 3H, 
NCH3), 3.20-3.26 (m, 2H, PhCH2), 3.67-3.72 (m, 1H, CHN), 3.95-4.03 (m, 1H, CHN), 4.11 (s, 3H, 
OMe), 5.85 (s, 1H, CH), 5.99 (s, 2H, O2CH2), 6.54 (s, 1H, CHar), 7.34-7.42 (m, 3H, CHar), 7.47-7.49 
(m, 2H, CHar); 13C-NMR (126 MHz, CD3OD): δ = 24.8 (PhCH2), 48.2 (NCH3), 54.2 (NCH3), 56.7 
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(CH2N), 60.5 (OMe), 61.5 (CH), 81.2 (Cq alkyne), 93.0 (Cq alkyne), 103.2 (O2CH2), 103.8 (CHar), 
115.0 (Cq), 121.9 (Cq), 124.1 (Cq), 129.8 (CHar), 131.0 (2C, CHar), 133.0 (2C, CHar), 136.7 (Cq), 
141.3 (Cq), 152.3 (Cq); HRMS (ESI): [M]+ calculated for C21H22O3N 336.15942, found 336.15954. 
4-Methoxy-5-[(3-methoxyphenyl)ethynyl]-6,6-dimethyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g] 
isoquinolin-6-ium iodide (123) 
 
According to general procedure X, tertiary amine 109 (15.4 mg, 0.04 mmol, 1 equiv) yielded 123 as 
a yellow solid (21.6 mg, 99%). m.p. 127-128 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.18 (s, 3H, 
NCH3), 3.20-3.25 (m, 2H, PhCH2), 3.52 (s, 3H, NCH3), 3.67-3.74 (m, 1H, CHN), 3.96-4.03 (m, 1H, 
CHN), 4.11 (s, 3H, OMe), 5.84 (s, 1H, CH), 5.99 (s, 2H, O2CH2), 6.54 (s, 1H, CHar), 6.97-7.06 (m, 
3H, CHar), 7.27 (t, 1H, J = 8.0, CHar); 13C-NMR (126 MHz, CD3OD): δ = 24.8 (PhCH2), 48.2 (NCH3), 
54.3 (NCH3), 56.0 (OMe), 56.7 (CH2N), 60.6 (OMe), 61.5 (CH), 80.9 (Cq alkyne), 92.8 (Cq alkyne), 
103.2 (O2CH2), 103.8 (CHar), 115.0 (Cq), 117.3 (CHar), 117.9 CHar), 122.8 (Cq), 124.1 (Cq), 125.4 
(CHar), 130.9 (CHar), 136.7 (Cq), 141.2 (Cq), 152.2 (Cq), 162.1 (Cq); HRMS (ESI): [M]+ calculated for 
C22H24O4N 366.16998, found 366.17008. 
4-Methoxy-6,6-dimethyl-5-(phenylethynyl)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-6-
ium iodide (124) 
 
According to general procedure X, tertiary amine 110 (13.5 mg, 0.04 mmol, 1 equiv) yielded 124 as 
a yellow solid (19 mg, 99%). m.p. 174-176 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.17 (s, 3H, 
NCH3), 3.19-3.27 (m, 2H, PhCH2), 3.50 (s, 3H, NCH3), 3.65-3.68 (m, 1H, CHN), 3.95-4.01 (m, 1H, 
CHN), 4.09 (s, 3H, OMe), 5.80 (s, 1H, CH), 5.98 (s, 2H, O2CH2), 6.53 (s, 1H, CHar), 6.91 (d, 2H, J 
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= 8.8, CHar), 7.41 (d, 2H, J = 8.8, CHar); 13C-NMR (126 MHz, CD3OD): δ = 24.8 (PhCH2), 48.1 
(NCH3), 54.2 (NCH3), 55.9 (OMe), 56.5 (CH2N), 60.5 (OMe), 61.7 (CH), 80.0 (Cq alkyne), 93.3 (Cq 
alkyne), 103.2 (O2CH2), 103.7 (CHar), 113.7 (Cq), 115.4 (Cq), 115.4 (2C, CHar), 124.0 (Cq), 134.7 
(2C, CHar), 136.7 (Cq), 141.2 (Cq), 152.2 (Cq), 162.5 (Cq); HRMS (ESI): [M]+ calculated for 
C22H24O4N 366.16998, found 366.17008. 
4-Methoxy-6,6-dimethyl-5-{[4-(trifluoromethyl)phenyl]ethynyl}-5,6,7,8-tetrahydro[1,3] 
dioxolo[4,5-g]isoquinolin-6-ium iodide (125) 
 
According to general procedure X, tertiary amine 111 (20.5 mg, 0.05 mmol, 1 equiv) yielded 125 as 
a yellow solid (28 mg, 99%). m.p. 141-142 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.21 (s, 3H, 
NCH3), 3.32-3.29 (m, 1H, PhCH), 3.40-3.43 (m, 1H, PhCH), 3.56 (s, 3H, NCH3), 3.72-3.76 (m, 1H, 
CHN), 3.99-4.05 (m, 1H, CHN), 4.12 (s, 3H, OMe), 5.91 (s, 1H, CH), 5.99 (s, 2H, O2CH2), 6.55 (s, 
1H, CHar), 7.67-7.75 (m, 4H, CHar); 13C-NMR (126 MHz, CD3OD): δ = 24.8 (PhCH2), 48.4 (NCH3), 
54.4 (NCH3), 56.9 (CH2N), 60.6 (OMe), 61.3 (CH), 83.6 (Cq alkyne), 91.2 (Cq alkyne), 103.2 
(O2CH2), 103.8 (CHar), 114.5 (Cq), 124.3 (Cq), 126.6 (q, 2C, J = 3.8, CHar), 127.4 (q, J = 270, 
Cq-CF3), 130.1 (Cq), 132.4 (q, 2C, J = 32.4, CHar), 133.7 (2C, CHar) 136.6 (Cq), 142.2 (Cq), 152.4 
(Cq); HRMS (ESI): [M]+ calculated for C22H21O3NF3 404.14680, found 404.14614. 
4-Methoxy-6,6-dimethyl-5-(thien-3-ylethynyl)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g] 
isoquinolin-6-ium iodide (126) 
 
According to general procedure X, tertiary amine 112 (12.3 mg, 0.04 mmol, 1 equiv) yielded 126 as 
a yellow solid (17.6 mg, 99%). m.p. 157-158 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.17 (s, 3H, 
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NCH3), 3.18-3.27 (m, 2H, PhCH2), 3.50 (s, 3H, NCH3), 3.66-3.70 (m, 1H, CHN), 3.94-4.01 (m, 1H, 
CHN), 4.09 (s, 3H, OMe), 5.81 (s, 1H, CH), 5.99 (s, 2H, O2CH2), 6.54 (s, 1H, CHar), 7.16 (dd, 1H, 
J1 = 5.0, J2 = 1.2, CHar), 7.44 (dd, 1H, J1 = 5.0, J2 = 3.1, CHar), 7.76 (dd, 1H, J1 = 3.1, J2 = 1.2, 
CHar); 13C-NMR (126 MHz, CD3OD): δ = 24.8 (PhCH2), 48.2 (NCH3), 54.2 (NCH3), 56.6 (OMe), 
56.6 (CH2N), 60.5 (OMe), 61.6 (CH), 80.9 (Cq alkyne), 88.4 (Cq alkyne), 103.2 (O2CH2), 103.8 
(CHar), 115.0 (Cq), 120.8 (Cq), 124.1 (Cq), 127.5 (CHar), 130.7 (CHar), 132.7 (CHar), 136.7 (Cq), 
141.2 (Cq), 152.2 (Cq); HRMS (ESI): [M]+ calculated for C19H20O3NS 342.11584, found 342.11586. 
5-[3-(4-Fluorophenoxy)prop-1-ynyl]-4-methoxy-6,6-dimethyl-5,6,7,8-tetrahydro-[1,3]dioxolo 
[4,5-g]isoquinolin-6-ium iodide (127) 
 
According to general procedure X, tertiary amine 120 (15 mg, 0.04 mmol, 1 equiv) yielded 127 as a 
slightly yellow solid (20.1 mg, 97%). m.p. 172-173 °C (decomposition); 1H-NMR (400 MHz, DMSO-
d6): δ = 2.99 (s, 3H, NCH3), 3.03-3.07 (m, 2H, PhCH2), 3.27 (s, 3H, NCH3), 3.57-3.61 (m, 2H, 
CH2N), 3.93 (s, 3H, OMe), 4.92 (d, 2H, J = 1.5, OCH2), 5.70 (s, 1H, CH), 6.04 (s, 2H, O2CH2), 6.60 
(s, 1H, CHar), 6.98-7.00 (m, 2H, CHar), 7.10-7.14 (m, 2H, CHar); 13C-NMR (101 MHz, DMSO-d6): δ = 
23.2 (PhCH2), 46.8 (NCH3), 52.5 (NCH3), 54.4 (CH2N), 56.1 (OCH2), 58.2 (CH), 59.6 (OMe), 79.0 
(Cq alkyne), 87.3 (Cq alkyne), 101.7 (O2CH2), 102.8 (CHar), 113.3 (Cq), 115.9 (d, 2C, J = 23.0, CHar-
CF), 116.6 (d, 2C, J = 9.0, CHar), 123.2 (Cq), 134.8 (Cq), 139.2 (Cq), 149.8 (Cq), 153.1 (Cq), 157.6 
(d, J = 236.0, Cq-F); HRMS (ESI): [M]+ calculated for C22H23O4NF 384.16056, found 384.16108. 
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7-Methoxy-1-[(2-methoxyphenyl)ethynyl]-2,2-dimethyl-1,2,3,4-tetrahydroisoquinolinium 
iodide (128) 
 
According to general procedure X, tertiary amine 97 (6 mg of the free amine, 0.02 mmol, 1 equiv) 
yielded 128 as a slightly yellow wax (8 mg, 93%). 1H-NMR (600 MHz, CD3OD): δ = 3.19-3.28 (m, 
5H, NCH3, PhCH2), 3.44 (s, 3H, NCH3), 3.83 (s, 3H, OMe), 3.85-3.88 (m, 1H, CHN), 3.90 (s, 3H, 
OMe), 4.00-4.04 (m, 1H, CHN), 6.06 (s, 1H, CH), 6.96-6.99 (m, 1H, CHar), 7.03 (dd, 1H, J1 = 8.5, J2 
= 2.4, CHar), 7.08 (d, 1H, J = 8.5, CHar), 7.21 (d, 1H, J = 2.4, CHar), 7.27 (d, 1H, J = 8.5, CHar), 
7.43-7.45 (m, 1H, CHar), 7.5 (d, 1H, CHar); 13C-NMR (151 MHz, CD3OD): δ = 24.1 (PhCH2), 47.1 
(NCH3), 53.0 (NCH3), 56.0 (OMe), 56.5 (OMe), 60.3 (CH2N), 67.4 (CH), 84.0 (Cq alkyne), 91.3 (Cq 
alkyne), 110.6 (Cq), 112.2 (CHar), 114.1 (CHar), 116.9 (CHar), 121.7 (CHar), 130.0 (2Cq), 131.5 
(CHar), 132.0 (CHar), 134.2 (CHar), 160.7 (Cq-OMe), 162.5 (Cq-OMe); HRMS (ESI): [M]+ calculated 
for C21H24O2N 322.18016, found 322.18024. 
5-[3-(4-Fluorophenoxy)propyl]-4-methoxy-6,6-dimethyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g] 
isoquinolin-6-ium iodide (244) 
 
According to general procedure X, tertiary amine 133 (9 mg, 0.02 mmol, 1 equiv) yielded 245 as a 
slightly yellow solid (12.4 mg, 99%). m. p. 178-180 °C; 1H-NMR (400 MHz, CD3OD): δ = 1.82-1.99 
(m, 3H, CH2, CH), 2.38-2.45 (m, 1H, CH), 3.06 (s, 3H, NCH3), 3.13-3.16 (m, 2H, PhCH2), 3.36 (s, 
3H, NCH3), 3.51-3.56 (m, 1H, CHN), 3.80-3.88 (m, 1H, CHN), 3.97 (t, 2H, J = 5.8, OCH2), 4.05 (s, 
3H, OMe), 4.72-4.73 (m, 1H, CH), 5.96 (d, 2H, J = 2.5, O2CH2), 6.49 (s, 1H, CHar), 6.85-6.89 (m, 
2H, CHar), 6.95-6.99 (m, 2H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 24.6 (PhCH2), 28.1 (CH2), 
Experimental Section 151 
 
30.4 (CH2), 51.6 (NCH3), 53.1 (NCH3), 55.0 (CH2N), 60.2 (OMe), 68.8 (CH), 68.8 (OCH2), 102.9 
(O2CH2), 103.6 (CHar), 116.6 (d, 2C, J = 25.0, CHar-CF), 116.7 (d, 2C, J = 10.0, CHar), 118.0 (Cq), 
124.2 (Cq), 136.1 (Cq), 141.2 (Cq), 151.6 (Cq), 156.4 (Cq), 158.7 (d, J = 236.0, Cq-F); HRMS (ESI): 
[M]+ calculated for C22H27O4NF 388.19186, found 388.19228. 
7-Methoxy-1-[(2-methoxyphenyl)ethynyl]-2,2-dimethyl-1,2,3,4-tetrahydroisoquinolinium 
iodide (129) 
 
According to general procedure X, tertiary amine 98 (12.6 mg of the free amine, 0.04 mmol, 1 
equiv) yielded 129 as a slightly yellow solid (14 mg, 76%). m.p. 139-141 °C; 1H-NMR (400 MHz, 
CD3OD): δ = 3.08-3.15 (m, 2H, PhCH2), 3.18 (s, 6H, NCH3), 3.69 (s, 3H, OMe), 3.70 (s, 3H, OMe), 
3.73-3.78 (m, 1H, CHN), 3.89-3.95 (m, 1H, CHN), 5.98 (s, 1H, CH), 6.90-6.94 (m, 2H, CHar), 6.99 
(d, 1H, J = 2.3, CHar), 7.03-7.06 (m, 2H, CHar), 7.16-7.23 (m, 2H, CHar); 13C-NMR (101 MHz, 
CD3OD): δ = 24.1 (PhCH2), 48.2 (NCH3), 52.4 (NCH3), 56.0 (2OMe), 59.9 (CH2N), 66.8 (CH), 79.9 
(Cq alkyne), 94.4 (Cq alkyne), 113.7 (CHar), 117.1 (CHar), 117.6 (CHar), 118.1 (CHar), 121.7 (Cq), 
122.5 (Cq), 125.5 (CHar), 130.0 (Cq), 131.0 (CHar), 131.6 (CHar), 160.7 (Cq-OMe), 161.1 (Cq-OMe); 
HRMS (ESI): [M]+ calculated for C21H24O2N 322.18016, found 322.18029. 
6,7-Dimethoxy-2,2-dimethyl-1-(phenylethynyl)-1,2,3,4-tetrahydroisoquinolinium iodide (130) 
 
According to general procedure X, tertiary amine 82 (2.7 mg, 0.01 mmol, 1 equiv) yielded 130 as a 
slightly yellow solid (4 mg, 99%). m.p. 136-138 °C (decomposition); 1H-NMR (600 MHz, CD3OD): δ 
= 3.16-3.23 (m, 2H, PhCH2), 3.29 (s, 3H, NCH3), 3.39 (s, 3H, NCH3), 3.78-3.83 (m, 1H, CHN), 3.84 
(s, 3H, OMe), 3.86 (s, 3H, OMe), 3.97-4.01 (m, 1H, CHN), 5.95 (s, 1H, CH), 6.91 (s, 1H, CHar), 
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7.07 (s, 1H, CHar), 7.41-7.48 (m, 3H, CHar), 7.58-7.60 (m, 2H, CHar); 13C-NMR (151 MHz, CD3OD): 
δ = 24.5 (PhCH2), 48.0 (NCH3), 52.3 (NCH3), 56.6 (OMe), 56.6 (OMe), 59.8 (CH2N), 66.7 (CH), 
80.4 (Cq alkyne), 94.4 (Cq alkyne), 111.7 (CHar), 112.8 (CHar), 120.7 (Cq), 121.6 (Cq), 122.6 (Cq), 
129.9 (CHar), 131.3 (CHar), 133.2 (CHar), 150.4 (Cq-OMe), 151.8 (Cq-OMe); HRMS (ESI): [M]+ 
calculated for C21H24O2N 322.18016, found 322.18023. 
Preparation of azides 
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1-Azido-2-methoxybenzene (A) and 1-azido-3-methoxybenzene (B) were prepared from the 
corresponding aniline, dissolved in HCl solution (1 M) under addition of NaNO2 and sodium 
azide.155 Benzyl azides (C-F) were prepared from the corresponding benzyl bromide via 
substitution with sodium azide in DMSO.156 2-(Azidomethyl)pyridine (G) was obtained from 2-
(chloromethyl)pyridine hydrochloride via azide substitution in water. (1,3-Benzodioxol-5-yl)methyl 
azide (H) was prepared from the corresponding alcohol via the benzyl tosylate.69 
General procedure XI: preparation of triazolyl-1,2,3,4-tetrahydroisoquinolinium chlorides 
To a solution of alkyne 54 (1 equiv) in degassed ethanol (0.05 mmol alkyne in 1 mL) the 
corresponding azide (1.2 equiv) was added followed by a degassed solution of copper sulfate (1 M 
in water, 1.18 equiv) and sodium ascorbate (2M in water, 1.5 equiv). The reaction mixture was 
stirred at RT overnight. After conversion of the alkyne, the solvent was removed under reduced 
pressure, and the residue was purified by flash chromatography. The resulting material was 
subsequently dissolved in 5% HCl in methanol (1 mL) and stirred overnight. The solvents were 
removed in vacuo and the residue was washed several times with petroleum ether and diethyl 
ether to give the desired compound. 
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1-(1-Benzyl-1H-1,2,3-triazol-4-yl)-7-methoxy-1,2,3,4-tetrahydroisoquinolinium chloride (64) 
 
According to general procedure XI, triazole 64 was obtained as a colourless solid (18 mg, 64% 
over 2 steps). m.p. 214-216 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.11-3.14 (m, 2H, PhCH2), 3.46-
3.60 (m, 2H, CH2N), 3.66 (s, 3H, OMe), 5.63 (s, 2H, PhCH2N), 5.95 (s, 1H, CH), 6.51 (d, 1H, J = 
2.8, CHar), 6.91 (dd, 1H, J1 = 8.5, J2 = 2.8, CHar), 7.22 (d, 1H, J = 8.5, CHar), 7.35 (s, 5H, CHar), 8.10 
(s, 1H, CH-triazole); 13C-NMR (101 MHz, CD3OD): δ = 25.3 (PhCH2), 40.7 (CH2N), 52.4 (CH), 55.1 
(PhCH2N), 55.8 (OMe), 113.1 (CHar), 116.4 (CHar), 124.7 (CHar), 126.7 (Cq), 129.3 (2C, CHar), 
129.7 (CHar), 130.1 (2C, CHar), 131.6 (CHar), 132.0 (Cq), 136.6 (Cq), 145.2 (Cq), 160.1 (Cq-OMe); 
HRMS (ESI): [M+H]+ calculated for C19H21ON4 321.17099, found 321.17107. 
7-Methoxy-1-[1-(2-methoxyphenyl)-1H-1,2,3-triazol-4-yl]-1,2,3,4-tetrahydroisoquinolinium 
chloride (65) 
 
According to general procedure XI, triazole 65 was obtained as a slightly yellow solid (24 mg, 63% 
over 2 steps). m.p. 233-235 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.16-3.21 (m, 2H, PhCH2), 3.53-
3.60 (m, 1H, CHN), 3.66-3.70 (m, 1H, CHN), 3.72 (s, 3H, OMe), 3.89 (s, 3H, OMe), 6.06 (s, 1H, 
CH), 6.62 (d, 1H, J
 
= 2.5, CHar), 6.95 (dd, 1H, J1 = 8.7, J2 = 2.5, CHar), 7.13-7.16 (m, 1H, CHar), 
7.25-7.30 (m, 2H, CHar), 7.51-7.55 (m, 1H, CHar), 7.68 (dd, 1H, J1 = 8.7, J2 = 2.5, CHar), 8.61 (s, 
1H, CH-triazole); 13C-NMR (101 MHz, CD3OD): δ = 25.4 (PhCH2), 40.9 (CH2N), 52.5 (CH), 55.9 
(OMe), 56.7 (OMe), 113.3 (CHar), 113.8 (CHar), 116.4 (CHar), 122.2 (CHar), 124.8 (Cq), 126.7 
(CHar), 128.6 (CHar), 131.6 (CHar), 132.0 (Cq), 132.3 (CHar), 144.5 (Cq), 153.1 (Cq-OMe), 160.2 (Cq-
OMe); HRMS (ESI): [M+H]+ calculated for C19H21O2N4 337.16590, found 337.16599. 
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7-Methoxy-1-[1-(3-methoxyphenyl)-1H-1,2,3-triazol-4-yl]-1,2,3,4-tetrahydroisoquinolinium 
chloride (66) 
 
According to general procedure XI, triazole 66 was obtained as a yellow solid (23 mg, 54% over 2 
steps). m.p. 227-229 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.16-3.19 (m, 2H, PhCH2), 3.53-3.56 (m, 
1H, CHN), 3.63-3.69 (m, 1H, CHN), 3.71 (s, 3H, OMe), 3.87 (s, 3H, OMe), 6.06 (s, 1H, CH), 6.65 
(d, 1H, J
 
= 2.3, CHar), 6.95 (dd, 1H, J1 = 8.6, J2 = 2.3, CHar), 7.06 (dd, 1H, J1 = 8.2, J2 = 1.3, CHar), 
7.25 (d, 1H, J = 8.6, CHar), 7.40-7.48 (m, 3H, CHar), 8.61 (s, 1H, CHar); 13C-NMR (101 MHz, 
CD3OD): δ = 25.3 (PhCH2), 40.6 (CH2N), 52.4 (CH), 55.9 (OMe), 56.2 (OMe), 107.5 (CHar), 113.4 
(CHar), 113.6 (CHar), 116.0 (CHar), 116.5 (CHar), 124.7 (CHar), 125.0 (Cq), 131.6 (CHar), 131.8 (Cq), 
131.9 (CHar), 139.1 (Cq), 145.6 (Cq), 160.2 (Cq-OMe), 162.3 (Cq-OMe); HRMS (ESI): [M+H]+ 
calculated for C19H21O2N4 337.16590, found 337.16598. 
7-Methoxy-1-[1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl]-1,2,3,4-tetrahydroisoquinolinium 
chloride (67) 
 
According to general procedure XI, triazole 67 was obtained as a colourless solid (27 mg, 71% 
over 2 steps). m.p. 198-200 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.08-3.17 (m, 2H, PhCH2), 3.47-
3.52 (m, 1H, CHN), 3.54-3.59 (m, 1H, CHN), 3.67 (s, 3H, OMe), 3.76 (s, 3H, OMe), 5.59 (s, 2H, 
PhCH2N), 5.94 (s, 1H, CH), 6.50 (d, 1H, J = 2.3, CHar), 6.88-6.92 (m, 4H, CHar), 7.22 (d, 1H, J = 
8.8, CHar), 7.25-7.26 (m, 1H, CHar), 8.07 (s, 1H, CH-triazole); 13C-NMR (126 MHz, CD3OD): δ = 
25.3 (PhCH2), 40.8 (CH2N), 52.5 (CH), 55.0 (PhCH2N), 55.8 (OMe), 113.1 (CHar), 114.9 (CHar), 
115.0 (CHar), 116.4 (CHar), 121.3 (CHar), 124.7 (Cq), 126.7 (Cq), 131.2 (CHar), 131.6 (CHar), 132.0 
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(CHar), 137.9 (Cq), 145.2 (Cq), 160.1 (Cq-OMe), 161.6 (Cq-OMe); HRMS (ESI): [M+H]+ calculated 
for C20H23O2N4 351.18155, found 351.18152. 
1-[1-(2-Bromobenzyl)-1H-1,2,3-triazol-4-yl]-7-methoxy-1,2,3,4-tetrahydroisoquinolinium 
chloride (68) 
 
According to general procedure XI, triazole 68 was obtained as a colourless solid (24 mg, 73% 
over 2 steps). m.p. 246-248 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.09-3.16 (m, 2H, PhCH2), 3.48-
3.53 (m, 1H, CHN), 3.56-3.61 (m, 1H, CHN), 3.68 (s, 3H, OMe), 5.76 (s, 2H, PhCH2N), 5.96 (s, 1H, 
CH), 6.52 (s, 1H, CHar), 6.92 (dd, 1H, J1 = 8.2, J2 = 2.1, CHar), 7.22 (d, 1H, J = 8.2, CHar), 7.28-7.34 
(m, 2H, CHar), 7.37-7.40 (m, 1H, CHar), 7.65 (d, 1H, J = 8.2, CHar), 8.04 (s, 1H, CH-triazole); 13C-
NMR (126 MHz, CD3OD): δ = 25.3 (PhCH2), 40.8 (CH2N), 52.5 (CH), 55.2 (PhCH2N), 55.8 (OMe), 
113.1 (CHar), 116.5 (CHar), 124.7 (Cq), 124.7 (Cq), 127.1 (CHar), 129.4 (CHar), 131.6 (CHar), 131.8 
(CHar), 132.0 (Cq), 132.2 (CHar), 134.5 (CHar), 135.5 (2C, Cq), 160.2 (Cq-OMe); HRMS (ESI): 
[M+H]+ calculated for C19H20ON4Br 399.08150, found 399.08109. 
1-[1-(3-Bromobenzyl)-1H-1,2,3-triazol-4-yl]-7-methoxy-1,2,3,4-tetrahydroisoquinolinium 
chloride (69) 
 
According to general procedure XI, triazole 69 was obtained as a colourless solid (31 mg, 75% 
over 2 steps). m.p. 245-247 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.11-3.14 (m, 2H, PhCH2), 3.48-
3.57 (m, 2H, CH2N), 3.68 (s, 3H, OMe), 5.63 (s, 2H, PhCH2N), 5.96 (s, 1H, CH), 6.54 (d, 1H, J = 
2.5, CHar), 6.93 (dd, 1H, J1 = 8.5, J2 = 2.5, CHar), 7.23 (d, 1H, J = 8.5, CHar), 7.27-7.35 (m, 2H, 
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CHar), 7.50-7.52 (m, 2H, CHar), 8.11 (s, 1H, CH-triazole); 13C-NMR (101 MHz, CD3OD): δ = 23.8 
(PhCH2), 39.2 (CH2N), 50.9 (CH), 52.8 (PhCH2N), 54.3 (OMe), 111.6 (CHar), 115.0 (CHar), 122.3 
(Cq), 123.1 (Cq), 125.4 (CHar), 126.6 (CHar), 130.1 (CHar), 130.4 (CHar), 130.4 (Cq), 130.7 (CHar), 
131.3 (CHar), 137.6 (2C, Cq), 158.7 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for C19H20ON4Br 
399.08150, found 399.08120. 
1-[1-(4-Bromobenzyl)-1H-1,2,3-triazol-4-yl]-7-methoxy-1,2,3,4-tetrahydroisoquinolinium 
chloride (70) 
 
According to general procedure XI, triazole 70 was obtained as a colourless solid (31 mg, 60% 
over 2 steps). m.p. 250-252 °C; 1H-NMR (400 MHz, CD3OD): δ = 3.10-3.14 (m, 2H, PhCH2), 3.47-
3.56 (m, 2H, CH2N), 3.68 (s, 3H, OMe), 5.60 (s, 2H, PhCH2N), 5.94 (s, 1H, CH), 6.53 (d, 1H, J = 
2.3, CHar), 6.91-6.94 (m, 1H, CHar), 7.22 (d, 1H, J = 8.5, CHar), 7.28 (d, 2H, J = 8.3, CHar), 7.53 (d, 
2H, J
 
= 8.3, CHar), 8.10 (s, 1H, CH-triazole); 13C-NMR (101 MHz, CD3OD): δ = 25.3 (PhCH2), 40.6 
(CH2N), 52.4 (CH), 54.4 (PhCH2N), 55.8 (OMe), 113.2 (CHar), 116.4 (CHar), 123.7 (Cq), 124.6 (Cq), 
126.1 (Cq), 128.5 (CHar), 131.2 (2C, CHar), 131.6 (CHar), 133.2 (2C, CHar), 135.9 (Cq), 160.1 (Cq-
OMe); HRMS (ESI): [M+H]+ calculated for C19H20ON4Br 399.08150, found 399.08114. 
7-Methoxy-1-[1-(pyridin-2-ylmethyl)-1H-1,2,3-triazol-4-yl]-1,2,3,4-tetrahydroisoquinolinium 
chloride (71) 
 
According to general procedure XI, triazole 71 was obtained as a colourless solid (24 mg, 64% 
over 2 steps). m.p. 107-109 °C; 1H-NMR (400 MHz, CD3OD): δ = 2.98-3.02 (m, 2H, PhCH2), 3.35-
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3.40 (m, 1H, CHN), 3.41-3.49 (m, 1H, CHN), 3.56 (s, 3H, OMe), 5.90 (s, 1H, CH), 6.03 (s, 2H, 
PhCH2N), 6.48 (d, 1H, J = 2.3, CHar), 6.78 (dd, 1H, J1 = 8.8, J2 = 2.3, CHar), 7.09 (d, 1H, J = 8.8, 
CHar), 7.82 (d, 1H, J = 8.0, CHar), 7.94-7.97 (m, 1H, CHar), 8.24 (s, 1H, CH-triazole), 8.50-8.53 (m, 
1H, CHar), 8.77 (d, 1H, J = 5.7, CHar); 13C-NMR (101 MHz, CD3OD): δ = 25.3 (PhCH2), 40.6 
(CH2N), 51.3 (PhCH2N), 52.2 (CH), 55.9 (OMe), 113.5 (CHar), 116.3 (CHar), 124.8 (Cq), 128.4 
(CHar), 128.4 (CHar), 128.5 (CHar), 131.6 (CHar), 131.7 (Cq), 143.6 (CHar), 145.5 (CHar), 149.1 (Cq), 
150.4 (Cq), 160.1 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for C18H20ON5 322.16624, found 
322.16632. 
1-[1-(1,3-Benzodioxol-5-ylmethyl)-1H-1,2,3-triazol-4-yl]-7-methoxy-1,2,3,4-
tetrahydroisoquinolinium chloride (72) 
 
According to general procedure XI, triazole 72 was obtained as a colourless solid (26 mg, 75% 
over 2 steps). m.p. 229-231 °C; 1H-NMR (400 MHz, CD3OD): δ = 2.92-2.98 (m, 2H, PhCH2), 3.26-
3.33 (m, 1H, CHN), 3.35-3.41 (m, 1H, CHN), 3.47 (s, 3H, OMe), 5.33 (s, 2H, PhCH2N), 5.73 (s, 2H, 
O2CH2), 5.76 (s, 1H, CH), 6.31 (d, 1H, J = 1.9, CHar), 6.60 (d, 1H, J = 8.0, CHar), 6.65 (s, 1H, CHar), 
6.69-6.72 (m, 2H, CHar), 7.02 (d, 1H, J = 8.4, CHar), 7.89 (s, 1H, CH-triazole); 13C-NMR (126 MHz, 
CD3OD): δ = 25.3 (PhCH2), 40.7 (CH2N), 52.4 (CH), 55.0 (OMe), 55.8 (PhCH2N), 102.8 (O2CH2), 
109.4 (CHar), 109.6 (CHar), 113.1 (CHar), 116.5 (CHar), 123.3 (CHar), 124.7 (Cq), 126.5 (CHar), 130.1 
(Cq), 131.5 (CHar), 132.0 (CHar), 145.1 (Cq), 149.4 (Cq-OCH2), 149.6 (Cq-OCH2), 160.1 (Cq-OMe); 
HRMS (ESI): [M+H]+ calculated for C20H21O3N4 365.16082, found 365.16085. 
General procedure XII: reduction of alkynylated tetrahydroisoquinolines 
To a solution of the corresponding alkynylated tetrahydroisoquinoline (1 equiv) in ethyl acetate (20 
mL), catalytic amounts of K2CO3 and palladium on carbon were added. The reaction mixture was 
stirred under a baloon of hydrogen overnight. The reaction mixture was filtered over Cellite and the 
organic solvents were removed in vacuo. The residue was purified via flash chromatography to 
give the target compound. Most of the amines were then converted to the corresponding HCl-salt 
by addition of HCl in diethyl ether (1 M). 
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7-Methoxy-1-(3-methoxyphenethyl)-1,2,3,4-tetrahydroisoquinoline (131) 
 
According to general procedure XII, alkynylated tetrahydroisoquinoline 77 (10 mg, 0.03 mmol, 1 
equiv) yielded 131 as a colourless oil (9.6 mg, 95%). Flash chromatography (acetone). Rf = 0.15 
(acetone); 1H-NMR (400 MHz, CD3OD): δ = 2.08-2.18 (m, 1H, CH2), 2.19-2.24 (m, 1H, CH2), 2.69-
2.89 (m, 4H, PhCH2), 3.03-3.07 (m, 1H, CHN), 3.32-3.35 (m, 1H, CHN), 3.74 (s, 3H, OMe), 3.77 (s, 
3H, OMe), 4.12-4.14 (m, 1H, CH), 6.68 (d, 1H, J = 2.6, CHar), 6.74-6.77 (m, 2H, CHar), 6.81-6.83 
(m, 2H, CHar), 7.04 (d, 1H, J = 8.5, CHar), 7.18-7.21 (m, 1H, CHar); 13C-NMR (101 MHz, CD3OD): δ 
= 28.1 (PhCH2), 33.1 (PhCH2), 38.4 (CH2), 41.4 (CH2N), 55.6 (OMe), 55.7 (OMe), 56.5 (CH), 112.3 
(CHar), 112.5 (CHar), 114.2 (CHar), 115.2 (CHar), 121.8 (CHar), 126.9 (Cq), 130.6 (Cq), 131.2 (Cq), 
138.3 (Cq), 144.4 (Cq), 159.6 (Cq-OMe), 161.4 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for 
C19H24O2N 298.18016, found 298.18017. 
4-methoxy-5-[2-(3-methoxyphenyl)ethyl]-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-
g]isoquinolin-6-ium chloride (132)  
 
According to general procedure XII, alkynylated tetrahydroisoquinoline 109 (40 mg, 0.11 mmol, 1 
equiv) yielded 132 converted to the HCl-salt as a colourless wax (24 mg, 54%). Flash 
chromatography (cyclohexane/ethyl acetate, gradient from 0 to 100% ethyl acetate). Rf = 0.33 
(petroleum ether/ethyl acetate, 1:2); 1H-NMR (500 MHz, CDCl3): δ = 2.00-2.37 (m, 2H, CH2), 2.77 
(d, 3H, J = 8.5, NCH3), 2.88-3.12 (m, 4H, 2PhCH2), 3.28-3.30 (m, 1H, CHN), 3.64-3.66 (m, 1H, 
CHN), 3.79 (s, 3H, OMe), 3.96 (s, 3H, OMe), 4.23-4.25 (m, 1H, CH), 5.90 (s, 2H, O2CH2), 6.33 (s, 
1H, CHar), 6.70-6.72 (m, 1H, CHar), 6.91-6.92 (m, 2H, CHar), 7.15-7.19 (m, 1H, CHar); 13C-NMR 
(126 MHz, CDCl3): δ = 22.0 (PhCH2), 32.4 (PhCH2), 36.0 (CH2), 40.9 (NCH3), 44.6 (CH2N), 55.3 
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(OMe), 59.2 (OMe), 59.9 (CH), 101.2 (CHar), 102.2 (CHar), 111.9 (CHar), 114.3 (CHar), 115.7 (Cq), 
121.1 (CHar), 123.6 (Cq), 129.3 (CHar), 134.5 (Cq), 140.0 (Cq), 141.9 (Cq), 149.6 (Cq-OMe), 159.7 
(Cq-OMe); HRMS (ESI): [M+H]+ calculated for C21H26O4N 356.18563, found 356.18575. 
5-[3-(4-Fluorophenoxy)propyl]-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g] 
isoquinoline (133) 
 
According to general procedure XII, alkynylated tetrahydroisoquinoline 120 (13 mg, 0.04 mmol, 1 
equiv) yielded 133 as a colourless oil (12 mg, 91%). Flash chromatography (petroleum ether/ethyl 
acetate, 1:2). Rf = 0.33 (acetone); 1H-NMR (400 MHz, CDCl3): δ = 1.71-1.77 (m, 2H, CH2), 1.88-
1.93 (m, 2H, CH2), 2.43 (s, 3H, NCH3), 2.44-2.47 (m, 1H, 3.03-3.07, PhCH), 2.71-2.86 (m, 2H, 
PhCH, CHN), 3.14-3.21 (m, 1H, CHN), 3.67-3.70 (m, 1H, CH), 3.91-3.94 (m, 2H, OCH2), 3.95 (s, 
3H, OMe), 5.84 (dd, 2H, J1 = 6.8, J2 = 1.4, O2CH2), 6.28 (s, 1H, CHar), 6.79-6.82 (m, 2H, CHar), 
6.91-6.96 (m, 2H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 23.4 (PhCH2), 26.7 (CH2), 31.0 (CH2), 
42.1 (NCH3), 44.5 (CH2N), 58.4 (CH), 59.2 (OMe), 68.6 (OCH2), 100.4 (O2CH2), 102.6 (CHar), 
115.4 (d, 2C, J = 7.0, CHar), 115.6 (d, 2C, J = 23.0, CHar-CF), 122.7 (Cq), 127.5 (Cq), 134.1 (Cq), 
140.5 (Cq), 147.5 (Cq), 155.3 (Cq), 157.0 (d, J = 236.0, Cq-F); HRMS (ESI): [M+H]+ calculated for 
C21H23O4NF 374.17621, found 374.17630. 
General procedure XIII: copper-catalysed alkynylation 
By analogy to the literature76 a reaction tube was charged with cotarnine iodide (25 mg, 0.07 mmol, 
1 equiv) the chiral ligand (3.96 µmol, 0.055 equiv), CuBr (0.52 mg, 3.6 µmol, 0.05 equiv) and a 
stirbar before being sealed and purged with argon, followed by addition of dichloromethane (1.7 
mL) and the corresponding acetylene (0.72 mmol, 10 equiv). The solution was cooled to –78 °C 
before the addition of triethylamine (10 µL, 0.07 mmol, 1 equiv). The solution was placed in a 
cooling bath, where it was warmed to –55 °C and stirred for 48h. The solvents were evaporated 
and the residue was purified via flash chromatography to give the desired compound.  
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4-Methoxy-6-methyl-5-(phenylethynyl)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline (107) 
Using the general procedure for the alkynylation of cotarnine iodide (general procedure XIII), 
different ligands were screened for the synthesis of 107 using phenylacetylene. The residue was 
purified via flash chromatography (petroleum ether/ethyl acetate, 3:1) to give the desired 
compound as a slightly yellow oil. Product ratio was determined by HPLC, Chiralpak IC column, 
40% DCM/EtOH (100:2) in hexanes, 0.5 mL/min, 254 nm (Table 19). 
Table 19: Ligand screening for the synthesis of 107 using general procedure XIII. 
Ligand yield 
[%] 
tR  
[min] 
area  
[mAU·s] 
tR  
[min] 
area 
[mAU·s] 
ee 
[%] 
 
136 99 6.38 5502.8 (49%) 12.20 5723.4 (51%) 2 
137 25 5.65 1.62·104 (52%) 11.16 1.48·104 (48%) 4 
138 56 7.21 4265.3 (48%) 13.00 4671.0 (52%) 4 
139 99 7.28 4994.2 (51%) 13.11 4711.8 (49%) 2 
140 15 5.72 1.09·104 (56%) 11.48 8642.1 (44%) 12 
141 26 5.90 1.01·104 (45%) 11.60 1.24·104 (55%) 10 
142 99 7.67 3282.4 (50%) 13.48 3269.4 (50%) 0 
Josiphos (143) 42 5.76 2.49·104 (55%) 11.54 2.05·104 (45%) 10 
(R)-QuinoxP® (144) 99 6.99 2787.5 (25%) 12.36 8187.9 (75%) 50 
145 41 4.85 1.93·104 (47%) 10.59 2.16·104 (53%) 6 
(R)-Phanephos  99 6.85 6160.1 (41%) 12.45 8999.3 (59%) 18 
147 
 
52 5.08 1.92·104 (54%) 10.94 1.63·104 (46%) 8 
(R)-BINAP (148) 99 6.91 1922.2 (25%) 12.37 5719.9 (75%) 50 
(R)-TolBINAP (149) 73 5.09 1.90·104 (58%) 11.12 1.37·104 (42%) 16 
(R)-XylBINAP (150) 61 5.22 1.20·104 (61%) 11.3 7586.5 (39%) 22 
(R)-MonoPhos (151) 53 5.34 9371.9 (52%) 11.58 8803.8 (48%) 4 
(S)-QUINAP* (152) 99 12.90 4.46·104 (99.2%) 39.74 345.9 (0.8%) 98 
* measured at 30% DCM/EtOH (100:2) in hexanes, 0.5 mL/min, 254 nm. 
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5-[3-(4-Fluorophenoxy)prop-1-ynyl]-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo 
[4,5-g]isoquinoline (120) 
Using the general procedure for the alkynylation of cotarnine iodide, different ligands were 
screened for the synthesis of 120 using 1-fluoro-4-(prop-2-ynyloxy)benzene.154 The residue was 
purified via flash chromatography (petroleum ether/ethyl acetate, 2:1) to give the desired target 
compound as slightly yellow oil. Product ratio was determined by HPLC, Chiralpak IC column, 50% 
DCM/EtOH (100:2) in hexanes, 0.5 mL/min, 254 nm. 
Table 20: Synthesis of 120 using general procedure XIII with QUINAP as chiral ligand. 
Ligand yield  
[%] 
tR(major) 
[min] 
area 
[mAU·s] 
tR(minor) 
[min] 
area 
[mAU·s] 
ee 
[%] 
(R)-BINAP 16 9.11 409.5 (43%) 17.87 532.8 (57%) 14 
(R)-QuinoxP 46 9.11 402.5 (45%) 17.90 488.3 (55%) 10 
(R)-TolBINAP 40 8.80 857.9 (48%) 17.39 916.7 (52%) 4 
(R)-XylBINAP 30 8.82 823.9 (39%) 17.31 1264.5 (61%) 22 
(S)-QUINAP 83 10.10 995.36 (81.3%) 19.42 228.4 (18.7%) 63 
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Alkynylation using various alkynes  
The general procedure XIII described above was used to synthesize various alkynylated cotarnine 
derivatives in an enantioselective fashion. Product ratio was determined by HPLC, Chiralpak IC 
column, 10% EtOH in hexanes, 0.5 mL/min, 254 nm. 
Table 21: Alkynylation of cotarnine iodide using general procedure XIII with QUINAP as chiral ligand. 
 
R 
(compound 
ID) 
yield 
[%] 
tR(major) 
[min] 
area [mAU·s] tR(minor) 
[min] 
area 
[mAU·s] 
ee 
[%] 
[α]D20 
(CH2Cl2, 
c=1.0) 
Phenyl 
(S)-107* 
99 12.90 4.5·104 
(99.2%) 
39.74 345.9 
(0.8%) 
98 –95.0° 
3-OMePh 
(S)-109 
92 16.10 1.1·105 
(99.3%) 
31.01 767.7 
(0.7%) 
99 –98.8° 
4-OMePh 
(S)-110 
88 20.24 7.2 ·104 
(99.4%) 
39.33 469.42 
(0.6%) 
99 –98.1° 
4-CF3Ph 
(S)-111 
95 10.43 4.9 ·104 
(98.6%) 
15.25 671.6 
(1.4%) 
97 –86.3° 
3-Thiophene 
(S)-112 
99 14.74 8.6 ·104 
(99.4%) 
28.08 559.6 
(0.6%) 
99 –107.3° 
Cyclopropane  
(S)-119*** 
75 15.13 1.6·105 
(99.3%) 
32.59 1216.15 
(0.7%) 
99 –56.9° 
CH2O-(4-F-Ph) 
(S)-120** 
83 10.10 995.36 
(81.3%) 
19.42 228.4 
(18.7%) 
63 –33.0° 
1-Cyclohexene 
(S)-161 
58 13.77 2.5 104 
(98.4%) 
25.64 403.1 
(1.6%) 
97 –78.1° 
* measured at 30% DCM/EtOH (100:2) in hexanes, 0.5 ml/min, 254 nm. 
** measured at 50% DCM/EtOH (100:2) in hexanes, 0.5 ml/min, 254 nm. 
*** product ratio determined at 210 nm. 
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5-(Cyclohexenylethynyl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo 
[4,5-g]isoquinoline (161) 
 
According to general procedure XIII using (S)-QUINAP, (S)-161 was obtained as a colourless oil 
(13.5 mg, 58%). Flash chromatography (petroleum ether/ethyl acetate, 3:1). Rf = 0.42 (petroleum 
ether/ethyl acetate, 2:1); [α]D20 = –78.1° (c = 1.0, CH2Cl2); 1H-NMR (400 MHz, CDCl3): δ = 1.52-
1.60 (m, 2H, CH2), 2.03-2.10 (m, 2H, CH2), 2.51 (s, 3H, NCH3), 2.57-2.69 (m, 2H, PhCH2), 2.87-
2.97 (m, 2H, CH2N), 4.00 (s, 3H, OMe), 4.82 (s, 1H, CH), 5.86 (s, 2H, O2CH2), 6.01-6.05 (m, 1H, 
CH), 6.30 (s, 1H, CHar); 13C-NMR (101 MHz, CDCl3): δ = 21.5 (CH2), 22.3 (CH2), 25.5 (CH2), 28.7 
(CH2), 29.6 (CH2), 28.7 (PhCH2), 43.0 (NCH3), 46.6 (CH2N), 51.0 (CH), 59.6 (OMe), 83.5 (Cq 
alkyne), 87.6 (Cq alkyne), 100.7 (O2CH2), 103.0 (CHar), 120.5 (Cq), 121.6 (Cq), 127.2 (Cq), 134.0 
(CH alkene), 134.6 (Cq), 139.9 (Cq), 148.2 (Cq); HRMS (ESI): calculated for [M+H]+ C20H24O3N 
326.17507, found 326.17501. 
8-Methoxy-1-((3-methoxyphenyl)ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinolinium chloride 
(160) 
 
According to general procedure XIII using (S)-QUINAP and 8-methoxy-2-methyl-3,4-
dihydroisoquinolinium iodide (158)157 followed by conversion to the HCl-salt by addition of HCl in 
diethylether (1 M), afforded (S)-(–)-160 as a slightly yellow solid (34 mg, 99%). Flash 
chromatography (gradient from 0 to 100% ethyl acetate in cyclohexane); Rf = 0.37 (petroleum 
ether/ethyl acetate, 1:1); [α]D20 = –5° (c = 1.0, CH2Cl2); m.p. 52-54 °C; 1H-NMR (600 MHz, CD3OD): 
δ = 3.09 (s, 3H, NCH3), 3.11-3.16 (m, 2H, PhCH2), 3.50-3.60 (m, 2H, CH2N), 3.74 (s, 3H, OMe), 
3.91 (s, 3H, OMe), 5.72 (s, 1H, CH), 6.88-7.00 (m, 5H, CHar), 7.23-7.34 (m, 2H, CHar); 13C-NMR 
(111 MHz, CD3OD): δ = 26.1 (PhCH2), 41.6 (NCH3), 48.3 (CH2N), 53.1 (CH), 55.8 (OMe), 56.5 
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(OMe), 79.2 (Cq alkyne), 90.7 (Cq alkyne), 110.2 (CHar), 116.8 (CHar), 117.9 (CHar), 119.6 (Cq), 
122.1 (CHar), 123.2 (Cq), 125.3 (CHar), 130.8 (CHar), 131.2 (CHar), 132.4 (Cq), 157.4 (Cq-OMe), 
161.0 (Cq-OMe); HRMS (ESI): [M+H]+ calculated for C20H22O2N 308.16451, found 308.16453. 
Benzyl 7-methoxy-1-[(3-methoxyphenyl)ethynyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(159) 
 
General procedure XIII was slightly modified as follows. 7-Methoxy-3,4-dihydroisoquinoline (58) 
(19 mg, 0.12 mmol, 1 equiv) was dissolved in DCM (1 mL), cooled to 0 °C and benzyl 
chloroformate (19 µL, 0.13 mmol, 1.1 equiv) was added dropwise. The reaction mixture was stirred 
for 2h. Then (R)-QUINAP (2.85 mg, 6.5 µmol, 0.055 equiv) and CuBr (0.85 mg, 5.9 µmol, 0.05 
equiv) were added, followed by DCM (0.7 mL) and 3-ethinylanisole (150 µL, 1.18 mmol, 10 equiv). 
The solution was cooled to –78 °C in an dry ice/acetone bath before the addition of triethylamine 
(16 µL, 0.12 mmol, 1 equiv). The solution was placed in a cooling bath, where it was 
warmed to -55 °C and stirred for 48h. The reaction was worked up by the addition of saturated 
NH4Cl (aq.) and extracted with diethyl ether. The combined organic extracts were washed with 
brine, dried with MgSO4 and the solvents evaporated in vacuo. The residue was purified via flash 
chromatography (petroleum ether/ethyl acetate = 9:1) to give 159 as a yellow oil (17 mg, 34%). Rf 
= 0.39 (petroleum ether/ethyl acetate, 3:1); [α]D20 = 0° (c = 1.0, CH2Cl2); 1H-NMR (400 MHz, 
CDCl3): δ = 2.75-2.94 (m, 2H, PhCH2), 3.45-3.58 (m, 1H, CHN), 3.77 (s, 3H, OMe), 3.79 (s, 3H, 
OMe), 4.14-4.34 (m, 1H, CHN), 5.17-5.33 (m, 2H, Cbz-CH2),6.08-6.21 (m, 1H, CH), 6.78-7.19 (m, 
7H, CHar), 7.33-7.41 (m, 5H, Cbz- CHar); 13C-NMR (101 MHz, CDCl3): δ = 27.6 (PhCH2), 39.0 
(CH2N), 47.5 (CH), 55.3 (OMe), 55.4 (OMe), 67.5 (Cbz-CH2), 83.2 (Cq-alkyne), 88.0 (Cq-alkyne), 
112.0 (CHar), 114.0 (CHar), 115.0 (CHar), 116.5 (CHar), 123.6 (Cq), 124.4 (CHar), 127.9 (CHar), 128.0 
(CHar), 128.5 (CHar), 128.6 (Cq), 129.2 (CHar), 130.0 (CHar), 134.6 (Cq), 136.5 (Cq), 154.1 (Cq), 
158.4 (Cq-OMe), 159.1 (Cq-OMe); HRMS (ESI): calculated for [M-H]+ C27H25NO4 428.18563, found 
428.18541. 
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4-methoxy-5-(3-methoxybenzyl)-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-6-
ium chloride (246)  
 
A suspension of cotarnine iodide 23 (50 mg, 0.14 mmol, 1 equiv) in THF (1 mL) was cooled to 
0 °C. Then 3-methoxybenzylmagnesium chloride (0.25 M in THF, 1.7 mL, 0.43 mmol, 3 equiv) was 
added dropwise. The resulting solution was stirred at 0 °C for 1h and then warmed to RT within 1h. 
The reaction was quenched by addition of methanol and the solvents were evaporated in vacuo. 
The residue was purified via flash chromatography (cyclohexane/ethyl acetate, gradient from 0 to 
100% ethyl acetate) and the target compound converted to the HCl-salt by addition of HCl in 
diethylether (1 M) to give 247 as a slightly yellow wax (23 mg, 42%). Rf = 0.26 (petroleum 
ether/ethyl acetate, 1:1); 1H-NMR (500 MHz, CDCl3): δ = 2.70 (s, 3H, NCH3), 2.84-3.27 (m, 4H, 
PhCH2), 3.53-3.69 (m, 2H, CH2N), 3.73 (s, 3H, OMe), 3.75 (s, 3H, OMe), 4.62 (bs, 1H, CH), 5.91 
(s, 2H, O2CH2), 6.33 (s, 1H, CHar), 6.74-6.82 (m, 3H, CHar), 7.12-7.15 (m, 1H, CHar), 12.52 (bs, 1H, 
NH); 13C-NMR (126 MHz, CDCl3): δ = 29.7 (PhCH2), 40.1 (PhCH2), 42.3 (NCH3), 46.5 (CH2N), 55.4 
(OMe), 59.0 (OMe), 61.7 (CH), 101.1 (O2CH2), 102.2 (CHar), 113.4 (CHar), 115.0 (CHar), 122.2 
(CHar), 124.7 (Cq), 129.4 (CHar), 134.3 (Cq), 137.5 (2Cq), 140.2 (Cq), 149.7 (Cq), 159.6 (Cq); HRMS 
(ESI): [M+H]+ calculated for C20H24O4N 342.16998, found 342.17004. 
6,8-Difluoro-4-methylumbelliferol acetate (221, DiFMUA) 
 
6,8-difluoro-4-methylumbelliferol (222, DIFMU)149 (100 mg, 0.47 mmol, 1 equiv) was dissolved in 
dichloromethane (5 ml), triethylamine (99 µl, 0.71 mmol, 1.5 equiv) was added followed by 
acetylchloride. The reaction mixture was stirred at RT overnight. Solvents were evaporated and the 
product was purified via flash chromatography to give a colourless solid (78 mg, 65%). m.p. 129-
131 °C; Rf = 0.39 (petroleum ether/ethyl acetate, 3:1); 1H-NMR (400 MHz, DMSO-d6): δ = 2.41 (s, 
3H, COCH3), 2.46 (s, 3H, CH3), 6.55 (s, 3H, CH), 7.75 (dd, 1H, J1 = 10.5, J2 = 2.3, CHar); 13C-NMR 
(101 MHz, DMSO-d6): δ = 18.3 (CH3), 19.8 (COCH3), 107.2 (d, J = 4, CHar), 115.7 (CH), 118.5-
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118.6 (m, Cq), 128.7 (dd, J1 = 18, J2 = 13, Cq), 138.7 (dd, J1 = 10, J2 = 3, Cq), 141.8 (dd, J1 = 253, 
J2 = 5, Cq), 150.0 (dd, J1 = 242, J2 = 4, Cq), 152.3-152.4 (m, Cq), 157.9 (CO), 167.2 (CO); HRMS 
(ESI): calculated for [M+H]+ C12H9O4F2 255.04634, found 255.04658.  
6 Tetrahydroisoquinoline Compound Library 
The following 103 compounds were tested on microtubule inhibition: 21, 23, 61, 62, 63, 74, 75, (S)-
75, (R)-75, 76, 77, (S)-77, (R)-77, 78, 79, (S)-79, (R)-79, 64, 65, 66, 68, 69, 70, 72, 81, 82, (S)-82, 
(R)-82, 83, 84, (S)-84, (R)-84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, (S)-98, (R)-98, 
99, 100, 101, 102, 103, 104, (R)-104, 105, 106, 107, (S)-107, (R)-107, 108, 109, (S)-109, (R)-109, 
110, 111, 112, 113, 114, 115, 116, 117, 118, 119, (S)-119, 120, (S)-120, (R)-120, 121, (S)-122, 
(R)-122, 123, 124, 126, 127, (S)-127, (R)-127, 128, 129, (S)-129, (R)-129, 130, 132, (S)-161, 162, 
246, 322, 323, 324, 325, 326, 327. 
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VII Summary 
The presented work deals with two major aspects of chemical biology: chemical synthesis and 
application of protein-based test systems. In the first part, the synthesis of a compound collection 
based on the tetrahydroisoquinoline skeleton is described and is followed by a second part that 
details the use of small molecule microarrays as a tool for the identification of high-affinity 
ligand-protein interactions. 
BIOS of a tetrahydroisoquinoline-based compound library 
Using the principles of biology-oriented synthesis a library of alkynylated tetrahydrosioquinolines 
was synthesised. This library was based on the biologically prevalidated core scaffold of 
tetrahydroisoquinoline (THIQ), a structural backbone occurring in various natural products of 
diverse origin, exerting numerous biological effects. A prominent member of the THIQ-family is the 
natural product noscapine (21) that has recently drawn a lot of interest to its anti-cancer effect. The 
significant in vivo antitumor activity coupled with its minimal toxicity render noscapine an interesting 
THIQ-based lead compound that entered clinical phase trials. To resemble the structural rigidity of 
noscapine, alkynylated THIQs were synthesised where the meconine residue was replaced by an 
alkyne (Figure 66). 
 
Figure 66: Parent natural compound noscapine (21) and outlined collection of alkynylated tetrahydroisoquinolines (THIQs). 
The THIQ core is highlighted in red. 
The synthesis of secondary THIQs S5 and S6 (A, Scheme 1) started from various 
phenylethylamines that were cyclized to result in the corresponding lactams (S1). After Boc-
protection these lactams (S2) were alkynylated using boron acetylides in a one-pot protocol. On 
the basis of the fully protected THIQ core S3 various modifications were possible. Library 
generations however, focused on triazole derivatives generated by click chemistry (S5) and diverse 
alkynylated THIQs available via Sonogashira coupling (S6). As the one-pot alkynylation reaction 
proved to be challenging, especially for electron rich dimethoxy lactams, an alternative approach 
21 
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via the alkynylation of TMS-triflate precipitated imines (S8) was developed. In most cases this 
approach resulted in enhanced yields for the synthesis of electron rich alkynylated THIQs. 
Together with the lactam alkynylation a very efficient methodology platform was established in 
order to access numerous secondary THIQs, that are challenging to obtain otherwise. 
A sub-library of tertiary and quaternary THIQs (B, Scheme 1) was synthesised by derivatization of 
substituted 2-methyl-3,4-dihydroisoquinolinium iodides (S9). Besides synthetic compounds, the 
natural product cotarnine 23 (R1 = 6,7-OCH2O, 8-OMe) was used. To this end, diverse alkynes 
were deprotonated with iPrMgCl and added to the iminium ion to yield N-methylated analogues 
S10 which were additionally converted into quaternary ammonium salts S11 (Scheme 1).  
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Scheme 1: Synthesis of a focused library of alkynylated tetrahydroisoquinolines. A) Synthesis of secondary THIQs. a) 1. NaH 
or DMAP/Et3N; 2. Boc2O, 57-89%; b) 1.TIPS-acetylene, n-BuLi, BF3·Et2O, –78 °C, 2. DIBAL-H, 17-73%; c) TBAF, THF, 0 °C, 86-
88%; d) Pd(PPh3)4, CuI, Et3N, THF, RT, R2I, then HCl/MeOH, 15-95%; e) CuSO4, Na-ascorbate, EtOH/H2O, R2N3, then HCl/MeOH, 
54-75%. f), TMS-OTf, THF, 0°C, 2h. g) iPrMgCl, R3-alkyne, THF, 0 °C, 31-90%. B) Synthesis of tertiary and quaternary THIQs. h) 
iPrMgCl, R3-alkyne, THF, 0 °C, 13-99% or CuBr/QUINAP, R3-alkyne, Et3N, CH2Cl2, –55 °C, i) MeI, acetonitrile, 99%. DMAP = 4-
dimethylaminopyridine, Boc2O = di-tert-butyl dicarbonate, TIPS = triisopropylsilyl, n-BuLi = n-Butyllithium, DIBAL-H = 
diisobutylaluminium hydride, TBAF = tetrabutylammonium fluoride, TMS = trimethylsilyl, OTf = triflate. 
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In order to obtain enantiomerically pure, or highly enantio-enriched analogues, further 
investigations concentrated on CuBr-catalysed enantioselective alkynylation reactions of iminium 
salts (S9). Extensive ligand screening efforts led to a very efficient method (CuBr/QUINAP) giving 
high ee and almost quantitative yields. The absolute stereochemistry of the obtained alkynylated 
THIQs could be assigned in analogy to reports published by Taylor and Schreiber (Org. Lett. 2006, 
8, 143-146). 
A library of 103 THIQ derivatives was screened for phenotypic changes associated with 
microtubule cytoskeleton and mitotic arrest in BSC-1 and HeLa cells. Several compounds induced 
phenotypic changes, such as accumulation of round-shaped cells with condensed DNA, which is 
indicative of mitotic arrest (Figure 67). Quite interestingly, only compounds closely related to the 
natural product noscapine were identified. In contrast to noscapine that contains two stereocenters, 
the identified compounds comprised only one stereocenter with the same (R)-stereochemistry at 
the carbon in the α position to the nitrogen. Compounds being more potent than noscapine were 
obtained, e.g. (R)-109. As new microtubule inhibitors due to tumor resistance are in urgent need, 
these structurally related, simplified small molecules could be of great interest. 
 
Figure 67: Schematic representation of cell-based phenotypic screening. Human cancer cells (HeLa cells) were incubated with 
alkynylated THIQs and checked for phenotypic changes like mitotic arrest. 
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Small molecule microarray screening as tool in chemical biology 
Screening is a systematic test procedure to identify certain properties of the test objects. In the 
context of chemical biology, screening experiments are performed to investigate the perturbation of 
whole cells, cellular networks or isolated biochemical assay systems by small molecules of 
synthetic or natural origin. Ultimately, the interplay of a specific small molecule probe with a protein 
is analysed. Over the years Osada et al. (RIKEN Advanced Science Institute, Japan) have 
developed various techniques for the direct study of ligand-protein interactions by immobilizing 
small molecules. After incubation of proteins with immobilized probes and subsequent washing, the 
proteins with high binding affinity for the corresponding small molecule probes "stick" to the 
surface. In the case of the small molecule microarrays on glass arrays, bound protein is detected 
with antibodies or fluorescent markers. If surface plasmon resonance (SPR) is used to detect the 
protein bound to a SPR-chip, the change of the total refection angle of polarized light on a gold 
surface is recorded. However, small molecule microarray binders do not necessarily yield enzyme 
inhibitors, as only the binding is detected with this method. 
For the preparation of such microarrays, high-precision automated spotting robots are used to 
produce spots with the diameters of about 100 µm on the glass slides. The main feature of the 
microarray technology is the highly efficient and fast data analysis, as thousands of compounds 
can be spotted on a single glass slide. The key feature of the small molecule microarray 
technology is the functional group independent immobilization. In a classical approach, the 
functional groups that allow for chemical immobilization without affecting the protein-ligand 
interaction need to be introduced into the small molecule probe. This usually requires elaborate 
structure-activity relationship studies. Osada et al. developed an immobilization strategy where 
glass or gold surfaces were coated with photo-activatable molecules that generate carbenes upon 
UV-irradiation. The resulting statistical immobilization renders chemical modification of probes 
unnecessary. Even complex natural products can be immobilized using this protocol (B, Figure 
68).  
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Figure 68: Schematic representation of small molecule microarray technology. A) Crystal structure of human APT1 and 2. 
Background: binding profile for both proteins, proteins binding to small molecule array were visualized using a fluorescently 
labelled antibody. Foreground: borinic acid microarray binder and derived boronic acids. B) Representation of small 
molecules immobilized on glass array. C) LYPLAL1 crystal structure. Background: binding profile. Foreground: small 
molecule LYPLAL1 inhibitor. 
Three proteins with high sequence and structure match were selected as the target proteins for 
evaluation of the microarray screening technology. Acyl protein thioesterase 1 (APT1), APT2 and 
lysophospholipase-like 1 (LYPLAL1) protein are part of the α/β hydrolase family. APT1 was 
identified as the key protein in the control of the Ras-cycle, a dynamic de- and repalmitoylation 
cycle that is responsible for the correct localization and function of this oncogene. The inhibition of 
APT1 is regarded as a new strategy for the treatment of cancers caused by Ras mutations. The 
isoenzyme APT2 was recently identified by pull-down experiments using known covalent APT1 β-
lactone inhibitors and its biological functions remain unclear. Despite the fact that APT2 is closely 
related to LYPLAL1 and APT1, not much is known about this protein. However, various recent 
literature reports suggest its involvement in obesity. Using a library of immobilized small molecules 
from the RIKEN institute (NPDepo), all three proteins could be fingerprinted, generating binding 
profiles for the three related proteins (A and C, Figure 68). As already implicated by the sequence 
and structural homology of APT1 and APT2, a virtually identical binding profile was observed. 
However, these profiles differed significantly from the binding profile of LYPLAL1. 
For APT1 and APT2, borinic acids and borinate esters could be identified as the high-affinity 
binders and potent inhibitors in a functional enzymatic assay (A, Figure 68). Lineweaver-Burk 
analysis showed a competitive inhibition of both enzymes, which suggests a coordination of the 
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boron atom to the serine within the active site. Inspired by the activity of boron-containing 
substances, simple phenylboronic acids were tested for their inhibitory potency and nanomolar, 
non-toxic and cell-permeable inhibitors, particularly of APT2, were indentified. Co-crystallization of 
inhibitors with APT1 or APT2 were not successful, as both proteins crystallised as dimers. The 
search for a crystallographic model system led to the yeast APT1 that crystallised as a monomer. 
The high sequence homology with human APT1 and its capability to depalmitoylate N-Ras renders 
yeast APT1 a suitable crystallographic model system. Subsequently, several boronic acids were 
co-crystallised with yeast APT1 and showed the expected binding to the serine residue of the 
catalytic triad. 
In order to validate the LYPLAL1 array binders, a functional enzymatic assay had to be developed. 
Based on a thorough analysis of the crystal structure, several substrates were tested. In contrast to 
APT1 and APT2, LYPLAL1 did not tolerate long hydrophobic substrates and, contrary to the 
literature speculations, LYPLAL1 did not exhibit detectable phospholipase activity. A study using 
4-nitrophenyl esters of different chain length as substrates, showed the preference for short chain 
length. The functional enzyme assay could confirm microarray binders as the first known LYPLAL1 
inhibitors (C, Figure 68). 
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VIII Zusammenfassung 
Die vorliegende Arbeit beschäftigt sich mit zwei Grundpfeilern der chemischen Biologie: Mit der 
Synthese- und Methodenentwicklung zur Synthese einer Substanzkollektion auf Basis des 
Tetrahydroisochinolin-Grundgerüsts sowie mit der Anwendung von Mikroarrays mit immobilisierten 
niedermolekularen Sonden als Werkzeug zum Auffinden von hoch-affinen Ligand-Protein-
Wechselwirkungen. 
BIOS einer Substanzkollektion auf Basis des Tetrahydroisochinolin-Grundgerüsts 
Unter Anwendung der Prinzipien der Biologie-orientierten Synthese wurde eine Substanzbibliothek 
von alkinilierten Tetrahydroisochinolinen (THIQs) dargestellt. Diese Substanz-Kollektion basiert auf 
dem biologisch prävalididerten Grundgerüst der Tetrahydroisochinoline, das ein häufig in 
Naturstoffen anzutreffendes Motiv ist. Inspiriert durch das natürlich vorkommende 
Tetrahydroisochinolin Noscapin (21), das besonders durch seine niedrige Toxizität kombiniert mit 
seiner Fähigkeit Krebszellen durch die Störung der Mikrotubulidynamik in den Zelltod zu führen 
attraktiv erscheint, wurde eine Substanzkollektion unter Beibehaltung des Noscapin-THIQ-
Grundgerüsts und Variation der Substituenten in α-Position des Stickstoffs erstellt (Abbildung 1).  
 
Abbildung 1: Naturstoff Noscapin (21) und synthetisierte Substanzkollektion alkinilierter Tetraydroisochinoline (THIQs). Das 
THIQ-Grundgerüst ist in rot hervorgehoben. 
Die Synthese der sekundären Tetrahydroisochinoline S5 und S6 (A, Schema 1) erfolgte 
ausgehend von verschiedenen Phenylethylaminen, die mittels Bischler-Napieralski-Cyclisierung zu 
den entsprechenden Lactamen (S2) umgesetzt wurden. Nach Boc-Schützung (S2) wurde eine 
Eintopf-Lactam-Alkinilierung unter Verwendung von Bor-Acetyliden und anschließender Reduktion 
durchgeführt. Auf Basis des geschützten Tetrahydroisochinolin-Grundgerüsts S4 waren zahlreiche 
Modifikationen möglich. Zur Diversifizierung der Substanzkollektion wurden zum einen Triazole 
mittels Click-Chemie (S5) synthetisiert und zum anderen diverse alkinilierte Tetrahydroisochinoline 
unter Verwendung der Sonogashira-Kupplung (S6) hergestellt. Da die Eintopf-Alkinilierung für 
21 
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elektronenreiche Dimethoxylactame nur in niedrigen Ausbeuten funktionierte, wurde ein zweiter 
Zugang durch die Alkinilierung von mit TMS-Triflat ausgefällten Iminen (S8) entwickelt. In den 
meisten Fällen konnten über diese Route höhere Ausbeuten bei der Synthese elektronenreicher 
Tetrahydroisochinoline erzielt werden. Zusammen mit der Lactam-Alkinilierung konnte so ein 
effizienter Zugang zu zahlreichen sekundären Tetrahydroisochinolinen geschaffen werden. Eine 
weitere Kollektion tertiärer und quaternärer Tetrahydroisochinoline (B, Schema 1) wurde mittels 
Derivatisierung substituierter 2-Methyl-3,4-dihydroisochinoliniumiodid (S9) synthetisiert. Neben 
synthetischen Iminiumsalze wurde auch das Naturstoffderivat Cotarnin 23 (R1 = 6,7-OCH2O, 8-
OMe) verwendet. Um N-methylierte Analoga S10 zu erhalten, wurden diverse Alkine nach 
Deprotonierung mit iPrMgCl zu dem entsprechenden Iminiumsalz gegeben. Eine Quaternisierung 
erfolgte anschließend über die Reaktion mit Methyliodid (S11). 
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Schema 1: Synthese einer Substanzkollektion alkinilierter Tetrahydroisochinoline. A) Synthese sekundärer 
Tetrahydroisochinoline. a) 1. NaH oder DMAP/Et3N; 2. Boc2O, 57-89%; b) 1.TIPS-Acetylen, n-BuLi, BF3·Et2O, –78 °C, 2. DIBAL-H, 
17-73%; c) TBAF, THF, 0 °C, 86-88%; d) Pd(PPh3)4, CuI, Et3N, THF, RT, R2I, dann HCl/MeOH, 15-95%; e) CuSO4, Na-Ascorbat, 
EtOH/H2O, R2N3, dann HCl/MeOH, 54-75%. f), TMS-OTf, THF, 0°C, 2h. g) iPrMgCl, R3-Alkin, THF, 0 °C, 31-90%. B) Synthese 
tertiärer und quaternärer Tetrahydroisochinoline. h) iPrMgCl, R3-Alkin, THF, 0 °C, 13-99% oder CuBr/QUINAP, R3-Alkin, Et3N, 
CH2Cl2, –55 °C, i) MeI, Acetonitril, 99%. DMAP = 4-Dimethylaminopyridin, Boc2O = di-tert-Butyldicarbonat, TIPS = 
Triisopropylsilyl, n-BuLi = n-Butyllithium, DIBAL-H = Diisobutylaluminiumhydrid, TBAF = Tetrabutylammoniumfluorid, TMS = 
Trimethylsilyl, OTf = Triflat. 
A 
B 
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Um enantiomerenreine Tetrahydroisochinoline zu erhalten, wurde eine kupferkatalysierte 
enantioselektive Alkinilierungsreaktion von Iminiumsalzen (S9) untersucht. Nach intensivem 
Liganden-Screening konnte mit CuBr/QUINAP eine sehr gute Alkinilierungsmethode gefunden 
werden, die mit hohen Ausbeuten und ee’s funktioniert. Die absolute Konfiguration der alkinilierten 
Tetrahydroisochinoline konnte in Analogie zu den Publikationen von Taylor und Schreiber 
bestimmt werden (Org. Lett. 2006, 8, 143-146). 
Die Substanzkollektion von 103 Tetrahydroisochinolin-Derivaten wurde auf phänotypische 
Änderungen in BSC-1 und HeLa-Zelllinien getestet. Alkinilierte Tetrahydroisochinoline zeigten eine 
sehr effektive Hemmung der Tubulinpolymerisation und verursachten Apoptose in HeLa-Zellen 
(Abbildung 2). Interessanterweise konnten ausschließlich mit Noscapin verwandte Strukturen als 
Hits identifiziert werden. Während Noscapin über zwei Stereozentren verfügt, wiesen die aktiven 
Substanzen lediglich ein Stereozentrum mit gleicher (R)-Konfiguration wie im Naturstoff in der 
α-Position zum Stickstoff auf. Letztlich konnte ein Tetrahydroisochinolinderivat (R)-109 identifiziert 
werden, das sowohl in vitro als auch in vivo stärker die Tubulin-Polymerisation inhibiert als der 
zugrunde liegende Naturstoff.  
 
Abbildung 2: Schematische Darstellung des phänotypischen Screenings. Humane Krebszellen (HeLa) wurden mit alkinilierten 
Tetrahydroisochinolinen inkubiert und auf phänotypische Änderungen hin untersucht. 
  
(R)-109 
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Mikroarrays mit immobilisierten niedermolekularen Sonden als Werkzeuge in der 
chemischen Biologie 
In der chemischen Biologie werden Screeningverfahren angewendet, um die Beeinflussung von 
ganzen Zellen, Zellverbünden oder isolierten biochemischen Testsystemen durch 
niedermolekulare Sonden synthetischen oder natürlichen Ursprungs zu untersuchen. Letztlich 
werden so die Wechselwirkungen einer bestimmten niedermolekularen Sonde mit einem Protein 
untersucht. Osada (RIKEN Advanced Science Institute, Japan) entwickelte über die Jahre 
verschiedene Techniken für die direkte Untersuchung dieser Ligand-Protein-Wechselwirkungen 
durch die Immobilisierung niedermolekularer Moleküle. Nach Inkubation von Proteinen mit 
immobilisierten Sonden und folgenden Waschvorgängen bleiben komplementäre Proteine mit 
hoher Bindungsaffinität an den entsprechenden Sonden „kleben“. Die Detektion von gebundenem 
Protein erfolgt bei Immobilisierung auf Glasoberflächen mit Antikörpern oder Fluoreszenzmarkern 
oder im Fall von Oberflächenplasmonenresonanz duch die Änderung des Totalreflexionswinkels 
von polarisiertem Licht an einer Goldoberfläche. Nicht zwangsläufig führen jedoch Protein-Binder 
auch zu Protein-Inhibitoren, da in dieser Methode keine Aussage über eine das Enzym hemmende 
Sonden-Protein-Wechselwirkung getroffen wird.  
Zur Herstellung dieser Mikroarrays werden Hochpräzisions-Spotter eingesetzt, um Substanzen als 
Spots mit Durchmesser von ca. 100 µm auf Glasplatten aufzubringen. Hauptmerkmal dieser 
Mikroarraytechnologie ist die hocheffiziente und schnelle Datenanalyse. Einzigartig wird diese 
Methode durch die verwendete Immobilisierungstechnik. Klassischerweise müssen für das 
Anbringen funktioneller Gruppen, die eine chemische Immobilisierung ermöglichen ohne die 
Sonde-Protein Wechselwirkung zu beeinflussen, aufwändige Struktur-Aktivitätsbeziehungen 
durchgeführt werden. Die von Osada entwickelte Immobilisierungsmethode ist von funktionellen 
Gruppen unabhänging. Die Verwendung von beschichteten Glasplatten mit photoaktivierbaren 
Carbenen ermöglicht eine statistische Immobilisierung und macht folglich eine vorherige 
chemische Modifikation der Sonden unnötig. So können selbst komplexe Naturstoffe auf Glas- 
oder Goldoberflächen immobilisiert werden (B, Abbildung 3).  
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Abbildung 3: Schematische Darstellung des Mikroarray Screenings. A) Kristallstrukturen von humanem APT1 and 2. 
Hintergund: Bindeprofil für beide Proteine. Proteine die an immobilisierte Sonden binden wurden mittels 
fluoreszenzmarkierten Antikörpern sichtbar gemacht. Vordergrund: Borinatester- und abgeleitete Boronsäure-
Mikroarraybinder. B) Darstellung eines Mikroarrays mit immobilisierten niedermolekularen Sonden. C) Kristallstruktur von 
humanem LYPLAL1. Hintergrund: Bindeprofil. Vordergrund: Identifizierter LYPLAL1-Inhibitor. 
Als Zielproteine für die Evaluierung des Mikroarrayscreenings wurden drei Proteine mit hoher 
Sequenz- und Strukturübereinstimmung gewählt. Acyl protein thioesterase 1 (APT1), APT2 und 
Lysophospholipase-like 1 (LYPLAL1) Protein sind Teil der α/β-Hydrolase Familie. APT1 wurde als 
wesentliches Protein bei der Steuerung des Ras-Zyklus identifiziert, eines dynamischen De- und 
Repalmitoylierungskreislaufes, der für die korrekte Lokalisierung und Funktion dieses Onkogens 
veranwortlich ist. Die Inhibition von APT1 wird als neue Strategie zur Behandlung von durch Ras-
Mutationen verursachten Krebsarten angesehen. Erst kürzlich wurde durch Pulldown-Exprimente 
mit als APT1 bekannten kovalenten β-Laktoninhibitoren APT2 als Isoenzym identifiziert. Dessen 
biologische Funktion ist jedoch noch weitgehend unklar. Über LYPLAL1 ist trotz großer 
Vewandtschaft zu APT1 außer zahlreichen Hinweisen über eine Beteiligung an Fettleibigkeit 
ebenfalls nichts bekannt. Durch Mikroarray-Screeningexperimente mit der Substanzbibliothek des 
RIKEN Instituts (NPDepo) konnte ein „chemischer Fingerabdruck“ mit charakteristischen 
Bindeprofilen für die drei verwandten Proteine erzeugt werden (A und C, Abbildung 3). Wie 
bereits Sequenz- und Strukturhomologie von APT1 und APT2 nahelegten, wurde auch ein nahezu 
identisches Bindeprofil festgestellt. Deutlich davon unterschied sich jedoch das Profil von 
LYPLAL1.  
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Für APT1 und APT2 konnten Borinsäuren bzw. Borinatester im Mikroarray als hochaffine 
Proteinbinder und in einem funktionalen enzymatischen Assay als potente Inhibitoren identifiziert 
werden (A, Abbildung 3). Mittels Lineweaver-Burk Analyse konnte eine kompetitive Inhibition der 
beiden Enzyme gezeigt werden, die eine Koordination des Boratoms an das Serin der aktiven 
Tasche nahelegt. Inspiriert durch die Aktivität der borhaltigen Substanzen, wurden einfache 
Phenylboronsäuren auf ihre Inhibitionseigenschaft hin überprüft. Tatsächlich konnten insbesondere 
für APT2 Inhibitoren im nanomolaren Bereich gefunden werden, die sowohl nicht toxisch als auch 
zellgängig waren. Kokristallisationen mit APT1 oder APT2 Inhibitoren waren nicht erfolgreich, da 
beide Proteine als Dimer kristallisierten. Die Suche nach einem kristallographischen Modellsystem 
führte schließlich zum als Monomer kristallisierenden APT1 aus Hefe, das hohe 
Sequenzhomologie mit humanem APT1 aufweist und ebenso in der Lage ist N-Ras zu 
depalmitoylieren. Einige Boronsäuren konnten kristallisiert werden und zeigten die erwartete 
Bindung an das Serin der katalytischen Triade.  
Für LYPLAL1 musste zuerst ein funktioneller Assay entwickelt werden, um die identifizierten 
Mikroarray-Binder zu validieren. Basierend auf einer genauen Analyse der Kristallstruktur wurden 
zahlreiche Substrate getestet. Im Gegensatz zu APT1 und APT2 setzt LYPLAL1 keine langen, 
hydrophoben Substrate um und entgegen den in der Literatur geäußerten Vermutungen ist 
LYPLAL1 auch keine Phospholipase. Eine Studie mit 4-Nitrophenylestern unterschiedlicher 
Kettenlänge zeigte die Bevorzugung kurzer Substrate. Im funktionalen Enzymassay konnten 
Mikroarray-Binder als Inhibitoren von LYPLAL1 identifiziert werden (C, Abbildung 3). 
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IX Appendix 
Boronic acids 
Boronic acids are of commercial and synthetic origin (kindly provided by Prof. Dr. Dennis Hall). 
For APT1 IC50 values were determined for compounds showing more than 80% inhibition at 50 µM. 
For APT2 IC50 values were determined for compounds showing more than 99% inhibition at 50 µM. 
Cpd ID Structure IC50 [µM] APT1 IC50 [µM] APT2 
248 BA01 
 
> 50 > 50 
249 BA02 
 
> 50 n. d. 
250 BA03 
 
14.7 ± 1.6 25.1 ± 1.41 
190 BA04 
 
0.51 ± 0.03 1.97 ± 0.10 
251 BA05 
 
4.6 ± 0.4 4.18 ± 0.77 
252 BA06 
 
> 50 n. d. 
253 BA07 
 
> 50 n. d. 
254 BA08 
 
> 50 > 50 
255 BA09 
 
n. d. n. d. 
256 BA10 
 
n. d. n. d. 
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Cpd ID Structure IC50 [µM] APT1 IC50 [µM] APT2 
257 BA11 
 
> 50 n. d. 
258 BA12 
 
> 50 n. d. 
259 BA13 
 
2.3 ± 0.1 0.529 ± 0.133 
260 BA14 
 
3.9 ± 1.0 2.87 ± 0.63 
261 BA15 
 
> 50 n. d. 
262 BA16 
 
16.9 ± 1.5 
 
3.55 ± 0.40 
263 BA18 
 
> 50 n. d. 
264 BA19 
 
> 50 n. d. 
265 BA20 
 
> 50 n. d. 
266 BA21 
 
17.2 ± 1.9 n. d. 
 191 BA22 
 
1.4 ± 0.1 0.418 ± 0.013 
192 BA23 
 
1.1 ± 0.2 0.138 ± 0.013 
267 BA24 
 
n. d. n. d. 
268 BA25 
 
> 50 > 50 
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Cpd ID Structure IC50 [µM] APT1 IC50 [µM] APT2 
269 BA26 
 
> 50 n. d. 
270 BA27 
 
> 50 n. d. 
271 BA28 
 
> 50 > 50 
272 BA29 
 
> 50 > 50 
273 BA30 
 
n. d. n. d. 
274 BA31 
 
> 50 n. d. 
275 BA33 
 
n. d. n. d. 
276 BA34 
 
> 50 > 50 
277 BA35 
 
> 50 > 50 
278 BA36 
 
6.3 ± 0.5 2.16 ± 0.17 
279 BA37 
 
3.7 ± 0.4 2.95 ± 0.15 
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Cpd ID Structure IC50 [µM] APT1 IC50 [µM] APT2 
280 BA38 
 
25.0 ± 2.1 n. d. 
281 BA39 
 
> 50 n. d. 
282 BA40 
 
> 50 n. d. 
283 BA41 
 
> 50 n. d. 
284 BA42 
 
> 50 > 50 
285 BA43 
 
n. d. n. d. 
286 BA44 
 
> 50 n. d. 
287 BA45 
 
n. d. n. d. 
288 BA46 
 
n. d. n. d. 
289 BA47 
 
> 50 n. d. 
290 BA49 
 
13.5 ± 1.4 11.3 ± 4.0 
291 BA50 
 
> 50 > 50 
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Cpd ID Structure IC50 [µM] APT1 IC50 [µM] APT2 
292 BA51 
 
> 50 n. d. 
293 BA52 
 
> 50 > 50 
294 BA53 
 
> 50 n. d. 
295 BA54 
 
> 50 n. d. 
296 BA55 
 
> 50 > 50 
297 BA56 
 
16.9 ± 1.5 n. d. 
298 BA57 
 
> 50 n. d. 
299 BA58 
 
> 50 n. d. 
300 BA59 
 
n. d. n. d. 
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Cpd ID Structure IC50 [µM] APT1 IC50 [µM] APT2 
301 BA60 
 
> 50 n. d. 
302 BA61 
 
> 50 > 50 
303 BA62 
 
10.2 ± 1.0 1.98 ± 0.09 
304 BA63 
 
> 50 n. d. 
305 BA64 
 
> 50 > 50 
306 BA65 
 
22.6 ± 2.6 n. d. 
307 BA66 
 
> 50 n. d. 
308 BA68 
 
> 50 > 50 
309 BA69 
 
> 50 > 50 
310 BA70 
 
> 50 n. d. 
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Cpd ID Structure IC50 [µM] APT1 IC50 [µM] APT2 
311 BA71 
 
n. d. n. d. 
312 BA72 
 
> 50 > 50 
313 BA73 
 
n. d. n. d. 
314 BA74 
 
3.2 ± 0.2 0.238 ± 0.025 
315 BA75 
 
n. d. n. d. 
316 BA76 
 
n. d. > 50 
317 BA77 
 
> 50 > 50 
 
Commercial THIQs and Derivatives  
Cpd ID Structure 
318 6,7-Dihydroxy-3,4-dihydroisoquinoline (DDIQ) 
 
319 7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline (7-HDIQ) 
 
320 6,7-Dimethoxyisoquinoline (6,7-DIQ) 
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321 7-Monomethoxyisoquinoline (7-MIQ) 
 
23 Cotarnine 
 
21 Noscapine 
 
162 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolinium chloride 
(DHTHIQ) 
 
322 MIC1501014 
 
323 IBS_STOCK1N-30368 
 
324 IBS_STOCK1N-31232 
 
325 IBS_STOCK1N-31719 
N
O
O
O
OH
H
Cl
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326 IBS_STOCK1N-32001 
 
327 IBS_STOCK1N-40298 
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